



廣東康華醫療股份有限公司 Guangdong Kanghua Healthcare Co., Ltd.*

(於中華人民共和國註冊成立的股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)

股份代號 Stock Code : 3689

*僅供識別 For identification purposes only

蒼生為念
厚德載醫

2019

INTERIM
REPORT
中報

合肥市殘疾人綜合服務中心

Contents

目錄

2	Corporate Information 公司資料
4	Financial Highlights 財務概覽
6	Management Discussion and Analysis 管理層討論及分析
40	Corporate Governance Highlights 企業管治概覽
43	Other Information 其他資料
52	Report on Review of Condensed Consolidated Financial Statements 簡明綜合財務報表之審閱報告
54	Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 簡明綜合損益及其他全面收益表
55	Condensed Consolidated Statement of Financial Position 簡明綜合財務狀況表
57	Condensed Consolidated Statement of Changes in Equity 簡明綜合權益變動表
58	Condensed Consolidated Statement of Cash Flows 簡明綜合現金流量表
59	Notes to the Condensed Consolidated Financial Statements 簡明綜合財務報表附註
96	Definitions 釋義



Corporate Information

公司資料

BOARD OF DIRECTORS

Executive Directors

Mr. Wang Junyang (*Chairman*)
Mr. Chen Wangzhi (*Chief Executive Officer*)
Mr. Wong Wai Hung Simon (*Vice Chairman*)
Ms. Wang Ai Qin

Non-executive Director

Mr. Lv Yubo

Independent Non-executive Directors

Mr. Yeung Ming Lai
Dr. Chen Keji
Mr. Chan Sing Nun

Audit Committee

Mr. Chan Sing Nun (*Chairman*)
Dr. Chen Keji
Mr. Yeung Ming Lai

Remuneration Committee

Mr. Chan Sing Nun (*Chairman*)
Ms. Wang Ai Qin
Mr. Yeung Ming Lai

Nomination Committee

Mr. Wang Junyang (*Chairman*)
Dr. Chen Keji
Mr. Yeung Ming Lai

SUPERVISORY COMMITTEE

Mr. Chen Shaoming (*Chairman*)
Mr. Wang Shaofeng
Mr. Yue Chunyang

JOINT COMPANY SECRETARIES

Mr. Wong Wai Hang Ricky
Ms. Chau Hing Ling

SECRETARY TO THE BOARD

Ms. Wang Yingda

董事會

執行董事

王君揚先生 (*主席*)
陳旺枝先生 (*行政總裁*)
王偉雄先生 (*副主席*)
王愛勤女士

非執行董事

呂玉波先生

獨立非執行董事

楊銘澧先生
陳可冀醫生
陳星能先生

審核委員會

陳星能先生 (*主席*)
陳可冀醫生
楊銘澧先生

薪酬委員會

陳星能先生 (*主席*)
王愛勤女士
楊銘澧先生

提名委員會

王君揚先生 (*主席*)
陳可冀醫生
楊銘澧先生

監事會

陳少明先生 (*主席*)
王少鋒先生
岳春陽先生

聯席公司秘書

黃偉恒先生
周慶齡女士

董事會秘書

王櫻達女士

AUTHORISED REPRESENTATIVES

Mr. Wong Wai Hung Simon
Mr. Wong Wai Hang Ricky

AUDITOR

Deloitte Touche Tohmatsu

LEGAL ADVISERS AS TO HONG KONG LAWS

Allen & Overy

REGISTERED OFFICE

3/F, Outpatient Zone One
Dongguan Kanghua Hospital
Nancheng Street Road
Dongguan
Guangdong Province
PRC

HEAD OFFICE IN THE PRC

1000 Dongguan Avenue
Dongguan
Guangdong Province
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Unit 3207, Metroplaza Tower 2
223 Hing Fong Road
Kwai Fong, New Territories
Hong Kong

H SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712–1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

STOCK CODE

3689

COMPANY'S WEBSITE

<http://www.kanghuagp.com>

授權代表

王偉雄先生
黃偉恒先生

核數師

德勤•關黃陳方會計師行

香港法律顧問

安理國際律師事務所

註冊辦事處

中國
廣東省
東莞市
南城街道
東莞康華醫院
門診一區3樓

中國總部

中國
廣東省
東莞市
東莞大道1000號

香港主要營業地點

香港
新界葵芳
興芳路223號
新都會廣場第二座3207室

H股證券登記處

香港中央證券登記有限公司
香港
灣仔
皇后大道東183號
合和中心
17樓1712–1716號舖

股份代號

3689

公司網站

<http://www.kanghuagp.com>

Financial Highlights

財務概覽

KEY FINANCIAL PERFORMANCE

主要財務表現

RMB million 人民幣百萬元




For the six months ended 30 June
截至六月三十日止六個月

		PoP Change 按期變動	2019 二零一九年 RMB'000 人民幣千元	2018 二零一八年 RMB'000 人民幣千元
Revenue	收益	+23.8%	914,364	738,589
Gross profit	毛利	+10.7%	185,946	168,048
Gross profit margin	毛利率	-2.5b.p.	20.3%	22.8%
Profit before taxation	除稅前溢利	+27.1%	84,689	116,229
Profit for the period attributable to owners of the Company	本公司擁有人應佔期內溢利	-21.0%	67,637	85,632
Earnings per share – basic	每股盈利 – 基本	-21.1%	20.2	25.6
Adjusted EBITDA	經調整EBITDA	+10.4%	136,615	123,742

PATIENT VISITS

病人人次


Thousand Visits 千人次



REVENUE PROPORTION BY MAJOR HEALTHCARE DISCIPLINES*


主要科室收益佔比*

2019 | 2018



REVENUE PoP GROWTH OF MAJOR HEALTHCARE DISCIPLINES*

主要科室期內收益同比升幅*



* The amount does not include revenue from rehabilitation and other healthcare services, hospital management services, sale of pharmaceutical products and others.

* 該金額不包括提供康復及其他醫療服務、醫院管理服務及銷售藥品的收益及其他。

Management Discussion and Analysis

管理層討論及分析

BUSINESS REVIEW AND OUTLOOK

Business Overview for the six months ended 30 June 2019

In the first half of 2019, the Group's consolidated revenue reached its record high to RMB914.4 million (six months ended 30 June 2018: RMB738.6 million), representing a period-on-period growth of 23.8%, mainly attributable to the growth of the Group's owned-hospital operations. In particular, Kanghua Hospital and Renkang Hospital, have delivered solid growth in revenue of 20.3% and 5.6%, respectively. However, the Group's results for the Reporting Period has been adversely affected by losses incurred at the Group's 60%-owned hospital, namely Zhonglian Cardiovascular Hospital, which the Group acquired in August 2018, mainly because Zhonglian Cardiovascular Hospital is still at its initial stage of ramping up its operations.



The Group's consolidated profit for the six months ended 30 June 2019 has dropped to RMB55.5 million (six months ended 30 June 2018: RMB89.4 million), representing a period-on-period decrease of 37.9%. However, the Group's Adjusted EBITDA has recorded a period-on-period increase of 10.4% to RMB136.6 million (six months ended 30 June 2018: RMB123.7 million), which indicates that the Group's core operation has remained strong after eliminating the effects of financing, investment-related income, effects of exchange rate changes and capital expenditures.

業務回顧和展望

截至二零一九年六月三十日止六個月的業務概覽

於二零一九年上半年，本集團的綜合收益創下歷史新高，達人民幣914.4百萬元（截至二零一八年六月三十日止六個月：人民幣738.6百萬元），同比增長23.8%，主要歸因本集團所擁有的醫院營運有所增長，尤其是康華醫院及仁康醫院已分別取得收益穩定增長為20.3%及5.6%。然而，本集團於報告期間的業績受到本集團擁有60%權益的醫院眾聯心血管病醫院（我們於二零一八年八月收購的眾聯心血管病醫院）所產生的虧損的不利影響，主要是由於眾聯心血管病醫院的經營處於加速運作的初始階段所致。



截至二零一九年六月三十日止六個月，本集團的綜合溢利已下降至人民幣55.5百萬元（截至二零一八年六月三十日止六個月：人民幣89.4百萬元），同比下降37.9%。然而，本集團的利息、稅項、折舊及攤銷前經調整盈利（「經調整EBITDA」）錄得同比增長10.4%至人民幣136.6百萬元（截至二零一八年六月三十日止六個月：人民幣123.7百萬元），表明本集團的核心業務於消除融資、投資相關收入、匯率變動及資本支出影響後仍保持強勁。

Management Discussion and Analysis

管理層討論及分析

The Group's rehabilitation and other related healthcare services segment, through its ownership of 57% equity interest in Anhui Hualin Medical Investment Co., Ltd. ("Anhui Hualin"), has recorded a revenue of RMB35.6 million (six months ended 30 June 2018: RMB14.6 million). Anhui Hualin directly and indirectly (through its wholly-owned subsidiary) holds sponsor interests in certain private non-enterprise entities in Anhui Province, the PRC. It mainly operates two rehabilitation hospitals, one general hospital, nine rehabilitation centres and one vocational training school.

Hospital Services

The Group's hospital services segment represented by the Group's owned hospitals, namely Kanghua Hospital, Renkang Hospital and Zhonglian Cardiovascular Hospital, has continued to deliver consistent growth in results, in particular (i) the total number of inpatient visits reached 36,025 (for six months ended 30 June 2018: 30,507), representing a period-on-period increase of 18.1%; (ii) the overall average spending per inpatient visit amounted to RMB14,883.7 (six months ended 30 June 2018: RMB13,969.5), representing a period-on-period increase of 6.5%; (iii) the overall bed utilisation rate dropped to 80.6% (six months ended 30 June 2018: 87.8%), mainly affected by the lower bed utilisation performance at Zhonglian Cardiovascular Hospital; (iv) the average length of stay was slightly lowered to 7.3 days (six months ended 30 June 2018: 7.6 days) as a result of further improved clinical processes; (v) the total number of outpatient visits reached 861,872 (six months ended 30 June 2018: 765,370), representing a period-on-period increase of 12.6%; (vi) the overall average spending per outpatient visit amounted to RMB347.6 (six months ended 30 June 2018: RMB338.1), representing a period-on-period increase of 2.8%; and (vii) the total number of surgical operations reached 20,994 (six months ended 30 June 2018: 18,875), representing a period-on-period increase of 11.2%.

本集團的康復及其他相關醫療服務分部，透過其擁有安徽樺霖醫療投資有限公司（「安徽樺霖」）的57%股權，已錄得收益人民幣35.6百萬元（截至二零一八年六月三十日止六個月：人民幣14.6百萬元）。安徽樺霖透過其全資附屬公司於中國安徽省多間民辦非企業單位直接及間接持有舉辦者權益。其主要經營兩間康復醫院、一間綜合醫院、九間殘疾人康復中心及一間職業培訓學校。

醫院服務

本集團擁有的醫院，即康華醫院、仁康醫院及眾聯心血管病醫院代表本集團的醫院服務分部，繼續取得穩定增長的業績，特別是：(i) 住院人次總數達36,025名（截至二零一八年六月三十日止六個月：30,507名），同比增加18.1%；(ii) 每名住院病人的整體平均開支為人民幣14,883.7元（截至二零一八年六月三十日止六個月：人民幣13,969.5元），同比增長6.5%；(iii) 病床的整體佔用率下降至80.6%（截至二零一八年六月三十日止六個月：87.8%），主要受眾聯心血管病醫院床位使用率較低的影響；(iv) 由於進一步改善臨床流程，平均住院天數小幅降至7.3天（截至二零一八年六月三十日止六個月：7.6天）；(v) 門診總人次達到861,872名（截至二零一八年六月三十日止六個月：765,370名），同比增長12.6%；(vi) 每名門診病人的整體平均支出為人民幣347.6元（截至二零一八年六月三十日止六個月：人民幣338.1元），同比增長2.8%；及(vii) 外科手術總數達到20,994例（截至二零一八年六月三十日止六個月：18,875例），同比增長11.2%。

Management Discussion and Analysis

管理層討論及分析

The table below sets forth certain key operational data of the Group's owned hospitals of the hospital services segment for the periods indicated:

下表載列本集團擁有的醫院服務分部的醫院於所示期間的若干主要營運數據：

		For the six months ended 30 June 截至六月三十日止六個月		
		Change 變動	2019 二零一九年	2018 二零一八年
Inpatient healthcare services	住院醫療服務			
Inpatient visits	住院人次	+18.1%	36,025	30,507
Average length of stay (days)	平均住院日數(天)	-0.3	7.3	7.6
Average spending per visit (RMB)	每人次平均開支(人民幣元)	+6.5%	14,883.7	13,969.5
Outpatient healthcare services	門診醫療服務			
Outpatient visits	門診人次	+12.6%	861,872	765,370
Average spending per visit (RMB)	每人次平均開支(人民幣元)	+2.8%	347.6	338.1
Physical examination services	體檢服務			
Physical examination visits	體檢人次	+15.7%	76,307	65,960
Average spending per visit (RMB)	每人次平均開支(人民幣元)	-3.5%	441.2	457.3

Kanghua Hospital

康華醫院

In the first half of 2019, Kanghua Hospital continued to respond to the initiatives of the government for the establishment of the Medical Association by actively participating in the establishment of the Medical Association with lower-level medical institutions such as town and street hospitals and community health service centres in Dongguan, and taking the lead in formulating relevant work implementation plans. During this period, Kanghua Hospital established new medical alliances in the fields of first aid, rehabilitation medicine and endocrine and metabolic medicine.

於二零一九年上半年，康華醫院繼續響應國家對於醫聯體組建的號召，積極加入與東莞鎮街醫院和社區衛生服務中心等下級機構的醫聯體組建工作，並牽頭制定相關工作實施方案。於本期間，康華醫院於急救、康復醫學及內分泌代謝領域設立新的醫療聯盟。



Management Discussion and Analysis

管理層討論及分析

In terms of specialist development and construction of medical centres, Kanghua Hospital also attained remarkable achievements, including:

- (i) Oncology disciplines: The number of patients admitted into the disciplines and the number of outpatient visits increased significantly as compared to the same period last year. This was accomplished through utilising brand new equipment to carry out various kinds of radiotherapy techniques, strengthening multidisciplinary joint therapy within the hospital and cooperating with authoritative oncology hospitals;
- (ii) Hematology Disease Centre: The centre carried out new technologies and new projects for stem cell transplantation in relation to recurrent leukemia and lymphoma. In addition, the multi-site consultation mode has been adopted for complex diseases so that well-known experts from all over the country are invited to come to the hospital for consultation and teaching, so as to improve the treatment level and rate of recovery from diseases in the centre; and
- (iii) Chest Pain Centre: In April 2019, the centre successfully passed the re-certification review by the China Chest Pain Centre and maintained the qualifications of a National Chest Pain Centre.

With the continuous improvement of its quality of medical services, Kanghua Hospital's industry influence continues to expand. In March 2019, the "Top 100 Competitive Non-Public Hospitals in China in 2018" list, published by Asclepius, an independent third-party hospital evaluation institute, again ranked Kanghua Hospital third place nationwide with excellent results.

在專科發展及醫學中心建設方面，康華醫院亦取得顯著成績，包括：

- (i) 腫瘤科：收治的患者人數及門診人次較去年同期大幅增加。此通過運用全新設備實施多種放射治療技術，加強醫院內多學科聯合治療並與權威腫瘤醫院合作；
- (ii) 血液病中心：該中心開展了新技術、新項目，針對復發性白血淋巴瘤進行幹細胞移植治療。此外，對疑難病症採用多地會診模式，邀請全國知名專家來院會診及授課，使中心的治療水平及疾病治愈率獲得提升；及
- (iii) 胸痛中心：於二零一九年四月，該中心成功通過中國胸痛中心的再認證審查，並維持國家級胸痛中心的資質。

隨著醫療服務質量的不斷提高，康華醫院的行業影響力不斷擴大。於二零一九年三月，由獨立第三方醫院評估機構Asclepius頒佈的「2018中國競爭力·非公立醫院100強」名單，康華醫院再次以優異的成績穩居全國第三。



Management Discussion and Analysis

管理層討論及分析

Renkang Hospital

In the first half of 2019, Renkang Hospital continued to optimize its operation management system as well as strengthen its management of medical technology and control of medical quality, treatment schemes and medical insurance expenses. This has contributed to the steady growth of the number of patients and revenue and the effective reduction of its operating costs.

Furthermore, Renkang Hospital continues to promote the development of special and exceptional specialities, including the disciplines of gynecology and obstetrics, paediatrics, stomatology, health examination, geriatrics and traditional Chinese medicine. Indeed, through the induction of talented individuals, investing in equipment, expanding inpatient wards and strengthening marketing efforts, the comprehensive strength and influence of these specialities are constantly enhanced. In the first half of 2019, Renkang Hospital became a member of the Southern Geriatric Disease Prevention and Control Alliance, the Dongguan Geriatric Medical Specialist Alliance and the Guangdong Province's Commission on Occupational Health.

Zhonglian Cardiovascular Hospital

In 2019, the Zhonglian Cardiovascular Hospital entered its third year of operation. With the rapid development of the hospital, it attracted cardiovascular specialists to join and well-known domestic experts to give diagnosis. Furthermore, the disciplines of Radiology and Clinical Laboratory obtained a number of patents and certifications and carried out a series of academic study. As a result, the number of patients in the first half of 2019 increased substantially, with over 7,500 outpatient visits, an increase of more than 70% compared to the same period last year, and around 900 inpatient visits an increase of over 100% compared to the same period last year. In addition, on the premise of guaranteeing medical quality and safety, the volume of surgeries in the hospital steadily increased. During the first half of 2019, 63 cases of cardiac surgery were performed, an increase of 26.0% compared to the same period last year, and 279 cases of interventional cardiac surgery were performed, an increase of 65.1% compared to the same period last year.

At present, the hospital is striving to build the discipline centres with Kanghua's characteristics, which would include the establishment of a hypertension centre and CCU-based heart failure wards, and to bolster the construction of the Chest Pain Centre. The Group believes that the Zhonglian Cardiovascular Hospital will continue to strengthen its influence and reputation in the field of cardiovascular specialty in Southwest China and deliver predictable returns in the future.

仁康醫院

於二零一九年上半年，仁康醫院持續優化醫院運營管理制度，以及加強對醫療技術的管理和對醫療質量、醫療方案、醫保費用的管控。此舉有助於患者人次及收益的穩定增長以及有效降低其營運成本。

此外，仁康醫院繼續推動特色及優勢專科的發展，包括婦產科、兒科、口腔科、健康體檢、老年病中心及中醫科。事實上，通過引進人才、投資設備、擴大住院病房及加強推廣力度，該等專科的綜合實力及影響力不斷提升。於二零一九年上半年，仁康醫院成為南方中西醫結合老年病防治聯盟單位、東莞市老年醫學專科聯盟合作單位及廣東省職業健康協會理事單位成員。

眾聯心血管醫院

於二零一九年，眾聯心血管醫院進入營運第三年。隨著醫院的快速發展，其吸引心血管專科人才加入和國內知名專家坐診。此外，放射科及檢驗科獲得多項專利及認證，並展開一系列學術研究。因此，於二零一九年上半年，接待患者人次大幅增加，門診人次超過7,500人，較去年同期增加70%以上，及住院人次約900人，較去年同期增加超過100%。此外，在保證醫療質量及安全的前提下，醫院的手術量穩步增加。於二零一九年上半年，醫院實施63例心外科手術，較去年同期增加26.0%，並實施心內科介入手術279例，較去年同期增加65.1%。

目前，該醫院正在努力建設康華特色的專科中心，其中包括設立一個高血壓中心及心衰病房，並加強胸痛中心的建設。本集團相信，眾聯心血管醫院將繼續加強其在中國西南地區心血管專業領域的影響力及聲譽，並在未來帶來可預見的回報。

Management Discussion and Analysis

管理層討論及分析

The table below sets forth the revenue contribution by healthcare disciplines of our hospital services segment for the periods indicated:

下表載列於所示期間按醫院服務分部的醫學專科劃分的收益貢獻：

		For the six months ended 30 June 截至六月三十日止六個月				
		2019 二零一九年		2018 二零一八年		
		% of revenue of the Group's owned hospitals 分佔本集團 擁有醫院的		% of revenue of the Group's owned hospitals 分佔本集團 擁有醫院的		
Healthcare disciplines ^(note)	醫學專科 ^(附註)	Change 變動	RMB'000 人民幣千元	收益百分比	RMB'000 人民幣千元	收益百分比
O&G related disciplines	婦產科有關科室	+7.6%	151,917	17.5	141,145	19.7
Cardiovascular related disciplines	心血管有關科室	+36.5%	122,340	14.1	89,618	12.5
Internal medicine related disciplines	內科有關科室	+20.9%	103,437	11.9	85,539	12.0
General surgery related disciplines	普通外科有關科室	+10.5%	69,676	8.0	63,051	8.8
Neurology related disciplines	神經醫學有關科室	+24.0%	59,624	6.9	48,077	6.7
Emergency medicine related disciplines	急診有關科室	+55.7%	58,320	6.7	37,449	5.3
Orthopaedics related disciplines	骨科有關科室	+6.2%	53,176	6.1	50,065	7.0
Paediatrics related disciplines	兒童醫學有關科室	+31.7%	31,533	3.6	23,934	3.4
Oncology related disciplines	腫瘤有關科室	+80.3%	25,121	2.9	13,930	1.9
Nephrology related disciplines	腎臟科有關科室	+26.1%	20,365	2.3	16,154	2.3
Medical aesthetic related disciplines	醫學美容有關科室	+18.7%	18,779	2.1	15,817	2.2
Physical examination	體檢科	+11.6%	33,668	3.9	30,163	4.2
Other disciplines	其他臨床科室	+21.3%	121,478	14.0	100,151	14.0
Total	總計		869,434	100.0	715,093	100.0

Note: The Group's healthcare disciplines can generally be classified into clinical disciplines and medical technology disciplines. Medical technology disciplines provide diagnostic and treatment support according to the requirements of clinical disciplines from time to time. Revenue derived from services delivered through medical technology disciplines is generally recognised in the relevant clinical disciplines that utilised such services.

附註：本集團的醫療專科一般可分為臨床專科和醫療技術專科。醫療技術專科根據臨床專科的要求不時提供診斷和治療支援。通過醫療技術專科提供服務產生的收益通常在使用這些服務的相關臨床專科中確認。

Management Discussion and Analysis

管理層討論及分析

In the first half of 2019, the Group performed 8,380 surgeries with level 3 or level 4 complexities (six months ended 30 June 2018: 5,619), representing a period-on-period increase of 49.1%. O&G disciplines, internal medicine disciplines, cardiovascular disciplines, general surgery disciplines and neurology disciplines (six months ended 30 June 2018: O&G disciplines, internal medicine disciplines, cardiovascular disciplines, general surgery disciplines and orthopaedics disciplines) were the top five revenue generating disciplines of the Group for the first half of 2019, accounting for approximately 58.4% of the Group's total revenue in the same period (six months ended 30 June 2018: 60.1%).

During the six months ended 30 June 2019, the revenue from all disciplines of the Group's owned hospitals recorded considerable growth, which was mainly driven by the demand of the Group's services offerings. In particular, (a) O&G related disciplines still remained the Group's strongest area and revenue from O&G related disciplines recorded a period-on-period increase of 7.6%. The Group's O&G related disciplines continue to be a stable revenue driver of the Group, and the increase is primarily attributable to the expansion of O&G related workforce and medical facilities and the growth of O&G service offerings at the VIP centre; (b) revenue from cardiovascular related disciplines recorded a strong period-on-period increase of 36.5%, primarily attributable to the revenue contribution of the newly acquired Zhonglian Cardiovascular Hospital in August 2018 and the continued growth in reputation of our treatments in cardiovascular diseases within Guangdong Province; (c) revenue from internal medicine related disciplines also recorded a considerable period-on-period increase of 20.9%, primarily attributable to the recruitment of more reputable healthcare experts and professionals to improve the service quality and treatment results; (d) revenue from neurology related disciplines recorded a period-on-period increase of 24.0%, primarily attributable to recruitment of new neurology specialists resulting in an overall improvement of medical capabilities in this area; and (e) oncology related disciplines recorded a significant period-on-period increase of 80.3%, primarily as a result of recruitment of oncology specialists in 2017 which has continued to increase the attraction of patients to Kanghua Hospital ever since. The Group will continue to recruit medical experts and talents, accelerate the installation and implementation of the medical equipment and promote the development of these disciplines comprehensively, as well as increase the capability to receive and treat critical tumor patients.

於二零一九年上半年，本集團已施行8,380例三、四級複雜手術（截至二零一八年六月三十日止六個月：5,619例），同比增長49.1%。婦產科、內科、心血管科、普通外科及神經科（截至二零一八年六月三十日止六個月：婦產科、內科、心血管科、普通外科及骨科）為二零一九年上半年本集團產生五大收益的專科，佔本集團同期總收益約58.4%（截至二零一八年六月三十日止六個月：60.1%）。

截至二零一九年六月三十日止六個月，本集團擁有醫院的所有專科的收益均錄得可觀增長，主要受本集團服務需求的推動。尤其是，(a) 婦產科有關科室仍為我們最強的科室，而婦產科有關科室的收益錄得7.6%的同比增長。本集團婦產科有關科室繼續成為本集團穩定的收益驅動力，有關增加主要由於擴充婦產科有關科室勞動力及醫療設施；以及我們於VIP中心的婦產科服務的增長所致；(b) 心血管有關科室的收益錄得36.5%的強勁同比增長，主要由於我們於二零一八年八月新收購的眾聯心血管醫院的收益貢獻以及我們於廣東省心血管疾病治療的聲譽持續增長所致；(c) 內科有關科室的收益亦錄得20.9%的可觀同比增長，主要是由於聘請信譽較高的醫護專家及專業人員以提升服務質素及治療效果所致；(d) 神經醫學有關科室的收益錄得24.0%的同比增長，主要是由於僱用新的神經病學專家，提升我們的整體醫療能力；及(e) 腫瘤有關科室錄得80.3%的大幅度同比增長，主要是由於二零一七年聘請腫瘤專家，自此吸引更多病人前往康華醫院。本集團將持續增聘該領域的醫療專家及人才，加快相關醫療設備的引進及投用流程，全面推動該等科室的發展，以提高對重症腫瘤病人的接收及治療能力。

Management Discussion and Analysis

管理層討論及分析

In 2019, the Group's main revenue driving strategies of our hospital services segment are:

- (i) *Cardiovascular disciplines*: The Group is cooperating with Provincial People's Hospital in all aspects, attracting well-known experts, improving the level of interventional treatment of complex Chronic Total Occlusion pathological changes in the Cardiac Centre and further expanding the influence of specialty practices;
- (ii) *Neurology disciplines*: The Group is establishing the Neuroscience Neural Care Unit, expanding wards, developing further facilities in the Stroke Centre and cooperating with lower-level hospitals;
- (iii) *Oncology disciplines*: The Group is using new radiotherapy equipment to consolidate and improve its advantages in the treatment of and technology used for nasopharyngeal cancer, breast cancer and cervical cancer, compared to others in the industry. The Group is further cooperating with the Cancer Centre of the University of Hong Kong-Shenzhen Hospital; and
- (iv) *Emergency medicine related disciplines*: The Group is establishing emergency wards, Emergency Intensive Care Unit wards, and Trauma Treatment Centres. The Group is also excelling in the treatment of trauma patients, strengthening the development of Extracorporeal Membrane Oxygenation (ECMO) technology, conducting emergency applications of ECMO technology and building a training base for cardiopulmonary cerebral resuscitation. Moreover, the Group is establishing additional Intensive Care Unit wards and increasing the number of beds in its hospitals. The Group is additionally developing treatment for certain diseases (severe pancreatitis and sepsis) and expanding its superior projects (Continuous Renal Replacement Therapy and ECMO technologies).

於二零一九年，本集團醫院服務分部的主要收益驅動策略為：

- (i) *心血管科*：本集團與省人民醫院各方面合作，吸引知名專家，提高心臟中心的複雜慢性完全閉塞病變介入治療水平，並進一步擴大專業做法的影響力；
- (ii) *神經科*：本集團正在卒中中心設立神經醫學神經系統疾病加護病房、擴大病房、開發更多設施，並與下級醫院合作；
- (iii) *腫瘤科*：與業內其他公司相比，本集團正在使用新的放射治療設備鞏固及改善其在鼻咽癌、乳腺癌及宮頸癌治療及技術方面的優勢。本集團正與香港大學深圳醫院癌症中心合作；及
- (iv) *急診有關科室*：本集團正在設立急診科病房、急診重病監護病房及創傷救治中心。本集團在創傷患者的治療、加強體外膜肺氧合(ECMO)技術的發展、開展ECMO技術的應急應用以及建立心肺腦復蘇訓練基地方面亦表現出色。此外，本集團正在設立更多的重症監護病房，並增加其醫院的病床數目。本集團正在開發若干疾病(重症胰腺炎及膿毒症)的治療，並擴充其優越項目(連續性腎臟替代治療及ECMO技術)。



Management Discussion and Analysis

管理層討論及分析

The Group's special services are high-end healthcare services that extend beyond basic medical services and are specifically catered for the more affluent patients who are willing to pay a premium for higher quality and customised services not generally available in public hospitals. The Group's special services consist of VIP healthcare services, reproductive medicine, plastic and aesthetic surgery and laser treatment. In first half of 2019, the total revenue derived from special services amounted to RMB90.6 million (six months ended 30 June 2018: RMB72.7 million), representing a period-on-period increase of 24.6%. In the first half of 2019, the average spending per inpatient visit of VIP healthcare services amounted to RMB29,830.5 (six months ended 30 June 2018: RMB23,785.9), representing a period-on-period increase of 25.4%, primarily attributable to our quality service offerings from Huaxin Building (a complex in Kanghua Hospital dedicated to VIP healthcare services), including comprehensive O&G services dedicated to VIP patients and our ability to increase the pricing as our services mature. Our revenue from VIP inpatient services recorded RMB35.6 million (six months ended 30 June 2018: RMB21.6 million), representing a period-on-period increase of 64.8%, primarily driven by the increase in average spending as our O&G service offerings at our VIP inpatient centre continues to gain reputation and market demand. Furthermore, our revenue from VIP outpatient service amounted to RMB19.3 million (six months ended 30 June 2018: RMB15.0 million), representing a period-on-period increase of 28.7%.

However, our revenue from reproductive medicine has dropped to RMB27.7 million (six months ended 30 June 2018: RMB29.5 million) with a period-on-period decrease of 6.1%. The drop of reproductive medicine is mainly caused by the retirement of a reproductive medicine specialist at Kanghua Hospital and the gradually stabilising demand due to the two-child policy in the Guangdong Province since its launch in year 2016.

本集團的特殊服務是在大眾醫療的基礎上延伸出的高端化醫療服務，主要針對高收入患者，彼等願意為普通公立醫院難以提供的高品質、定制化服務支付額外費用。本集團的特殊服務包括貴賓醫療服務、生殖醫學、整形及美容手術及激光治療。於二零一九年上半年，來自特殊服務的總收益為人民幣90.6百萬元（截至二零一八年六月三十日止六個月：人民幣72.7百萬元），同比增長24.6%。於二零一九年上半年，貴賓醫療服務的每住院人次平均開支為人民幣29,830.5元（截至二零一八年六月三十日止六個月：人民幣23,785.9元），同比增長25.4%，主要是由於華心樓（康華醫院專門用於貴賓醫療服務的綜合大樓）可提供優質的高端服務（包括開放貴賓婦產科服務）及我們在服務成熟時提高定價的能力。我們的貴賓住院服務收益錄得人民幣35.6百萬元（截至二零一八年六月三十日止六個月：人民幣21.6百萬元），同比增長64.8%，主要受平均支出增加的推動，因為我們的貴賓住院中心的婦產科服務繼續贏得聲譽及市場需求。此外，我們貴賓門診服務的收益為人民幣19.3百萬元（截至二零一八年六月三十日止六個月：人民幣15.0百萬元），同比增長28.7%。

然而，我們的生殖醫學收益已下降至人民幣27.7百萬元（截至二零一八年六月三十日止六個月：人民幣29.5百萬元），同比下降6.1%。生殖醫學的下降主要是由於康華醫院的生殖醫學專家退休以及因廣東省自二零一六年推出二胎政策以來需求逐漸穩定。



Management Discussion and Analysis

管理層討論及分析

The table below sets forth some key operating data and revenue for the Group's special services:

下表列出本集團特殊服務的若干關鍵營運數據及收益：

Special Services	特殊服務	Change 變動	For the six months ended 30 June 截至六月三十日止六個月	
			2019 二零一九年	2018 二零一八年
VIP healthcare services	貴賓醫療服務			
Inpatient visits	住院人次	+31.6%	1,192	906
Outpatient visits	門診人次	+18.9%	32,488	27,330
Revenue (RMB'000)	收益(人民幣千元)	+50.1%	54,820	36,529
Reproductive medicine	生殖醫學			
Number of outpatient visits	門診人次	-8.3%	26,602	29,019
Revenue (RMB'000)	收益(人民幣千元)	-6.0%	27,720	29,488
Plastic and aesthetic surgery	整形美容外科			
Revenue (RMB'000)	收益(人民幣千元)	+20.7%	2,725	2,258
Laser treatment	激光治療			
Revenue (RMB'000)	收益(人民幣千元)	+20.9%	5,303	4,387
Total revenue from special services (RMB'000)	特殊服務的總收益 (人民幣千元)	+24.6%	90,568	72,662

Rehabilitation and other Healthcare Services

During the first half of 2018, the Group have successfully acquired 57% equity interest in Anhui Hualin. Anhui Hualin directly and indirectly (through its wholly-owned subsidiary) holds sponsor interests in the managed and controlled entities, all of which are private non-enterprise entities in the PRC. At the date of this interim report, our rehabilitation and other healthcare services segment has two rehabilitation hospitals, one rehabilitation clinic, one Class I general hospital, nine rehabilitation centres for the disabled, one vocational training school and one pharmacy store company in Anhui Province, the PRC (collectively referred to as the "Anhui Hualin Group"). The Anhui Hualin Group has generated significant synergistic value to the Group and expanded our presence in the rehabilitation healthcare sector in the PRC.

Anhui Hualin Group currently employs more than 500 staff and has served more than 50,000 patients in 2018. The Anhui Hualin Group has a stable cooperation with the Anhui Disabled Persons Federation and local governments in the provision of home-based care services for the elderly and training services for the disabled. The Anhui Hualin Group is also a major organisation offering children rehabilitation services in Anhui Province, the PRC.

康復及其他醫療服務

於二零一八年上半年，本集團成功收購安徽樺霖的57%股權。安徽樺霖直接及間接（透過其全資附屬公司）持有受管理及控制實體的舉辦者權益，而該等實體均為中國的民辦非企業單位。於本中期報告日期，我們的康復及其他醫療服務分部擁有中國安徽省兩間康復醫院、一間康復門診、一間一級綜合醫院、九間殘疾人康復中心、一間職業培訓學校及一間藥店公司（統稱為「安徽樺霖集團」）。安徽樺霖集團為本集團帶來了巨大的協同價值，並擴大了我們在中國康復醫療行業的影響力。

安徽樺霖集團目前擁有500多名員工，二零一八年患者超過50,000名。安徽樺霖集團與安徽省殘疾人聯合會及當地政府在提供老年人居家養老及殘疾人培訓服務方面有著穩定的合作關係。安徽樺霖集團亦為中國安徽省提供兒童康復服務的主要機構。

Management Discussion and Analysis

管理層討論及分析

As at 30 June 2019, the three hospitals operated by Anhui Hualin Group have a total of 220 registered beds. During the Reporting Period, Anhui Hualin Group had 12,562 (from 1 April 2018 to 30 June 2018: 7,361) outpatient visits, 890 (from 1 April 2018 to 30 June 2018: 567) inpatient visits and served 29,212 (from 1 April 2018 to 30 June 2018: 3,718) rehabilitation patients. Revenue from rehabilitation and other healthcare services amounts to RMB35.6 million (from 1 April 2018 to 30 June 2018: RMB14.7 million), representing a period-on-period increase of 142.8%.

Since the completion of the acquisition, with the support of the Group's resources, capital and development strategy, Anhui Hualin Group has developed steadily, with its network of medical institutions constantly expanding. Following the successful opening of the Hefei Kanghua Rehabilitation Hospital in 2018, in the first half of 2019, after participating in the government's public bidding, Anhui Hualin Group successfully won the bids of two rehabilitation centre projects: the Changfeng County Beicheng Rehabilitation Centre and the Feixi County Kanghua Children's Rehabilitation Centre, which are scheduled to commence operations in October 2019.

In the first half of 2019, Anhui Hualin Group actively developed its network of institutions, while also focusing on the development and operation of existing medical institutions and rehabilitation centres. In this period, the newly established Hefei Kanghua Rehabilitation Hospital also entered into the formal operation stage from the trial operation stage. By creating a customisable management method, actively exploring and fostering referral channels, as well as developing rehabilitation specialties, the Group has successfully strengthened its brand image in the local area. In the first half of 2019, the hospital also entered into out-patient and in-patient medical insurance agreements with Hefei Medical Insurance Centre, pursuant to which it has obtained the qualifications of a locally designated medical insurance institution. In addition, the Group's chain rehabilitation centres actively increased its business volume with the help of resources, venues, scale, experience and other advantages, enhancing overall brand influence in Anhui Province's rehabilitation market.

於二零一九年六月三十日，安徽樺霖集團經營的三間醫院共有220張註冊床位。於報告期內，安徽樺霖集團的門診人次、住院人次及康復服務接待人數分別達12,562名（二零一八年四月一日至二零一八年六月三十日：7,361名）、890名（二零一八年四月一日至二零一八年六月三十日：567名）及29,212名（二零一八年四月一日至二零一八年六月三十日：3,718名）。康復及其他醫療服務的收益為人民幣35.6百萬元（二零一八年四月一日至二零一八年六月三十日：人民幣14.7百萬元），同比增加142.8%。

自收購事項完成以來，在本集團資源、資金及發展戰略的支持下，安徽樺霖集團穩步發展，醫療機構網絡不斷擴大。繼二零一八年合肥康華康復醫院成功開業後，安徽樺霖集團於二零一九年上半年參與政府公開招標並成功中標兩個康復中心項目，包括：長豐縣北城康復中心及肥西縣康華兒童康復中心，計劃於二零一九年開始投入營運。

於二零一九年上半年，安徽樺霖集團積極開發機構網絡的同時亦注重現有醫療機構及康復中心的開發及營運。在此期間，新設立的合肥康華康復醫院亦從試營運階段進入正式營運階段。通過建立定制化管理模式，積極開拓和發展轉診渠道以及打造特色康復專科，本集團成功在當地提升品牌形象。二零一九年上半年，該醫院亦與合肥市醫保中心簽訂門診和住院醫保協議，從而取得當地醫保定點機構資質。此外，本集團旗下各連鎖康復中心亦借助資源、場地、規模、經驗等優勢積極增大業務量，在安徽省的康復市場打造出品牌的整體影響力。



Management Discussion and Analysis

管理層討論及分析

In the future, Anhui Hualin Group will continue to accrue talents through various channels and training, constantly enhance its medical software and hardware configuration, comprehensively improve the level of its medical services, further increase its business revenue, and continue to make beneficial contributions to the Group.

Hospital Management Services

In 2016, the Group entered into a management agreement with Zhonglian Cardiovascular Hospital. It was the Group's first managed hospital and represented its first step of extending the Group's presence to outside of Guangdong Province. Zhonglian Cardiovascular Hospital commenced operations in March 2017 and has developed at a promising pace.

In August 2018, the Group completed the acquisition of 60% equity interest of Zhonglian Cardiovascular Hospital, which has since become a non-wholly-owned subsidiary of the Company. The Board considers that full integration and consolidation of Zhonglian Cardiovascular Hospital into the Group's operations will enable the Group to benefit from the operating prospects of Zhonglian Cardiovascular Hospital to a greater extent in the long term. Since the acquisition of Zhonglian Cardiovascular Hospital and up to the date of this interim report, the Group has had no other management arrangement with third party hospitals. The Company will continue to search for appropriate opportunities to undertake hospital management operations.

Sale of Pharmaceutical Products

The Group's sale of pharmaceutical products segment includes a pharmaceuticals and medical consumables trading company established for the purpose of streamlining pharmaceuticals and medical consumables sales directly to the patients at the Group's hospitals and walk-in customers who may not be patients of the Group's hospitals. The operation of this pharmacy company has in general lowered our overall cost of revenue through centralizing of purchase function and thereby increasing the overall margin of the Group. Revenue from sales of pharmaceutical products for the Reporting Period amounted to RMB8.8 million (six months ended 2018: RMB6.9 million), representing a period-on-period increase of 27.5%.

未來，安徽樺霖集團將堅持多途徑人才引進及培養，不斷夯實醫療軟件及硬件配置，全面提升醫療服務水平，進一步提升業務收益並繼續為本集團作出利好貢獻。

醫院管理服務

於二零一六年，本集團已與眾聯心血管病醫院訂立管理協議。此乃本集團管理的首間醫院，代表本集團向廣東省外擴張業務的第一步。眾聯心血管病醫院於二零一七年三月開始運營，發展勢頭良好。

於二零一八年八月，本集團完成收購眾聯心血管病醫院60%的股權，眾聯心血管病醫院自此成為本公司的非全資附屬公司。董事會認為，將眾聯心血管病醫院全面整合及合併至本集團的運營中，可使本集團從該醫院的經營前景中獲得顯著的長期收益。自收購眾聯心血管病醫院及直至本中期報告日期，本集團並無與第三方醫院的其他管理安排。本公司將繼續尋找適當機會承接醫院管理業務。

銷售藥品

本集團銷售藥品分部包括為將藥品及醫療耗材直接銷售予本集團醫院的患者以及非本集團醫院患者的上門客戶而設立的藥品及醫療耗材貿易公司。該製藥公司的運作一般透過集中採購功能降低我們的整體收益成本，從而提高本集團的整體利潤率。報告期內銷售藥品的收益為人民幣8.8百萬元（截至二零一八年六月三十日止六個月：人民幣6.9百萬元），同比增長27.5%。

Management Discussion and Analysis

管理層討論及分析

Industry Outlook and Strategy

Entering 2019, the One Belt One Road Initiative had been promoted in all aspects and the strategy of Healthy China 2030 had been fully implemented. The demand for an international healthcare market had also increased, and the healthcare consumption upgrade of domestic had quickened. In the first half of 2019, new policies in the field of medicine and healthcare were frequently instituted in China and the pace of medical reform was further accelerated. Among these policies, those which are important for the direction of the medical services industry include:

- (1) *Promoting social capital to run medical services*: policies are encouraging and supporting social capital to provide medical services, including simplifying the process of assessment and obtaining approval, promoting the division of labor between public medical institutions and social medical service providers, improving medical insurance support policies and improving the consolidated regulatory system.
- (2) *Implementing diagnosis-related group payment*: policies are promoting the change of medical insurance payment methods from “payment by project” to “payment by disease”. That is, setting a fixed reimbursement standard for each disease and reimbursing the expenses to medical institutions by medical insurance institutions in accordance with a unified standard. This new method of payment will effectively solve the problem of excessive drug use in hospitals, unreasonable inspections and treatment plans and improve the quality of medical services.
- (3) *Supporting the inheritance and innovation of Traditional Chinese Medicine (“TCM”)*: policies are strengthening the training of talents in TCM, including through promoting the combination of college education and doctor-accepted education and improving the evaluation system of professional titles of TCM doctors. Simultaneously, the state will be supporting the construction of scientific research and innovation arrangements such as TCM laboratories, as well as increasing pilot clinical collaborations between TCM and Western medicine for major and difficult diseases.
- (4) *Encouraging the construction of elderly care services system with the combination of medical care and nursing care*: policies are strengthening market mechanisms, improving the training of nursing professionals for the elderly and encouraging social forces to participate in the elderly care services market. This will continuously improve the elderly care services system which is predicated on home care and relies on the social community, effectively meeting the diversified and multi-level needs of medical care and elderly services of the elderly.

行業前景及策略

步入二零一九年，「一帶一路」戰略全面推進，「健康中國2030」戰略全面實施，國際醫療市場需求回暖，國內醫療消費升級加速。二零一九年上半年，中國醫藥健康領域新政策頻出，醫療改革的節奏進一步加快，其中給予醫療服務行業的重要導向包括：

- (1) *促進社會辦醫*：鼓勵及支持社會辦醫，包括簡化準入審批服務；促使公立醫療機構與社會辦醫者分工合作；完善醫療保險支持政策以及完善綜合監管體系。
- (2) *實施疾病診斷相關分組支付*：推動醫保支付方式從「按項目支付」到「按病種支付」的變革，即制定每種疾病的定額償付標準，並由醫保機構依照統一標準向醫療機構報銷費用。此支付方式將有效解決醫院過量用藥以及檢查項目和治療方案不合理的問題，提高醫療服務質量。
- (3) *支持中醫藥（「中醫藥」）事業的傳承和創新發展*：加強中醫藥人才培養，包括促進院校教育和醫師承教育相結合，以及完善中醫師職稱評定制度。同時，國家將支持建設中醫藥實驗室等科研創新體系，以及增加針對重大疑難疾病的中西醫臨床協作試點。
- (4) *鼓勵建設醫養結合的養老服務體系*：健全市場機制，強化養老護理專業人員培訓以及鼓勵社會力量參與養老服務市場，從而持續完善以居家為基礎、以社區為依托的養老服務體系，有效滿足老年人多樣化、多層次的養老及醫療服務需求。

(5) *Continuing to promote the construction of medical association:* policies are further integrating and medical resources are being shared within the regions. Additionally, policies are accelerating the establishment of a graded diagnosis and treatment model that consists of a first diagnosis in primary hospitals, a two-way referral system between higher and lower hospitals and the division of treatment for acute and chronic diseases.

In the first half of 2019, closely following the trend of medical reform policies, the Group actively promoted the establishment of the Medical Association and deepened the layout strategy of its medical network through constantly consolidating the quality of its own medical services. In the future, it is believed that under the relevant support policies, the Group will further optimize its medical management system, focus on the development of key and characteristic specialties, develop a comprehensive layout in the One Health industry and expand its industry influence.

Future Plans for Material Investments and Capital Assets

Save as disclosed in this interim report, the Group does not have other plans for material investments or capital assets as of the date of this interim report.

(5) 繼續推動醫聯體組建：進一步整合共享區域內醫療資源，加快建立基層醫院首診、上下級醫院雙向轉診、急慢性疾病分治的分級診療模式。

二零一九年上半年，本集團緊隨醫改政策動向，在不斷夯實自身醫療服務質量的基礎上，積極推動醫聯體的組建和深化醫療網絡布局戰略。未來，相信在相關政策的扶持下，本集團將進一步優化醫療管理體系，專注發展重點及特色專科，以及開拓在大健康領域的全方位布局，擴大康華的行業影響力。

重大投資及資本資產之未來計劃

除本中期報告披露者外，本集團於本中期報告日期並無其他重大投資計劃或資本資產計劃。

Management Discussion and Analysis

管理層討論及分析

FINANCIAL REVIEW

Segment Revenue

The Group generates revenue primarily from: (i) hospital services – providing healthcare services through its owned hospitals, namely Kanghua Hospital, Renkang Hospital and Zhonglian Cardiovascular Hospital (since August 2018), comprising inpatient healthcare services, outpatient healthcare services and physical examination services; (ii) rehabilitation and other healthcare services – providing rehabilitation services to patients with physical or mental disabilities and other healthcare related services including elderly care and training service for the disabled; (iii) providing hospital management services to a hospital owned by an independent third party; (iv) sale of pharmaceutical products and medical consumables to patients of the Group's hospitals and walk-in customers who may not be patients of the Group's hospitals; and (v) others.

The following tables below set forth the revenue, costs of revenue, gross profit and gross profit margin of the Group by segment for the periods indicated:

For the six months ended 30 June 2019 (unaudited)

		Hospital services	Rehabilitation and other healthcare services 康復及其他	Sale of pharmaceutical products	Others	Total
		醫院服務 RMB' 000 人民幣千元	醫療服務 RMB' 000 人民幣千元 (Note) (附註)	銷售藥品 RMB' 000 人民幣千元	其他 RMB' 000 人民幣千元	總計 RMB' 000 人民幣千元
Revenue	收益	869,434	35,569	8,839	522	914,364
Cost of revenue	收益成本	(694,153)	(27,385)	(6,786)	(94)	(728,418)
Gross profit	毛利	175,281	8,184	2,053	428	185,946
Gross profit margin	毛利率	20.2%	23.0%	23.2%	82.0%	20.3%

財務回顧

分部收益

本集團主要從以下各項賺取收益：(i) 醫院服務 – 通過其本身擁有的醫院（即康華醫院、仁康醫院及眾聯心血管病醫院（自二零一八年八月起））提供醫療服務，包括住院醫療服務、門診醫療服務及體檢服務；(ii) 康復及其他醫療服務 – 為身體或精神殘疾病人提供康復服務及其他醫療相關服務，包括老年護理及殘疾人訓練服務；(iii) 為一名獨立第三方擁有的醫院提供醫院管理服務；(iv) 向本集團醫院的病人及未必為本集團醫院病人的步入式客戶銷售藥品及醫療耗材；及(v) 其他。

下表載列所示期間本集團按分部劃分的收益、收益成本、毛利及毛利率：

截至二零一九年六月三十日止六個月（未經審核）

Management Discussion and Analysis

管理層討論及分析

For the six months ended 30 June 2018 (unaudited)

截至二零一八年六月三十日止六個月(未經審核)

		Hospital services	Rehabilitation and other healthcare services	Hospital management services	Sales of pharmaceutical products	Total
		醫院服務	康復及其他醫療服務	醫院管理服務	銷售藥品	總計
		RMB' 000	RMB' 000	RMB' 000	RMB' 000	RMB' 000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
			(Note)			
			(附註)			
Revenue	收益	715,093	14,651	1,922	6,923	738,589
Cost of revenue	收益成本	(557,289)	(6,832)	(941)	(5,479)	(570,541)
Gross profit	毛利	157,804	7,819	981	1,444	168,048
Gross profit margin	毛利率	22.1%	53.4%	51.0%	20.9%	22.8%

Note: The operation of rehabilitation and other healthcare services was acquired in April 2018.

附註：康復及其他醫療服務之業務營運於二零一八年四月收購。

Revenue from the Group's hospital services amounted to RMB869.4 million (six months ended 30 June 2018: RMB715.1 million), representing a period-on-period increase of 21.6%, accounting for 95.1% (six months ended 30 June 2018: 96.8%) of the total revenue of the Group.

本集團醫院服務的收益為人民幣869.4百萬元(截至二零一八年六月三十日止六個月：人民幣715.1百萬元)，同比增長21.6%，佔本集團總收益95.1%(截至二零一八年六月三十日止六個月：96.8%)。

Management Discussion and Analysis

管理層討論及分析

Revenue from hospital services comprised of (i) revenue from inpatient healthcare services amounting to RMB536.2 million (six months ended 30 June 2018: RMB426.2 million), representing a period-on-period increase of 25.8%, accounting for 58.6% (six months ended 30 June 2018: 57.7%) of the total revenue of the Group; (ii) revenue from outpatient healthcare services amounting to RMB299.6 million (six months ended 30 June 2018: RMB258.8 million), representing a period-on-period increase of 15.8%, accounting for 32.8% (six months ended 30 June 2018: 35.0%) of the total revenue of the Group; and (iii) revenue from physical examination services amounting to RMB33.7 million (six months ended 30 June 2018: RMB30.2 million), representing a period-on-period increase of 11.6%, accounting for 3.7% (six months ended 30 June 2018: 4.1%) of the total revenue of the Group. The increase in revenue from hospital services is mainly due to (i) an increase in the number of inpatient, outpatient and physical examination visits during the period and an increase in overall average spending during the period; (ii) the continuing strong growth in revenue across all of our major disciplines and our VIP special services; and (iii) the consolidation of revenue from Zhonglian Cardiovascular Hospital (acquired since August 2018). During the first half of 2019, the revenue from our VIP special services accounts for approximately 9.9% of the Group's total revenue (six months ended 30 June 2018: 9.8%) and 10.4% of the Group's revenue from our hospital services segment (six months ended 30 June 2018: 10.2%). The solid growth in revenue from our hospital services has demonstrated that the demand of our service continues to remain strong and the reputation of the Kanghua brand has further strengthened especially in the Guangdong region.

Revenue from rehabilitation and other healthcare services amounted to RMB35.6 million (six months ended 30 June 2018: RMB14.7 million), representing a period-on-period increase of 142.2%, accounting for 3.9% (six months ended 30 June 2018: 2.0%) of the total revenue of the Group. In April 2018, the Group acquired Anhui Hualin which is principally engaged in provision of rehabilitation services to the patients with physical or mental disabilities and other healthcare related services including care services for elderly and training service for the disabled. The increase in revenue is mainly attributable to the establishment of Hefei Kanghua Rehabilitation Hospital in November 2018 (a rehabilitation specialty hospital aiming to be rated as a class III rehabilitation hospital) and the transformation of other rehabilitation hospitals and centres within Anhui Hualin Group, which has drawn patient visits in the Anhui region.

醫院服務的收益包括(i)住院醫療服務的收益人民幣536.2百萬元(截至二零一八年六月三十日止六個月:人民幣426.2百萬元),同比增長25.8%,佔本集團總收益58.6%(截至二零一八年六月三十日止六個月:57.7%);(ii)門診醫療服務的收益人民幣299.6百萬元(截至二零一八年六月三十日止六個月:人民幣258.8百萬元),同比增長15.8%,佔本集團總收益32.8%(截至二零一八年六月三十日止六個月:35.0%);及(iii)體檢服務的收益人民幣33.7百萬元(截至二零一八年六月三十日止六個月:人民幣30.2百萬元),同比增長11.6%,佔本集團總收益3.7%(截至二零一八年六月三十日止六個月:4.1%)。醫院服務的收益增長主要由於:(i)期內住院、門診及體檢人次增加以及平均開支全面增加;(ii)主要科室及VIP特殊服務的收益持續強勁增長;及(iii)眾聯心血管病醫院(自二零一八年八月起收購)的收益合併。於二零一九年上半年,VIP特殊服務的收益約佔本集團總收益9.9%(截至二零一八年六月三十日止六個月:9.8%)及佔本集團醫院服務分部收益的10.4%(截至二零一八年六月三十日止六個月:10.2%)。我們醫院服務收益的穩健增長表明我們服務的需求持續強勁,康華品牌的聲譽進一步增強,特別是在廣東地區。

康復及其他醫療服務的收益為人民幣35.6百萬元(截至二零一八年六月三十日止六個月:人民幣14.7百萬元),同比增加142.2%,佔本集團總收益3.9%(截至二零一八年六月三十日止六個月:2.0%)。於二零一八年四月,本集團收購安徽樺霖,其主要從事為身體或精神殘障人士提供康復服務及其他醫療相關服務,包括長者護理服務及傷殘人士培訓服務。收益增加主要歸因於合肥康華康復醫院(一家以評級為三級康復醫院為發展目標的康復專科醫院)於二零一八年十一月設立以及安徽樺霖集團內其他康復醫院及中心的改造,吸引安徽地區的患者前來就診。

During the six months ended 30 June 2019, the Group did not have any revenue from the hospital management services segment (six months ended 30 June 2018: RMB1.9 million). Our hospital management agreement with Zhonglian Cardiovascular Hospital ceased when the Group acquired the controlling interest in Zhonglian Cardiovascular Hospital in August 2018.

Revenue from sale of pharmaceutical products and medical consumables amounted to RMB8.8 million (six months ended 30 June 2018: RMB6.9 million), representing a period-on-period increase of 27.7%, accounting for 1.0% (six months ended 30 June 2018: 0.9%) of the total revenue of the Group. The increase in revenue is mainly attributable to the increase in the number of outpatient visits in both Kanghua Hospital and Renkang Hospital which drove pharmaceutical and medical consumable sales within both hospitals.

Cost of Revenue

Cost of revenue of the Group's hospital services segment (consisting of inpatient healthcare services, outpatient healthcare services and physical examination services) primarily consisted of pharmaceuticals, medical consumables, staff cost, depreciation, service expenses, utilities expenses, rental expenses and other costs. Cost of revenue of the Group's hospital services segment increased to RMB694.2 million (six months ended 30 June 2018: RMB557.3 million), representing a period-on-period increase of 24.6%. The significant increase in cost of revenue of our hospital services segment is mainly attributable to full consolidation of the cost incurred at Zhonglian Cardiovascular Hospital, which has caused the increase in cost of revenue more rapidly than revenue. As Zhonglian Cardiovascular Hospital is still at its initial stage of ramping up its operation, during the Reporting Period, it is running at negative gross margin.

Cost of revenue of the Group's rehabilitation and other healthcare services segment amounted to RMB27.4 million (six months ended 30 June 2018: RMB6.8 million), representing a period-on-period increase of 302.9%, and primarily consisted of staff costs, medical consumables, depreciation, utilities and rental expenses. The significant increase in cost of revenue of our rehabilitation and other healthcare services segment is mainly attributable to the full consolidation of the Anhui Hualin Group's result for the Reporting Period as compared to only three months last year since its acquisition in April 2018 and the rise in operating cost relating to the new Hefei Kanghua Rehabilitation Hospital which was established in November 2018.

截至二零一九年六月三十日止六個月，本集團並無任何來自醫院管理服務分部的收益（截至二零一八年六月三十日止六個月：人民幣1.9百萬元）。本集團於二零一八年八月收購眾聯心血管醫院的控股權益後，我們與眾聯心血管醫院訂立的醫院管理協議已終止。

銷售藥品及醫療消耗品的收益為人民幣8.8百萬元（截至二零一八年六月三十日止六個月：人民幣6.9百萬元），同比增長27.7%，佔本集團的總收益1.0%（截至二零一八年六月三十日止六個月：0.9%）。收益增加主要由於康華醫院及仁康醫院的門診人次增加，促進兩間醫院的藥品及醫療消耗品銷售所致。

收益成本

本集團醫院服務分部（包括住院醫療服務、門診醫療服務及體檢服務）的收益成本主要包括藥品、醫療消耗品、員工成本、折舊、服務開支、水電費、租金開支和其他成本。本集團醫院服務分部的收益成本增加至人民幣694.2百萬元（截至二零一八年六月三十日止六個月：人民幣557.3百萬元），同比增長24.6%。我們醫院服務分部的收益成本大幅增加，主要由於眾聯心血管醫院的成本全面合併，導致收益成本較收益增長更快所致。由於眾聯心血管病醫院在報告期內仍處於加速運作的初始階段，故其毛利率仍為負值。

本集團的康復及其他醫療服務的收益成本為人民幣27.4百萬元（截至二零一八年六月三十日止六個月：人民幣6.8百萬元），同比增長302.9%，主要包括員工成本、醫療消耗品、折舊、水電費及租金開支。康復及其他醫療服務分部的收益成本大幅增加主要由於二零一八年四月收購以來，安徽樺霖集團於報告期內的業績較去年三個月實現全面整合以及與二零一八年十一月設立的新合肥康華康復醫院相關的營運成本上升所致。

Management Discussion and Analysis

管理層討論及分析

During the six months ended 30 June 2019, the Group did not have any cost of revenue from our hospital management services segment (six months ended 30 June 2018: RMB0.94 million). Our hospital management agreement with Zhonglian Cardiovascular Hospital ceased when the Group acquired the controlling interest in Zhonglian Cardiovascular Hospital in August 2018.

Cost of revenue of the Group's sales of pharmaceutical products segment amounted to RMB6.8 million (six months ended 30 June 2018: RMB5.5 million), representing a period-on-period increase of 23.6%, mainly representing cost of purchase of pharmaceutical and medical consumable products, which is in line with the increase in revenue.

For the six months ended 30 June 2019, pharmaceuticals, medical consumables and staff cost accounted for approximately 32.0% (six months ended 30 June 2018: 33.8%), 27.3% (six months ended 30 June 2018: 27.0%) and 27.5% (six months ended 30 June 2018: 27.3%), respectively, of the total cost of revenue of the Group. Our total staff related costs including salary, bonus and other benefits had increased by 21.1% as compared with the prior period, mainly attributable to an increase in general salary level and bonus and impact of full consolidation of Anhui Hulin Group and Zhonglian Cardiovascular Hospital in the current period.

截至二零一九年六月三十日止六個月，本集團並無任何來自醫院管理服務分部的收益成本（截至二零一八年六月三十日止六個月：人民幣0.94百萬元）。本集團於二零一八年八月收購眾聯心血管醫院的控股權益後，我們與眾聯心血管醫院訂立的醫院管理協議已終止。

本集團銷售藥品分部的收益成本增加至人民幣6.8百萬元（截至二零一八年六月三十日止六個月：人民幣5.5百萬元），同比增長23.6%，主要指藥品及醫療消耗品採購成本，與收益增長相符。

截至二零一九年六月三十日止六個月，藥品、醫療消耗品及員工成本分別佔本集團總收益成本約32.0%（截至二零一八年六月三十日止六個月：33.8%）、27.3%（截至二零一八年六月三十日止六個月：27.0%）及27.5%（截至二零一八年六月三十日止六個月：27.3%）。我們的員工相關成本總額（包括薪金、花紅及其他福利）較上個期間增加21.1%，主要由於本期間安徽樺霖集團及眾聯心血管病醫院的總薪酬水平及花紅增加以及全面整合的影響所致。

Gross Profit and Gross Profit Margin

Total gross profit of the Group amounted to RMB185.9 million (six months ended 30 June 2018: RMB168.0 million), representing a period-on-period increase of 10.7%. The overall gross profit margin decreased to 20.3% (six months ended 30 June 2018: 22.8%), primarily due to:

- (i) our significant growth in cardiovascular related disciplines, neurology related disciplines, emergence medicine related disciplines and oncology related disciplines during the current period. These medical disciplines usually require treatments typically involve more delicate, precise and advanced surgeries and diagnostics support and command a higher margin than basic medical services;
- (ii) the growth in our VIP centres that are targeted towards high-end patients and typically command higher margin than basic healthcare services (VIP services related revenue recorded a period-on-period growth of 50.1%);
- (iii) the increase in the average spending of patients and the ability to increase healthcare consultation prices leveraging the reputation of the “Kanghua” brand that is gaining wider recognition in the Guangdong region; and
- (iv) however, the above impact has been considerably offset by (i) the consolidation of Zhonglian Cardiovascular Hospital which is currently running at negative gross margin and the impact of such losses accounted for the full six months period in the current Reporting Period since its acquisition in August 2018; (ii) Zhonglian Cardiovascular Hospital has incurred significant amount of fixed staff costs and other fixed costs at its initial stage of operation; (iii) an increase in overall depreciation and amortisation expenses of 322.3% caused by the impact of purchase of various new medical equipment and new leasehold improvement incurred in Kanghua Hospital, as well as the impact of application of new accounting standard (IFRS 16) relating to leases; and (iv) the rise in operating cost relating to the new Hefei Kanghua Rehabilitation Hospital which was established in November 2018.

毛利及毛利率

本集團總毛利為人民幣185.9百萬元（截至二零一八年六月三十日止六個月：人民幣168.0百萬元），同比增長10.7%。整體毛利率下降至20.3%（截至二零一八年六月三十日止六個月：22.8%），主要原因是：

- (i) 本期間心血管有關科室、神經醫學有關科室、急診有關科室及腫瘤有關科室的大幅增長。該等醫學專科通常要求治療通常涉及更精細、精確和高級的手術和診斷支援，並且比基本醫療服務具有更高的利潤率；
- (ii) 針對高端病人的VIP中心增長，通常比基本醫療服務的利潤率更高（VIP服務相關收益同比增長50.1%）；
- (iii) 病人的平均開支增加且提升醫療諮詢價格的能力因「康華」品牌在廣東地區不斷擴大知名度而增長；及
- (iv) 然而，上述影響已大幅度由以下各項抵銷(i)自二零一八年八月收購以來，眾聯心血管醫院進行合併，目前錄得負毛利率，有關虧損的影響佔據本報告期內整整六個月期間；(ii)眾聯心血管病醫院在其運作初始階段已產生大量固定員工成本及其他固定成本；(iii)康華醫院購買各種新醫療設備及新租賃裝修的影響導致整體折舊及攤銷開支增加322.3%，以及應用與租賃有關的新會計準則（國際財務報告準則第16號）的影響；及(iv)與二零一八年十一月設立的合肥康華康復醫院有關的營運成本上升。

Management Discussion and Analysis

管理層討論及分析

Key Operational Information of our Owned Hospitals

我們擁有的醫院的主要營運資料

The follow table sets forth certain key operational information of each of the hospitals owned by the Group for the periods indicated:

下表列出於所示期間本集團擁有的每間醫院的若干主要營運資料：

		For the six months ended 30 June 截至六月三十日止六個月		
		Change 變動	2019 二零一九年	2018 二零一八年
Inpatient healthcare services		住院醫療服務		
Inpatient visits:		住院人次：		
Kanghua Hospital	康華醫院	+17.5%	28,224	24,023
Renkang Hospital	仁康醫院	+6.5%	6,903	6,484
Zhonglian Cardiovascular Hospital	眾聯心血管醫院	N/A 不適用	898	N/A 不適用
Total inpatient visits	住院總人次	+18.1%	36,025	30,507
Average spending per visit (RMB)		每人次平均開支(人民幣元)		
Kanghua Hospital	康華醫院	+5.3%	15,945.3	15,137.1
Renkang Hospital	仁康醫院	-4.1%	9,251.9	9,643.7
Zhonglian Cardiovascular Hospital	眾聯心血管醫院	N/A 不適用	24,808.5	N/A 不適用
Outpatient healthcare services		門診醫療服務		
Outpatient visits:		門診人次：		
Kanghua Hospital	康華醫院	+13.4%	662,145	584,055
Renkang Hospital	仁康醫院	+6.0%	192,140	181,315
Zhonglian Cardiovascular Hospital	眾聯心血管醫院	N/A 不適用	7,587	N/A 不適用
Total outpatient visits	門診總人次	+12.6%	861,872	765,370
Average spending per visit (RMB)		每人次平均開支(人民幣元)		
Kanghua Hospital	康華醫院	+1.7%	373.1	367.0
Renkang Hospital	仁康醫院	+4.9%	256.8	244.9
Zhonglian Cardiovascular Hospital	眾聯心血管醫院	N/A 不適用	420.3	N/A 不適用
Physical examination services		體檢服務		
Physical examination visits:		體檢人次：		
Kanghua Hospital	康華醫院	+29.8%	48,928	37,700
Renkang Hospital	仁康醫院	-4.1%	27,109	28,260
Zhonglian Cardiovascular Hospital	眾聯心血管醫院	N/A 不適用	270	N/A 不適用
Total physical examination visits	體檢總人次	+15.7%	76,307	65,960

Other Income

The other income of the Group primarily consisted of bank and other interest income, fair value gain and investment income from financial assets at FVTPL, government subsidies, rental income and others. In the first half of 2019, other income amounted to RMB19.6 million (six months ended 30 June 2018: RMB28.5 million), representing a period-on-period decrease of approximately 31.2%, primarily due to (i) the decrease in fair value gain on financial assets at FVTPL to RMB5.8 million (six months ended 30 June 2018: RMB6.3 million) due to slightly worse performance of our portfolio investment fund as compared to same period last year; (ii) the decrease in investment income from financial assets at FVTPL to RMB7.2 million (six months ended 30 June 2018: RMB9.9 million) primarily due to certain principal-protected structured deposits having not yet matured during the Reporting Period; and (iii) a decrease in bank and other interest income to RMB0.6 million (six months ended 30 June 2018: RMB5.6 million) mainly due to a decrease in average bank balance and the cease of interest income from loan to Zhonglian Cardiovascular Hospital since acquisition in August 2018.

As part of the Group's cash management to maximise return on idle cash, the Group invested in certain principal-protected structured deposit products issued by a PRC commercial bank, unlisted fund and portfolio investment fund (all classified as financial assets at FVTPL) to achieve higher interest income and return without interfering with business operations or capital expenditures to earn better return on our excess cash balance.

其他收入

本集團的其他收入主要包括銀行及其他利息收入、按公平值計入損益的金融資產的公平值收益及投資收入、政府補貼、租金收入及其他。於二零一九年上半年，其他收入為人民幣19.6百萬元（截至二零一八年六月三十日止六個月：人民幣28.5百萬元），同比減少約31.2%，主要是由於(i)我們的投資組合基金表現略遜於去年同期導致按公平值計入損益的金融資產的公平值收益減少至人民幣5.8百萬元（截至二零一八年六月三十日止六個月：人民幣6.3百萬元）；(ii)於報告期內若干保本結構性存款尚未到期導致按公平值計入損益的金融資產的投資收入減少至人民幣7.2百萬元（截至二零一八年六月三十日止六個月：人民幣9.9百萬元）；及(iii)自二零一八年八月收購以來銀行平均結餘減少及向眾聯心血管醫院提供貸款的利息收入減少導致銀行及其他利息收入減少至人民幣0.6百萬元（截至二零一八年六月三十日止六個月：人民幣5.6百萬元）。

作為本集團為盡量提高閒置現金回報的現金管理的一部份，本集團投資於一家中國商業銀行發行的若干保本結構性存款產品、非上市基金以及投資組合基金（全部分類為按公平值計入損益的金融資產）以獲取更高利息收入及回報，以便在不影響業務營運或資本開支的情況下利用剩餘資金賺取更高的回報率。

Management Discussion and Analysis

管理層討論及分析

Other Expenses, Gains and Losses

The other expenses, gains and losses of the Group primarily consisted of net exchange gain, loss on disposal of property, plant and equipment, allowance for credit loss with respect to accounts receivables and donations. In the first half of 2019, other expenses, gains and losses amounted to a net loss of RMB1.0 million (six months ended 30 June 2018: net gain of RMB0.2 million), primarily due to (i) a recorded net exchange gain of RMB1.0 million (six months ended 30 June 2018: net exchange gain of RMB1.1 million) mainly arising from our Hong Kong dollar denominated financial assets; (ii) a decrease in allowance for credit loss with respect to accounts receivables to RMB0.2 million (six months ended 30 June 2018: RMB0.8 million); and (iii) donations made during the Reporting Period of RMB1.7 million (six months ended 30 June 2018: nil).

Administrative Expenses

The administrative expenses of the Group primarily consisted of staff costs, repairs and maintenance expenses, office expenses, depreciation and amortisation, rental expenses, utilities expenses, entertainment and travelling expenses and other expenses. In the first half of 2019, administrative expenses amounted to RMB113.0 million (six months ended 30 June 2018: RMB80.6 million), representing a period-on-period increase of approximately 40.2%, primarily due to (i) an increase in administrative staff related costs to RMB45.6 million (six months ended 30 June 2018: RMB32.4 million) as a result of increase in number of administrative staff headcounts; (ii) an increase in deprecation and amortisation to RMB16.6 million (six months ended 30 June 2018: RMB5.6 million) due to expansion of our operations as well as the impact of application of new accounting standard (IFRS 16) relating to leases; and (iii) an increase in overall expenses from acquisitions of Anhui Hualin and Zhonglian Cardiovascular Hospital last year.

其他開支、收益及虧損

本集團的其他開支、收益及虧損主要包括匯兌收益淨額、出售物業、廠房及設備的虧損以及有關應收賬款及捐款的信貸虧損撥備。於二零一九年上半年，其他開支、收益及虧損為淨虧損人民幣1.0百萬元（截至二零一八年六月三十日止六個月：淨收益人民幣0.2百萬元），主要由於：(i)錄得主要由我們的港元計值金融資產產生的匯兌收益淨額人民幣1.0百萬元（截至二零一八年六月三十日止六個月：匯兌收益淨額人民幣1.1百萬元）；(ii)有關應收賬款的信貸虧損撥備減少至人民幣0.2百萬元（截至二零一八年六月三十日止六個月：人民幣0.8百萬元）；及(iii)於報告期內作出捐款人民幣1.7百萬元（截至二零一八年六月三十日止六個月：零）。

行政開支

本集團的行政開支主要包括員工成本、維修及保養開支、辦公室開支、折舊和攤銷、租金開支、水電開支、交際和交通開支以及其他開支。於二零一九年上半年，行政開支為人民幣113.0百萬元（截至二零一八年六月三十日止六個月：人民幣80.6百萬元），同比增長約40.2%，主要由於：(i)行政人員增多導致行政員工相關成本增加至人民幣45.6百萬元（截至二零一八年六月三十日止六個月：人民幣32.4百萬元）；(ii)擴大我們的業務營運以及應用有關租賃的新會計政策（國際財務報告準則第16號）的影響導致折舊及攤銷增加至人民幣16.6百萬元（截至二零一八年六月三十日止六個月：人民幣5.6百萬元）；及(iii)去年收購安徽樺霖及眾聯心血管醫院的整體開支增加所致。

Finance Costs

Finance costs for the six months ended 30 June 2019 amounted to RMB6.9 million (six months ended 30 June 2018: nil). The finance costs represent the interest element relating to lease liabilities charged to profit or loss during the current period. The Group had no bank borrowing throughout both periods.

Income Tax Expenses

The income tax expenses of the Group primarily consisted of PRC enterprise income tax. In the first half of 2019 income tax expenses amounted to RMB29.1 million (six months ended 30 June 2018: RMB26.8 million), representing a period-on-period increase of approximately 8.6%. The subsidiaries of the Group are generally subject to income tax rate of 25% on their respective taxable income. Our effective tax rate for the Reporting Period is 34.4% (six months ended 30 June 2018: 23.1%), the increase is primarily due to the tax effect of tax losses for losses incurred in Anhui Hualin Group and Zhonglian Cardiovascular Hospital not being recognised.

Profit for the Period

In the first half of 2019, profit for the Reporting Period amounted to RMB55.5 million (six months ended 30 June 2018: 89.4 million), representing a period-on-period decrease of 37.9% and profit attributable to the shareholders amounted to RMB67.6 million (six months ended 30 June 2018: RMB85.6 million), representing a period-on-period decrease of approximately 21.0%.

融資成本

截至二零一九年六月三十日止六個月的融資成本為人民幣6.9百萬元(截至二零一八年六月三十日止六個月：無)。融資成本為與本期間自損益扣除的租賃負債相關的利息要素。本集團於該等期間並無籌借銀行借款。

所得稅開支

本集團的所得稅開支主要包括中國企業所得稅。於二零一九年上半年，所得稅開支為人民幣29.1百萬元(截至二零一八年六月三十日止六個月：人民幣26.8百萬元)，同比增加約8.6%。本集團之附屬公司一般須就其應課稅所得收入按25%之所得稅稅率繳納稅項。我們於報告期內的實際稅率為34.4%(截至二零一八年六月三十日止六個月：23.1%)，增加主要由於安徽樺霖集團及眾聯心血管醫院產生的稅收虧損的稅收影響未確認。

期內溢利

於二零一九年上半年，報告期內的溢利為人民幣55.5百萬元(截至二零一八年六月三十日止六個月：人民幣89.4百萬元)，同比減少約37.9%以及股東應佔溢利為人民幣67.6百萬元(截至二零一八年六月三十日止六個月：人民幣85.6百萬元)，同比減少約21.0%。

Management Discussion and Analysis

管理層討論及分析

FINANCIAL POSITION

Property, Plant and Equipment, Right-of-Use Assets and Deposits Paid for Acquisition of Property, Plant and Equipment

During the six months ended 30 June 2019, the Group acquired property, plant and equipment and incurred expenditure on construction in progress of RMB36.7 million (six months ended 30 June 2018: RMB34.1 million) and RMB32.4 million (six months ended 30 June 2018: RMB10.2 million), respectively, mainly for the purpose of upgrading and expanding the service capacity of our hospital operations.

During the six months ended 30 June 2019, the Group entered into new lease agreements for the use of properties in the PRC for 2 to 3 years. The Group is required to make fixed monthly payments. On lease commencement, the Group recognised right-of-use assets and lease liabilities of RMB1.0 million each relating to those new leases. As at 30 June 2019, the Group has right-of-use assets of RMB331.5 million which includes leasehold lands of RMB152.0 million (classified as prepaid lease payments as at 31 December 2018) and leasehold land and buildings relating to leases of RMB179.5 million recognised in accordance with IFRS 16.

In addition, as at 30 June 2019, the Group has deposits paid for acquisition of property, plant and equipment amounting to RMB101.6 million (31 December 2018: RMB81.1 million). The deposits mainly represent amount paid for acquisition of new medical equipment and other new facilities as the Group continues to upgrade its medical facilities and expand its operation capacity.

財務狀況

物業、廠房及設備、使用權資產以及就購買物業、廠房及設備支付的按金

截至二零一九年六月三十日止六個月，本集團購買物業、廠房及設備以及就在建工程產生支出分別為人民幣36.7百萬元（截至二零一八年六月三十日止六個月：人民幣34.1百萬元）及人民幣32.4百萬元（截至二零一八年六月三十日止六個月：人民幣10.2百萬元），主要用以升級及擴大我們的醫院營運的服務能力。

截至二零一九年六月三十日止六個月，本集團訂立新租賃協議，以在中國使用物業2至3年。本集團須按月支付固定費用。於租賃開始時，本集團就該等新租賃確認各自使用權資產及租賃負債人民幣1.0百萬元。於二零一九年六月三十日，本集團的使用權資產為人民幣331.5百萬元，其中包括租賃土地人民幣152.0百萬元（於二零一八年十二月三十一日分類為預付租賃款項）及根據國際財務報告準則第16號確認與租賃有關的租賃土地及樓宇人民幣179.5百萬元。

此外，於二零一九年六月三十日，本集團就購買物業、廠房及設備支付按金人民幣101.6百萬元（二零一八年十二月三十一日：人民幣81.1百萬元）。按金主要指就由於本集團繼續升級醫療設施並擴充經營能力而購買新的醫療設備及其他新設施支付的款項。

Accounts and Other Receivables

The account receivables of the Group primarily consisted of balances due to social insurance funds, certain corporate customers and individual patients. As at 30 June 2019, accounts receivables increased to RMB227.0 million (31 December 2018: RMB176.5 million), of which 76.2% (31 December 2018: 77.7%) were aged within 90 days. Average accounts receivables turnover days for the Reporting Period is 39.9 days (six months ended 30 June 2018: 29.0 days). The increase in accounts receivables and accounts receivable turnover days is primarily due to (i) expansion of the Group's hospitals operations; (ii) the temporary delay in accounts settlement from Dongguan social insurance funds due to social insurance scheme reform; and (iii) settlement of accounts from Anhui Disabled Persons Federation and certain corporate accounts are usually made towards the second half of the year.

The other receivables of the Group primarily consisted of prepayments to suppliers, interest receivables and others. As at 30 June 2019, other receivables increased to RMB32.7 million (31 December 2018: RMB30.5 million) primarily due to (i) a decrease in prepayments to suppliers to RMB9.1 million (31 December 2018: RMB11.7 million); and (ii) an increase in other receivables mainly due to expansion of the Group's operations in general.

Accounts and Other Payables

The accounts and other payables of the Group primarily consisted of accounts payables, accrued expenses, receipt in advance, payables for acquisition of property, plant and equipment, provision for medical dispute claims and others. As at 30 June 2019, accounts and other payables increased to RMB497.0 million (31 December 2018: RMB481.8 million) primarily due to (i) increase in accounts payable to RMB312.3 million (31 December 2018: RMB263.9 million) due to expansion of the Group's operations; (ii) decrease of accrued expenses to RMB53.5 million (31 December 2018: RMB77.5 million) mainly due to decrease in accrued staff salary and other operational and administrative charges at the interim date as compared with the year-end date; and (iii) decrease in payable for acquisition of property, plant and equipment to RMB46.7 million (31 December 2018: RMB54.5 million) due to settlement of certain payables for medical equipment purchases and improvement works made to our owned-hospitals during the period.

應收賬款及其他應收款項

本集團的應收賬款主要包括應付社保基金、若干公司客戶和個人病人的結餘。於二零一九年六月三十日，應收賬款增加至人民幣227.0百萬元(二零一八年十二月三十一日：人民幣176.5百萬元)，其中76.2%(二零一八年十二月三十一日：77.7%)的賬齡為90天內。報告期間平均應收賬款周轉天數為39.9天(截至二零一八年六月三十日止六個月：29.0天)。應收賬款及應收賬款周轉天數增加主要是由於(i)本集團的醫院擴大經營；(ii)社會保險計劃改革導致東莞社會保險基金賬目結算暫時延誤；及(iii)安徽省殘疾人聯合會及若干公司的賬目結算通常在下半年結算所致。

本集團的其他應收款項主要包括對供應商的預付款、應收利息及其他。於二零一九年六月三十日，其他應收款項增至人民幣32.7百萬元(二零一八年十二月三十一日：人民幣30.5百萬元)，主要由於(i)對供應商的預付款減少至人民幣9.1百萬元(二零一八年十二月三十一日：人民幣11.7百萬元)；及(ii)大概主要因擴大本集團的業務營運導致其他應收款項增加。

應付賬款及其他應付款項

本集團的應付賬款及其他應付款項主要包括應付賬款、應計開支、預收款項、收購物業、廠房及設備應付款項、醫療糾紛索賠撥備及其他。於二零一九年六月三十日，應付賬款及其他應付款項增加至人民幣497.0百萬元(二零一八年十二月三十一日：人民幣481.8百萬元)，主要由於：(i)擴大本集團的業務營運導致應付賬款增加至人民幣312.3百萬元(二零一八年十二月三十一日：人民幣263.9百萬元)；(ii)應計開支減少至人民幣53.5百萬元(二零一八年十二月三十一日：人民幣77.5百萬元)，主要由於截至中期結算日的應計員工薪金及其他營運和行政費用較年度結算日減少；及(iii)收購物業、廠房及設備應付款項減少至人民幣46.7百萬元(二零一八年十二月三十一日：人民幣54.5百萬元)，是由於在期內結算醫療設備購買及裝修工程的若干應付款項。

Management Discussion and Analysis

管理層討論及分析

Net Current Assets and Net Assets

As at 30 June 2019, the Group had net current assets of RMB204.2 million (31 December 2018: RMB286.0 million) and net assets position of RMB1,464.4 million (31 December 2018: RMB1,509.5 million).

LIQUIDITY AND CAPITAL RESOURCES

Financial Resources

The Group continued to maintain a strong financial position with cash and cash equivalents of RMB208.5 million as at 30 June 2019 (31 December 2018: RMB203.3 million). With steady cash inflow from operations and coupled with sufficient cash and bank balances, in the opinion of the Directors, the Group will have adequate and sufficient liquidity and financial resources to meet the working capital requirement of the Group for at least the next twelve months from the end of the Reporting Period.

As at 30 June 2019, the Group had investments (classified as financial assets at FVTPL) in aggregate of RMB496.3 million (31 December 2018: RMB479.1 million) primarily consisting of (i) portfolio investment fund of RMB73.8 million (31 December 2018: RMB54.0 million), representing funds deposited with a discretionary fund manager in Hong Kong mandated to achieve appropriate return consistent with the Group's cash management policy. The portfolio included a mixture of cash and shares that are primarily listed in Hong Kong; and (ii) structured bank deposits of RMB422.5 million (31 December 2018: RMB402.0 million), representing principal-protected products issued by a PRC commercial bank. As at 31 December 2018, the Group had an unlisted fund measured at fair value of US\$3.4 million (equivalent to approximately RMB23.2 million) representing an investment in equity securities of a private company in the PRC for the purpose of capital gain, strategic long-term investment and potential cooperation in healthcare. During the year ended 31 December 2018, the Group entered into an agreement to dispose the unlisted fund and the relevant gain was recognised in profit or loss during the year ended 31 December 2018.

流動資產淨值及淨資產

於二零一九年六月三十日，本集團的流動資產淨值及淨資產狀況分別為人民幣204.2百萬元(二零一八年十二月三十一日：人民幣286.0百萬元)及人民幣1,464.4百萬元(二零一八年十二月三十一日：人民幣1,509.5百萬元)。

流動資金及資本資源

財務資源

本集團於二零一九年六月三十日繼續維持強勁的財務狀況，現金及現金等價物達人民幣208.5百萬元(二零一八年十二月三十一日：人民幣203.3百萬元)。鑒於經營活動產生穩定的現金流入，加上足夠的現金及銀行結餘，董事認為，本集團將有足夠和充足的流動資金及財務資源，以滿足本集團於報告期間結束後至少未來十二個月的營運資金需求。

於二零一九年六月三十日，本集團作出投資(分類為按公平值計入損益的金融資產)合共人民幣496.3百萬元(二零一八年十二月三十一日：人民幣479.1百萬元)，主要包括(i)投資組合基金人民幣73.8百萬元(二零一八年十二月三十一日：人民幣54.0百萬元)，指授權存放至香港全權基金經理管理的基金，以達致符合本集團現金管理政策的適當回報。組合包括現金及主要在香港上市的股份；及(ii)結構性銀行存款人民幣422.5百萬元(二零一八年十二月三十一日：人民幣402.0百萬元)，指由一家中國商業銀行發行的保本產品。於二零一八年十二月三十一日，本集團按公平值計量的非上市基金3.4百萬美元(相當於約人民幣23.2百萬元)，指於中國一家私人公司的權益證券投資，以獲取資本收益、長期戰略投資及潛在醫療合作為目的。於截至二零一八年十二月三十一日止年度，本集團訂立協議出售非上市基金，而相關收益於截至二零一八年十二月三十一日止年度在損益確認。

Management Discussion and Analysis

管理層討論及分析

As part of the Group's cash management policy to manage excess cash, the Group purchases investment products from financial institutions to achieve higher interest income without interfering with business operations or capital expenditures. The Group carefully balances the risks and returns associated with the investment products when making the investment decisions. The senior management of the Group is closely involved in securitizing any decision of the Group to purchase investment products. The investment products should generally satisfy the following criteria, (i) its term should generally not exceed one year; (ii) it should not interfere with the Group's business operations or capital expenditures; (iii) it should be issued by a reputable bank with which the Group has a long-term relationship, preferably exceeding five years; and (iv) the underlying investment portfolio should generally be low risk.

Cash Flow Analysis

The table below sets forth the information as extracted from the condensed consolidated statement of cash flows of the Group for the periods indicated:

		For the six months ended 30 June		
		截至六月三十日止六個月		
		2019	2018	
		二零一九年	二零一八年	
		RMB'000	RMB'000	
		人民幣千元	人民幣千元	
		Change		
		變動		
Net cash generated from operating activities	經營活動所得現金淨額	+85.9%	65,696	35,341
Net cash used in investing activities	投資活動所用現金淨額	-16.8%	(103,762)	(124,716)
Net cash generated from (used in) financing activities	融資活動所得(所用)現金淨額	+179.1x	43,281	(243)
Net increase (decrease) in cash and cash equivalents	現金及現金等價物增加(減少)淨額	+105.8%	5,215	(89,618)

Net cash generated from operating activities

During the current period, the net cash generated from operating activities amounted to RMB65.7 million (six months ended 30 June 2018: RMB35.3 million), representing a period-on-period increase of 85.9%, which is primarily due to (i) our improved Adjusted EBITDA for the Reporting Period; and (ii) changes in working capital including increase in accounts payables.

作為本集團藉以管理超額現金的其中一項現金管理政策，本集團在不影響正常業務運作及資本支出的前提下，向金融機構購買理財投資產品，以管理超額現金並獲取更高的利息收益。本集團在制定相關投資決策時，會謹慎衡量投資產品的風險與收益。本集團高級管理層亦密切參與有關購買投資產品的一切相關決策。本集團選擇的投資產品須符合以下幾項標準：(i)其收益週期一般不超過一年；(ii)其將不涉及本集團的正常業務運作或資本支出；(iii)其應由與本集團有長期合作關係（一般超過5年）及具有良好信譽的銀行發行；及(iv)其基礎投資組合通常應具低風險。

現金流量分析

下表載列從本集團於所示期間自簡明綜合現金流量表摘錄的資料：

經營活動所得現金淨額

於本期間，經營活動所得現金淨額為人民幣65.7百萬元（截至二零一八年六月三十日止六個月：人民幣35.3百萬元），同比增加85.9%，主要由於(i)報告期內經調整EBITDA增加；及(ii)營運資金變動，包括應付賬款增加。

Management Discussion and Analysis

管理層討論及分析

Net cash used in investing activities

During the current period, the net cash used in investing activities amounted to RMB103.8 million (six months ended 30 June 2018: RMB124.7 million), representing a period-on-period decrease of 16.8%, which is primarily due to (i) no significant acquisition being made during the current period; (ii) a decrease in investment income received, financial assets at FVTPL and interest received as compared with the same period last year; and (iii) an increase in purchase of and deposits paid for acquisition of property, plant and equipment as compared with the same period last year.

Net cash generated from (used in) financing activities

During the current period, the net cash generated from financing activities amounted to RMB43.3 million (six months ended 30 June 2018: net cash used in financing activities of RMB0.2 million), representing a period-on-period increase of 179.1 times, which is primarily due to (i) the Group made net advances from the non-controlling shareholders of Anhui Hualin and Zhonglian Cardiovascular Hospital of RMB60.8 million (six months ended 30 June 2018: nil); and (ii) repayment of lease liabilities of RMB10.7 million (six months ended 30 June 2018: nil).

Significant Investment, Acquisition and Disposal

Save as disclosed in this interim report, the Group had no significant investment, acquisition and/or disposal during the Reporting Period.

Cash Management Activities

As part of the Group's cash management, the Group has from time to time invested into investment products issued by a reputable PRC commercial bank with terms ranging from 92 days to 93 days and portfolio investment funds to achieve higher interest income without interfering with business operations or capital expenditures. The investment products are not rated by any credit agency but are classified as low-risk by the issuing bank and listed securities with low risk profile. The Group carefully balances the risks and returns associated with the investment products when making the investment decisions. The senior management of the Group is closely involved in scrutinizing any decision of the Group to purchase investment products.

投資活動所用現金淨額

於本期間，投資活動所用現金淨額為人民幣103.8百萬元(截至二零一八年六月三十日止六個月：人民幣124.7百萬元)，同比減少16.8%，主要由於(i)本期間並無重大收購事項；(ii)所得的投資收入、按公平值計入損益的金融資產及已收利息較去年同期有所減少；及(iii)就購置物業、廠房及設備的購買額及已付按金較去年同期有所增加。

融資活動所得(所用)現金淨額

於本期間，融資活動所得現金淨額為人民幣43.3百萬元(截至二零一八年六月三十日止六個月：融資活動所用現金淨額人民幣0.2百萬元)，同比增加179.1倍，主要是由於(i)本集團已向安徽樺霖及眾聯心血管醫院的非控股股東提供人民幣60.8百萬元的預付款項淨額(截至二零一八年六月三十日止六個月：無)；及(ii)償還租賃負債人民幣10.7百萬元(截至二零一八年六月三十日止六個月：無)。

重大投資、收購及出售

除本中期報告所披露者外，本集團於報告期間內並無任何重大投資、收購及/或出售。

現金管理活動

作為本集團現金管理的一部份，本集團不時投資至由一家聲譽良好的中國商業銀行發行期限介乎92至93日的投資產品及投資組合基金，在不影響業務運作或資本開支的前提下，以獲取更高的利息收益。投資產品未獲任何信貸評級機構評級，但由發行銀行分類為低風險，以及低風險的上市證券。本集團在制定相關投資決策時，會謹慎衡量投資產品的風險與收益。本集團高級管理層亦密切參與審核購買投資產品的一切相關決策。

Capital Expenditure

The Group regularly makes capital expenditures to expand its operations, maintain its medical facilities and improve its operating efficiency. Capital expenditure primarily consists of purchases of property, plant and equipment. The capital expenditure of the Group in the first half of 2019 was RMB57.2 million (six months ended 30 June 2018: RMB34.8 million). The Group financed its capital expenditure through cash flows generated from operating activities.

USE OF PROCEED FROM THE INITIAL PUBLIC OFFERING

The Company's H shares were listed on the Stock Exchange on 8 November 2016. The Company's net proceeds from the initial public offering of its H shares amount to approximately RMB782.6 million (equivalently to approximately HK\$874.9 million) after deducting underwriting commissions and all related expenses. The net proceeds from the initial public offering have been and will be utilised in accordance with the purposes set out in the Prospectus.

Up to 30 June 2019, of the net proceeds from the initial public offering, (i) RMB54.5 million, representing approximately 7.0% of the net proceeds, has been utilised as general working capital; (ii) RMB105.0 million, representing approximately 13.4% of the net proceeds, has been utilised on expansion of the Group's current operations and upgrading of hospital's facilities; and (iii) RMB157.4 million, representing approximately 20.1% of the net proceeds, has been utilised for acquisition and potential acquisition of businesses. As at 30 June 2019, the balance of unutilised net proceeds amounts to RMB465.7 million, part of which has been used to purchase certain financial products (classified as financial assets at FVTPL) to achieve higher interest income and capital return without interfering with business operations or capital expenditures to earn better return on our excess cash balance, which is consistent with the Group's defined cash management policy, and the remaining balance has been kept at the bank accounts of the Group (included in bank balances and cash). As at the date of this interim report, the Company does not anticipate any material change to its plan on the use of proceeds as stated in the Prospectus.

資本開支

本集團定期作出資本開支以擴大營運、維持醫療設施並提高經營效率。資本開支主要包括購買物業、廠房及設備。本集團於二零一九年上半年的資本開支為人民幣57.2百萬元(截至二零一八年六月三十日止六個月：人民幣34.8百萬元)。本集團以通過經營活動所得現金流量為資本開支提供資金。

首次公開發售所得款項用途

本公司H股於二零一六年十一月八日於聯交所上市。本公司於扣除包銷佣金及所有相關費用後，首次公開發售H股所得款項淨額約為人民幣782.6百萬元(相等於約874.9百萬港元)。首次公開發售所得款項淨額已按照並將持續按照招股章程所載用途使用。

截至二零一九年六月三十日，首次公開發售所得款項淨額中(i)人民幣54.5百萬元(佔所得款項淨額約7.0%)已被用作一般營運資金；(ii)人民幣105.0百萬元(佔所得款項淨額約13.4%)已被用於擴大本集團現有業務及升級醫院設施；及(iii)人民幣157.4百萬元(佔所得款項淨額約20.1%)已被用於業務收購及潛在收購。截至二零一九年六月三十日，尚未動用之所得款項淨額結餘為人民幣465.7百萬元，當中部分已被用於購買若干金融產品(分類為按公平值計入損益的金融資產)，從而獲得較高的利息收入及資本回報，又不會干擾業務營運或產生資本開支並就我們的超額現金結餘賺取更好的回報，同時符合本集團的現金管理之守則，以及餘額乃存於本集團的銀行賬戶(計入銀行結餘及現金)。於本中期報告日期，本公司預計招股章程所述所得款項使用計劃不會發生任何重大變動。

Management Discussion and Analysis

管理層討論及分析

The following table sets forth the intended purposes for the net proceeds from the initial public offering, the utilisation of such proceeds and the timeline of utilisation estimated by the management:

下表載列首次公開發售所得款項淨額的擬定用途、該等所得款項的動用情況及管理層估計的動用期限：

Purpose 用途	Net proceeds from the initial public offering intended for the purpose as disclosed in the Prospectus (RMB million) 招股章程所述， 首次公開發售所得 款項淨額的擬定用途 (人民幣百萬元)	Utilisation up to 30 June 2019 (RMB million) 截至二零一九年 六月三十日的 動用情況 (人民幣百萬元)	Unutilised amount (RMB million) 未動用金額 (人民幣百萬元)	Expected timeline for the utilisation of the unutilised amount ^(Note) 使用未動用 金額的預期期限 ^(附註)
Expansion of the Group's current operations and upgrading of hospital facilities 擴大本集團現有業務及升級醫院設施	70.4	5.0	65.4	By the end of 31 December 2020 於二零二零年十二月 三十一日前
Expansion of operating capacity and capability in multi-disciplinary specialised treatment and diagnosis and upgrade of medical facilities 擴大營運實力及多學科診治能力以及 升級醫療設施	281.7	100.0	181.7	By the end of 31 December 2020 於二零二零年十二月 三十一日前
Expansion of hospital management operations 擴大醫院管理營運	78.3	–	78.3	By the end of 31 December 2020 於二零二零年十二月 三十一日前
Expansion of healthcare operations in the PRC through selective mergers and acquisitions 通過選擇性併購擴大於中國的醫療業務	273.9	157.4	116.5	By the end of 31 December 2019 於二零一九年十二月 三十一日前
Working capital and other general corporate purposes 營運資金及其他一般公司用途	78.3	54.5	23.8	By the end of 31 December 2020 於二零二零年十二月 三十一日前
Total 總計	782.6	316.9	465.7	

Note: Such timeline is an estimation of the management only and is subject to change on account of the Group's operating conditions and market conditions from time to time. In particular, it should not be taken as an indication that any potential transaction is under negotiation and/or will materialise.

附註：有關期限僅為管理層的估計及可視乎本集團的營運狀況及不時的市況予以更改。尤其是，其不應被視為任何潛在交易正在磋商及／或任何潛在交易將會落實的跡象。

INDEBTEDNESS

Bank Loans

As at 30 June 2019, the Group had no bank borrowings (31 December 2018: nil).
As at 30 June 2019, the Group had no banking facilities (31 December 2018: nil).

Contingent Liabilities

The Group is subject to legal proceedings and claims in the ordinary course of business, primarily arising from medical disputes brought on by patients. Provision for medical disputes is made based on the status of potential and active claims outstanding as at the end of the relevant period, and primarily taking into account any judicial appraisal or court determination against the Group. As at 30 June 2019, the total stated claim amount of the Group's on-going medical disputes was approximately RMB6.8 million (31 December 2018: RMB9.8 million) and there were certain medical disputes without claim amount stated. Based on the Group's assessment, during the Reporting Period, approximately RMB0.2 million (six months ended 30 June 2018: RMB0.8 million) had been provided and included in accounts and other payables of the Group.

As at 30 June 2019, the Group had no contingent liabilities or guarantees that would have a material impact on the financial position or operation of the Group.

Pledge of Assets

As at 30 June 2019, none of the Group's assets had been pledged (31 December 2018: none).

Capital Commitments

The capital commitments of the Group were primarily attributable to construction costs relating to the expansion and renovation of the Group's medical facilities. As at 30 June 2019, the capital commitments in respect of property, plant and equipment contracted for but not provided in the condensed consolidated financial statements were RMB112.9 million (31 December 2018: RMB116.0 million).

債項

銀行貸款

於二零一九年六月三十日，本集團並無銀行借款（二零一八年十二月三十一日：無）。於二零一九年六月三十日，本集團並無銀行融資額度（二零一八年十二月三十一日：無）。

或然負債

本集團受制於法律訴訟及於日常業務過程中由病人提出的醫療糾紛索賠。醫療糾紛的撥備是根據有關期間結束時可能和尚未了結的進行中索賠個案狀況而作出，主要考慮本集團將面臨的任何司法判決或法院裁決。於二零一九年六月三十日，本集團尚未了結的醫療糾紛索賠總額約為人民幣6.8百萬元（二零一八年十二月三十一日：人民幣9.8百萬元），而有部份醫療糾紛未有列明索賠金額。根據本集團作出的評估，於報告期內，本集團已作出約人民幣0.2百萬元（截至二零一八年六月三十日止六個月：人民幣0.8百萬元）的撥備，並計入本集團的應付賬款及其他應付款項中。

於二零一九年六月三十日，本集團並無會對本集團的財務狀況或經營產生重大影響的或然負債或擔保。

資產質押

於二零一九年六月三十日，本集團並無資產已被質押（二零一八年十二月三十一日：無）。

資本承擔

本集團的資本承擔主要歸因於與本集團醫療設施擴建及翻新有關的建築成本。於二零一九年六月三十日，本集團已訂約但未於簡明綜合財務報表撥備之物業、廠房及設備的資本承擔為人民幣112.9百萬元（二零一八年十二月三十一日：人民幣116.0百萬元）。

Management Discussion and Analysis

管理層討論及分析

Financial Instruments

The Group's financial instruments primarily consisted of accounts and other receivables, amount due from a non-controlling shareholder of a subsidiary, financial assets at FVTPL, bank balances and cash, restricted bank balances, accounts and other payable, dividend payable, amount due to a shareholder and amounts due to non-controlling shareholders of subsidiaries. The management of the Company manages and monitors these exposures to ensure appropriate measures are implemented in a timely and effective manner.

Exposure to fluctuation in Exchange rates

The proceeds raised by the Company in its initial public offering of its H Shares is denominated in Hong Kong dollars. The Group deposits a certain amount of its financial assets in Hong Kong dollars, and is mainly exposed to fluctuation in exchange rates of Hong Kong dollars against RMB. The Group is therefore exposed to foreign exchange risk.

The Group has not used any derivatives financial instruments to hedge against its exposure to currency risk. The management manages the currency risk by closely monitoring the movement of the foreign currency rates and will consider hedging significant foreign currency exposure should such a need arise.

Gearing Ratio

As at 30 June 2019, the Group's gearing ratio (total interest-bearing bank loans divided by total equity and multiplied by 100%) was zero (31 December 2018: zero).

金融工具

本集團的金融工具主要包括應收賬款及其他應收款項、應收一間附屬公司的一名非控股股東款項、按公平值計入損益的金融資產、銀行結餘及現金、受限制銀行結餘、應付賬款及其他應付款項、應付股息、應付一名股東款項以及應付附屬公司非控股股東的款項。本公司管理層管理和監控這些風險承擔，以確保及時有效地採取適當措施。

匯率波動風險

本公司H股首次公開發售所募集的所得款項以港元計值。本集團以港元存放部份金額的金融資產，主要受港元兌人民幣匯率波動的影響。因此，本集團面臨外匯風險。

本集團並未應用任何衍生金融工具對沖其貨幣風險承擔。管理層通過密切監測外幣匯率的變動來管理貨幣風險，並將考慮在有需要時就重大外幣承擔進行對沖。

資產負債比率

於二零一九年六月三十日，本集團之資產負債比率（計息銀行貸款總額除以總權益並乘以100%）為零（二零一八年十二月三十一日：零）。

EMPLOYEES, REMUNERATION POLICIES AND TRAINING SCHEMES

The Group's comprehensive staff remuneration policy comprise basic salary determined with reference to the individual's position, seniority and length of service, performance bonus determined with reference to the metrics specific to the individual's job function and other benefits. The Group regularly benchmarks against available market data and adjusts its remuneration structure with a view to remaining competitive. As at 30 June 2019, the Group had a total of 3,488 (31 December 2018: 3,448) full-time staff.

The Group provides structured training and education programmes to enable its staff to consistently deliver high quality services. These programmes aim to equip the staff with a sound foundation of the medical principles and knowledge as well as practical skills in their respective practice area and foster a high standard of practice, organisation capability and vigilant attitude. Regular internal and external mandatory trainings are organised for medical staff to keep them abreast of the latest development in healthcare. From time to time, the Group identifies and sponsors its staff with high development potential to undertake further studies and professional training in prestigious academic institutions and participate in industry conventions. Medical teams also benefit from the experience and knowledge exchange during seminars and sharing sessions regularly held. The Group encourages medical staff to apply for professional and technical qualifications and enroll in specialised training programmes and assessments from time to time, including induction training for new employees, development training for young and middle-aged core talent, medical service quality training and management training for young core talent, with a view to ensuring that their relevant professional competencies meet the required standards. Through various training and education programmes, the Group also aims to foster a proactive risk reporting culture among staff, which is important in the early detection of clinical failure and damage control.

僱員、薪酬政策及培訓計劃

本集團全面的員工薪酬政策包括參考個人職位、資歷及服務年期計算的基本工資、參考個人工作職能特有指標的績效花紅和其他福利。本集團定期以現有市場數據為基準，調整其薪酬架構，保持競爭力。於二零一九年六月三十日，本集團有合共3,488名（二零一八年十二月三十一日：3,448名）全職員工。

本集團提供系統培訓及教育計劃，以使員工能夠持續提供高質量的服務。該等計劃旨在裝備員工，使其具備彼等各自實踐領域的醫療原則及知識以及執業技能的堅實基礎，並培養高標準的實踐、組織能力及嚴謹態度。本集團為醫務人員組織定期的內部及外部強制性培訓，以使彼等了解醫療的最新發展。本集團會不時甄選出發展潛力大的員工及贊助彼等在著名學術機構進一步開展學習及專業培訓以及參加行業會議。醫療團隊亦從定期舉行的研討會及分享會上的經驗及知識交流中受益。本集團鼓勵醫務人員報考專業技術職稱及不定期接受內部人員專項培訓及考核，包括新員工入職培訓、中青年骨幹拓展培訓、醫療服務質量培訓以及青年幹部管理培訓等，以確保彼等之相關業務能力符合標準。通過各種培訓及教育計劃，本集團亦力圖在員工中培養主動風險報告文化，這對於及早發現臨床誤診及損害控制實屬重要。

Corporate Governance Highlights

企業管治概覽

INTERIM DIVIDEND

The Board has determined that no dividend will be paid in respect of the current interim period (six months ended 30 June 2018: nil).

REPURCHASE, SALE OR REDEMPTION OF THE COMPANY'S SECURITIES

During the Reporting Period, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities.

EVENTS AFTER THE REPORTING PERIOD

Save as disclosed in this interim report, there was no significant event after the Reporting Period.

REVIEW OF INTERIM REPORT

The Company's audit committee has reviewed the Group's interim results and the interim report for the six months ended 30 June 2019 and has opined that applicable accounting standards and requirements have been complied with and that adequate disclosures have been made by the Company.

The Company's audit committee consists of three independent non-executive directors of the Company, Mr. Chan Sing Nun (the chairman of the audit committee), Mr. Yeung Ming Lai and Dr. Chen Keji. Among them, Mr. Chan Sing Nun has the appropriate professional qualifications (a certified public accountant accredited by the Hong Kong Institute of Certified Public Accountants).

The auditor of the Company has also reviewed the Group's interim results for the six months ended 30 June 2019 in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

中期股息

董事會已決定概不會就本中期期間派付股息(截至二零一八年六月三十日止六個月：無)。

購回、出售或贖回本公司證券

於報告期內，本公司或其任何附屬公司概無購買、出售或贖回本公司任何上市證券。

報告期後事項

除本中期報告所披露者外，報告期後並無任何重大事項。

審閱中期報告

本公司審核委員會已審閱本集團截至二零一九年六月三十日止六個月之中期業績及中期報告，並認為本公司已遵守適用會計準則及要求並已作出充分披露。

本公司審核委員會由本公司三名獨立非執行董事，即陳星能先生(審核委員會主席)、楊銘澧先生及陳可冀醫生組成。其中陳星能先生具有適當的專業資格(由香港會計師公會認可的執業會計師)。

本公司核數師亦已按照香港會計師公會頒佈的香港審閱工作準則第2410號「由實體的獨立核數師執行中期財務資料審閱」審閱本集團截至二零一九年六月三十日止六個月之中期業績。

CORPORATE GOVERNANCE

The Company is committed to maintaining high standards of corporate governance practices. The Board is of the opinion that the Company has complied with the applicable code provisions under the CG Code during the six months ended 30 June 2019.

The Board is committed to promoting good corporate governance to safeguard the interests of the Shareholders and believes that maintaining a high standard of corporate governance is essential to the success of the Company and would provide a practice enhancing greater accountability and transparency and meeting the expectations of the Group's stakeholders. The Company will continue to review and enhance its corporate governance to ensure that it will continue to meet the applicable requirements of the CG Code.

CHANGES IN INFORMATION OF DIRECTORS, SUPERVISORS AND CHIEF EXECUTIVES

Changes in the information of the Directors since 1 January 2019 are as follows:

1. Since March 2019, Mr. Chan Sing Nun, an independent non-executive director, has been the chief financial officer of Muse Group Holdings Limited, a company that is principally engaged in operating of retail stores for luxury and high-end branded fashion products; and
2. Since January 2019, Mr. Chan Sing Nun, an independent non-executive director, has resigned as the financial manager of Brandwell Limited, a consulting services company.

Save as disclosed above, since 1 January 2019, there has been no change in information required to be disclosed pursuant to Rule 13.51B(1) of the Hong Kong Listing Rules.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE HONG KONG LISTING RULES

The Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Hong Kong Listing Rules.

企業管治

本公司致力於維持高水平的企業管治常規。董事會認為，本公司於截至二零一九年六月三十日止六個月期間，已遵守企業管治守則之適用守則條文。

董事會致力推動良好的企業管治，以保障股東的利益，亦相信維持高水平的企業管治乃本公司的成功要素，有助建立高度問責及透明的常規，以達致本集團各利益相關者的期望。本公司將繼續審閱及提升其企業管治，確保其繼續符合企業管治守則的適用規定。

董事、監事及行政總裁資料的變更

自二零一九年一月一日以來，董事資料變動如下：

1. 自二零一九年三月起，獨立非執行董事陳星能先生擔任妙思集團控股有限公司（一家主要從事經營奢華和高端品牌時裝產品零售店的公司）的財務總監；及
2. 自二零一九年一月起，獨立非執行董事陳星能先生辭任奔威有限公司（一家諮詢服務公司）的財務經理。

除上文所披露者外，自二零一九年一月一日以來，根據香港上市規則第13.51B(1)條，概無資料變更須予披露。

根據香港上市規則持續披露責任

本公司並無香港上市規則第13.20、13.21及13.22條項下的任何其他披露責任。

Corporate Governance Highlights

企業管治概覽

COMPLIANCE WITH THE MODEL CODE

The Company has adopted the Model Code as a code of conduct of the Company for Directors' and Supervisors' securities transactions. Having made specific enquiry of all Directors and Supervisors, the Directors and the Supervisors have complied with the required standard set out in the Model Code during the six months ended 30 June 2019. Employees who are, or likely to be, in possession of unpublished inside information in relation to the Company or the Shares are prohibited from dealing in the Shares during the black-out period.

APPRECIATION

On behalf of the Board, I would like to take this opportunity to express our appreciation to the management team and staff of the Group for their contribution and also to extend my sincere gratitude to all our shareholders and business partners for their continuous support.

For and on behalf of the Board

Wang Junyang
Chairman

Dongguan, the PRC
30 August 2019

標準守則的合規

本公司已採納標準守則作為本公司董事和監事進行證券交易的行為守則。經向所有董事及監事作出具體查詢後，截至二零一九年六月三十日止六個月期間，董事及監事已遵守標準守則規定的所需標準。凡已經或可能管有未發佈有關本公司或股份內幕消息的僱員，一概不得於禁止交易期間買賣股份。

致謝

本人謹代表董事會藉此機會對本集團管理團隊及員工作出的貢獻表示感謝，同時對全體股東及業務夥伴的持續支持表示誠摯的感謝。

代表董事會

王君揚
主席

中國，東莞
二零一九年八月三十日

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS IN SECURITIES

As at 30 June 2019, the interests and short positions of the Directors, the Supervisors and the chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she were taken or deemed to have under such provisions of the SFO), or as recorded in the register maintained by the Company under section 352 of the SFO, or as notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code were as follows:

(a) The Company

Name of Director 董事姓名	Class of Shares 股份類別	Nature of interest 權益性質	Number of Shares 股份數目	Approximate percentage in Shares of the same class ⁽⁵⁾ 相同類別 股份所佔 概約百分比 ⁽⁵⁾	Approximate percentage of the Company's total issued share capital ⁽⁵⁾ 佔本公司 已發行股本 總額概約 百分比 ⁽⁵⁾
Mr. Wang Junyang 王君揚先生	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽²⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽²⁾	250,000,000 (Long position) (好倉)	100%	74.76%
Mr. Chen Wangzhi 陳旺枝先生	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽³⁾ ; family interest of spouse ⁽⁴⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽³⁾ ；配偶的家族權益 ⁽⁴⁾	250,000,000 (Long position) (好倉)	100%	74.76%
Ms. Wang Aiqin 王愛勤女士	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽³⁾ ; family interest of spouse ⁽⁴⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽³⁾ ；配偶的家族權益 ⁽⁴⁾	250,000,000 (Long position) (好倉)	100%	74.76%

董事、監事及最高行政人員於證券之權益

於二零一九年六月三十日，本公司董事、監事及最高行政人員於本公司或其任何相聯法團（定義見證券及期貨條例第XV部）之股份、相關股份及債權證中擁有根據證券及期貨條例第XV部第7及第8分部須知會本公司及香港聯交所的權益及淡倉（包括彼等根據證券及期貨條例之該等條文被視為或被當作擁有的權益及淡倉），或須列入由本公司按證券及期貨條例第352條存置之登記冊內，或根據標準守則須知會本公司及香港聯交所的權益及淡倉如下：

(a) 本公司

Other Information

其他資料

Notes:

- (1) Pursuant to a concert party agreement, each of Mr. Wang Junyang, Ms. Wang Aici, Mr. Chen Wangzhi and Ms. Wang Aiqin has agreed to jointly control their respective interests in the Company and the decisions as to the business and operations of the Group shall be in accordance with the unanimous consent of all of them. Therefore, each of them is deemed to be interested in all the Shares held by them in aggregate by virtue of the SFO.
- (2) As at 30 June 2019, Kanghua Group (held as to 97.46% by Mr. Wang Junyang) held 197,500,000 Domestic Shares and Xingye Group (held as to 80% by Mr. Wang Junyang) held 25,000,000 Domestic Shares. As Mr. Wang Junyang controls more than one third of the voting power at the general meeting of each of Kanghua Group and Xingye Group, Mr. Wang Junyang is deemed to be interested in the same number of Shares in which each of Kanghua Group and Xingye Group is interested by virtue of the SFO.
- (3) As at 30 June 2019, Xingda Property (held as to 50% each by Mr. Chen Wangzhi and Ms. Wang Aiqin) held 27,500,000 Domestic Shares. As each of Mr. Chen Wangzhi and Ms. Wang Aiqin controls more than one third of the voting power at the general meeting of Xingda Property, each of Mr. Chen Wangzhi and Ms. Wang Aiqin is deemed to be interested in the same number of Shares in which Xingda Property is interested by virtue of the SFO.
- (4) As Mr. Chen Wangzhi and Ms. Wang Aiqin are husband and wife, each of them is deemed to be interested in all the Shares held by them in aggregate by virtue of the SFO.
- (5) The shareholding percentages are calculated on the basis of 250,000,000 Domestic Shares and 84,394,000 H Shares issued by the Company as at 30 June 2019.

附註：

- (1) 根據一項一致行動協議，王君揚先生、王愛慈女士、陳旺枝先生及王愛勤女士均同意共同控制其各自於本公司的權益，而就本集團業務及營運的決定應當作上述人士一致同意。因此，基於證券及期貨條例，上述各方視為於彼等合共持有的所有股份擁有權益。
- (2) 於二零一九年六月三十日，康華集團（王君揚先生持有97.46%）持有197,500,000股內資股，而興業集團（王君揚先生持有80%）持有25,000,000股內資股。由於王君揚先生於康華集團及興業集團各自的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，王君揚先生被視為於康華集團及興業集團各自擁有的相同數目股份擁有權益。
- (3) 於二零一九年六月三十日，興達物業（陳旺枝先生及王愛勤女士分別各自持有50%）持有27,500,000股內資股。由於陳旺枝先生及王愛勤女士在興達物業的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，陳旺枝先生及王愛勤女士被視為於興達物業擁有的相同數目股份擁有權益。
- (4) 由於陳旺枝先生及王愛勤女士為夫妻，故基於證券及期貨條例，其各自被視為於彼等合共持有的所有股份中擁有權益。
- (5) 持股比例以本公司於二零一九年六月三十日發行的250,000,000股內資股及84,394,000股H股計算。

(b) Associated corporations of the Company

(b) 本公司相聯法團

Name of Director 董事姓名	Associated corporation 相聯法團	Nature of interest 權益性質	Approximate percentage interest in the associated corporation 佔相聯法團 權益概約百分比
Mr. Wang Junyang 王君揚先生	Kanghua Group 康華集團	Beneficial owner 實益擁有人	97.46%
Mr. Wang Junyang 王君揚先生	Xingye Group 興業集團	Beneficial owner 實益擁有人	80%
Mr. Chen Wangzhi 陳旺枝先生	Xingda Property 興達物業	Beneficial owner; family interest of spouse 實益擁有人；配偶的家族權益	100%
Ms. Wang Aiqin 王愛勤女士	Xingda Property 興達物業	Beneficial owner; family interest of spouse 實益擁有人；配偶的家族權益	100%

Save as disclosed above, as at 30 June 2019, to the knowledge of the Board, none of the Directors, the Supervisors or chief executives of the Company had any interests or short positions in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be (i) notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which the Directors, the Supervisors and chief executives of the Company were taken or deemed to have under such provisions of the SFO); (ii) recorded in the register kept by the Company pursuant to Section 352 of the SFO; or (iii) notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code.

除上文所披露者外，於二零一九年六月三十日，據董事會所知，概無本公司董事、監事及最高行政人員於本公司或其任何相聯法團（定義見證券及期貨條例第XV部）之股份、相關股份及債權證中擁有(i)根據證券及期貨條例第XV部第7及第8分部須知會本公司及香港聯交所的權益及淡倉（包括彼等根據證券及期貨條例之該等條文被視為或被當作擁有的權益及淡倉）；(ii)須列入由本公司按證券及期貨條例第352條存置之登記冊內的權益及淡倉；或(iii)根據標準守則須知會本公司及香港聯交所的權益及淡倉。

Other Information

其他資料

INTERESTS OF SUBSTANTIAL SHAREHOLDERS

As at 30 June 2019, according to the register kept by the Company pursuant to Section 336 of the SFO and so far is known to, or can be ascertained after reasonable enquiry by the Directors, the following person/entity had an interest or short position in the Shares and underlying Shares which would fall to be disclosed to the Company and the Hong Kong Stock Exchange pursuant to Divisions 2 and 3 of Part XV of the SFO, or be directly and indirectly interested in 5% or more of the nominal value of any class of share capital carrying rights to vote on all circumstances at general meetings of the Company:

(a) Interests in the Shares of the Company

Name 姓名／名稱	Class of Shares 股份類別	Nature of interest 權益性質	Number of Shares 股份數目	Approximate percentage in Shares of the same class 相同類別 股份所佔 概約百分比	Approximate percentage of the Company's total issued share capital 佔本公司 已發行股本 總額概約 百分比
Mr. Wang Junyang 王君揚先生	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽²⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽²⁾	250,000,000 (Long position) (好倉)	100%	74.76%
Ms. Wang Aici 王愛慈女士	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾	250,000,000 (Long position) (好倉)	100%	74.76%
Kanghua Group 康華集團	Domestic Shares 內資股	Beneficial owner 實益擁有人	197,500,000 (Long position) (好倉)	79%	59.06%
Xingye Group 興業集團	Domestic Shares 內資股	Beneficial owner 實益擁有人	25,000,000 (Long position) (好倉)	10%	7.48%
Mr. Chen Wangzhi 陳旺枝先生	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽³⁾ ; family interest of spouse ⁽⁴⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽³⁾ ；配偶的家族權益 ⁽⁴⁾	250,000,000 (Long position) (好倉)	100%	74.76%

主要股東的權益

於二零一九年六月三十日，按照本公司根據證券及期貨條例第336條存置的登記冊，及就董事所知或經作出合理查詢後可確定，以下人士／實體於股份或相關股份中擁有根據證券及期貨條例第XV部第2及3分部之條文須向本公司及香港聯交所披露的權益或淡倉，或直接或間接擁有於本公司股東大會上在任何情況下有權投票的任何類別股本中面值5%或以上的權益：

(a) 於本公司股份的權益

Other Information

其他資料

Name 姓名／名稱	Class of Shares 股份類別	Nature of interest 權益性質	Number of Shares 股份數目	Approximate percentage in Shares of the same class 相同類別 股份所佔 概約百分比	Approximate percentage of the Company's total issued share capital 佔本公司 已發行股本 總額概約 百分比
Ms. Wang Aiqin 王愛勤女士	Domestic Shares 內資股	Interest of a party to an agreement regarding interest in the Company ⁽¹⁾ ; interest in a controlled corporation ⁽³⁾ ; family interest of spouse ⁽⁴⁾ 有關於本公司權益的協議作為權益的一方 ⁽¹⁾ ；於受控制法團的權益 ⁽³⁾ ；配偶的家族權益 ⁽⁴⁾	250,000,000 Long position (好倉)	100%	74.76%
Xingda Property 興達物業	Domestic Shares 內資股	Beneficial owner 實益擁有人	27,500,000 (Long position) (好倉)	11%	8.22%
Mr. Xie Zhikun ("Mr. Xie") 解直錕先生(「解先生」)	H Shares H股	Interest in a controlled corporation ⁽⁵⁾ 於受控制法團的權益 ⁽⁵⁾	16,719,700 (Long position) (好倉)	19.81%	5.00%
Zhonghai Chengfeng (Beijing) Asset Management Co., Ltd. ("Zhonghai Chengfeng") 中海晟豐(北京)資本管理 有限公司(「中海晟豐」)	H Shares H股	Interest in a controlled corporation ⁽⁵⁾ 於受控制法團的權益 ⁽⁵⁾	16,719,700 (Long position) (好倉)	19.81%	5.00%
Zhonghai Chengrong (Beijing) Asset Management Co., Ltd. ("Zhonghai Chengrong") 中海晟融(北京)資本管理 有限公司(「中海晟融」)	H Shares H股	Interest in a controlled corporation ⁽⁵⁾ 於受控制法團的權益 ⁽⁵⁾	16,719,700 (Long position) (好倉)	19.81%	5.00%

Other Information

其他資料

Name 姓名／名稱	Class of Shares 股份類別	Nature of interest 權益性質	Number of Shares 股份數目	Approximate percentage in Shares of the same class 相同類別 股份所佔 概約百分比	Approximate percentage of the Company's total issued share capital 佔本公司 已發行股本 總額概約 百分比
Zhongzhi Investment Management Co., Ltd. ("Zhongzhi Investment") 中植投資管理有限公司 (「中植投資」)	H Shares H股	Interest in a controlled corporation ⁽⁵⁾ 於受控制法團的權益 ⁽⁵⁾	16,719,700 (Long position) (好倉)	19.81%	5.00%
Huzhou Zhongze Taifu Investment Co., Ltd. ("Huzhou Zhongze") 湖州中澤泰富投資有限公司 (「湖州中澤」)	H Shares H股	Interest in a controlled corporation ⁽⁵⁾ 於受控制法團的權益 ⁽⁵⁾	16,719,700 (Long position) (好倉)	19.81%	5.00%
Huzhou Feipeng Capital Management Co., Ltd. ("Huzhou Feipeng") 湖州飛鵬資本管理有限公司 (「湖州飛鵬」)	H Shares H股	Beneficiary of a trust (other than a discretionary interest) 信託的受益人(酌情權益除外)	16,719,700 (Long position) (好倉)	19.81%	5.00%
New China Asset Management (Hong Kong) Limited 新華資產管理(香港) 有限公司	H Shares H股	Investment manager 投資經理	8,689,000 (Long position) (好倉)	10.30%	2.60%
Lin Lijun ("Mr. Lin") 林利軍(「林先生」)	H Shares H股	Interest in a controlled corporation ⁽⁶⁾ 於受控制法團的權益 ⁽⁶⁾	11,146,200 (Long position) (好倉)	13.21%	3.33%
LVC Assets Management Limited	H Shares H股	Interest in a controlled corporation ⁽⁶⁾ 於受控制法團的權益 ⁽⁶⁾	11,146,200 (Long position) (好倉)	13.21%	3.33%
LVC KH Investment L.P.	H Shares H股	Beneficial owner 實益擁有人	11,146,200 (Long position) (好倉)	13.21%	3.33%

Other Information

其他資料

Name 姓名／名稱	Class of Shares 股份類別	Nature of interest 權益性質	Number of Shares 股份數目	Approximate percentage in Shares of the same class 相同類別 股份所佔 概約百分比	Approximate percentage of the Company's total issued share capital 佔本公司 已發行股本 總額概約 百分比
Haitian (HK) Holdings Limited (formerly named as "Haitian (HK) Financial Development Limited") 海天(香港)控股有限公司 (前命名為「海天(香港) 金融發展有限公司」)	H Shares H股	Beneficial owner 實益擁有人	5,052,600 (Long position) (好倉)	5.98%	1.51%
Zhan Yongxiang 詹永祥	H Shares H股	Beneficial owner 實益擁有人	5,021,966 (Long position) (好倉)	5.95%	1.50%
Mr. Wang Mingsong 王明松先生	H Shares H股	Interest in a controlled corporation ⁽⁷⁾ 於受控制法團的權益 ⁽⁷⁾	4,880,000 (Long position) (好倉)	5.78%	1.46%
Bo An Investments Pte, Ltd. ("Bo An Investments") 博安投資私人有限公司 (「博安投資」)	H Shares H股	Interest in a controlled corporation ⁽⁷⁾ 於受控制法團的權益 ⁽⁷⁾	4,880,000 (Long position) (好倉)	5.78%	1.46%
Huaxia International Company Limited ("Huaxia International") 華夏國際有限公司 (「華夏國際」)	H Shares H股	Beneficial owner 實益擁有人	4,880,000 (Long position) (好倉)	5.78%	1.46%

Other Information

其他資料

Notes:

- (1) Pursuant to a concert party agreement, each of Mr. Wang Junyang, Ms. Wang Aici, Mr. Chen Wangzhi and Ms. Wang Ai Qin has agreed to jointly control their respective interests in the Company and the decisions as to the business and operations of the Group shall be in accordance with the unanimous consent of all of them. Therefore, each of them is deemed to be interested in all the Shares held by them in aggregate by virtue of the SFO.
- (2) Mr. Wang Junyang holds 97.46% and 80% in Kanghua Group and Xingye Group, respectively. As Mr. Wang Junyang controls more than one third of the voting power at the general meeting of each of Kanghua Group and Xingye Group, Mr. Wang Junyang is deemed to be interested in the same number of Shares in which each of Kanghua Group and Xingye Group is interested by virtue of the SFO.
- (3) Each of Mr. Chen Wangzhi and Ms. Wang Ai Qin holds 50% in Xingda Property. As each of Mr. Chen Wangzhi and Ms. Wang Ai Qin controls more than one third of the voting power at the general meeting of Xingda Property, each of Mr. Chen Wangzhi and Ms. Wang Ai Qin is deemed to be interested in the same number of Shares in which Xingda Property is interested by virtue of the SFO.
- (4) As Mr. Chen Wangzhi and Ms. Wang Ai Qin are husband and wife, each of them is deemed to be interested in all the Shares held by them in aggregate by virtue of the SFO.
- (5) Mr. Xie holds 99.80% in Zhonghai Chengfeng, which in turn holds 100% in Zhonghai Chengrong, which in turn holds 100% in Zhongzhi Investment, which in turn holds 100% in Huzhou Zhongze, which in turn holds 100% in Huzhou Feipeng. Each of Mr. Xie, Zhonghai Chengfeng, Zhonghai Chengrong, Zhongzhi Investment and Huzhou Zhongze is deemed to be interested in the same number of Shares in which Huzhou Feipeng is interested by virtue of the SFO.
- (6) Mr. Lin holds 100% in LVC Assets Management Limited, which in turn controls LVC KH Investment L.P. Each of Mr. Lin and LVC Assets Management Limited is deemed to be interested in the same number of Shares in which LVC KH Investment L.P. is interested by virtue of SFO.
- (7) Mr. Wang Mingsong holds 100% in Bo An Investments, which in turns holds 100% in Huaxia International. Each of Mr. Wang Mingsong and Bo An Investments is deemed to be interested in the same number of Shares in which Huaxia International is interested by virtue of the SFO.

附註：

- (1) 根據一項一致行動協議，王君揚先生、王愛慈女士、陳旺枝先生及王愛勤女士均同意共同控制其各自於本公司的權益，而就本集團業務及營運的決定應當作上述人士一致同意。因此，基於證券及期貨條例，上述各方視為於彼等合共持有的所有股份擁有權益。
- (2) 王君揚先生分別持有康華集團和興業集團97.46%及80%。由於王君揚先生於康華集團及興業集團各自的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，王君揚先生被視為於康華集團及興業集團各自擁有的相同數目股份擁有權益。
- (3) 陳旺枝先生及王愛勤女士各自持有興達物業50%的股份。由於陳旺枝先生及王愛勤女士在興達物業的股東大會上控制超過三分之一的投票權，基於證券及期貨條例，陳旺枝先生及王愛勤女士被視為於興達物業擁有的相同數目股份擁有權益。
- (4) 由於陳旺枝先生及王愛勤女士為夫妻，故基於證券及期貨條例，其各自被視為於彼等合共持有的所有股份中擁有權益。
- (5) 解先生持有中海晟豐99.80%，而中海晟豐持有中海晟融100%，而中海晟融持有中植投資100%，而中植投資持有湖州中澤100%，而湖州中澤持有湖州飛鵬100%。基於證券及期貨條例，解先生、中海晟豐、中海晟融、中植投資、湖州中澤視為於湖州飛鵬擁有的相同數目股份擁有權益。
- (6) 林先生持有LVC Assets Management Limited 100%，而LVC Assets Management Limited控制LVC KH Investment L.P.。基於證券及期貨條例，林先生及LVC Assets Management Limited各自被視為於LVC KH Investment L.P.擁有的相同數目股份擁有權益。
- (7) 王明松先生持有博安投資100%，而博安投資持有華夏國際100%。基於證券及期貨條例，王明松先生及博安投資各自被視為於華夏國際擁有的相同數目股份擁有權益。

(b) Substantial shareholders of other members of the Group

Name of shareholder 股東姓名／名稱	Name of member of the Group 本集團成員公司名稱	Nature of interest 權益性質	Approximate percentage interest held by the substantial shareholder 主要股東 持有權益 概約百分比
Kangdi Enterprise ⁽¹⁾⁽²⁾ 康帝實業 ⁽¹⁾⁽²⁾	Renkang Hospital 仁康醫院	Beneficial owner 實益擁有人	15%
Ms. Zhang Dandan ⁽¹⁾⁽³⁾ 張丹丹女士 ⁽¹⁾⁽³⁾	Renkang Hospital 仁康醫院	Beneficial owner 實益擁有人	15%
Ms. Wang Aier ⁽¹⁾⁽⁴⁾ 王愛兒女士 ⁽¹⁾⁽⁴⁾	Renkang Hospital 仁康醫院	Beneficial owner 實益擁有人	13%

Notes:

- (1) Pursuant to an entrusted management agreement, each of Kangdi Enterprise, Ms. Zhang Dandan and Ms. Wang Aier irrevocably vested their entire voting power at any general meeting of Renkang Hospital to the Company.
- (2) Kangdi Enterprise is held as to 50% by Mr. Wang Zhengren and as to 50% by Ms. Wang Keying, all of whom are members of the Wang Family and cousins of Mr. Wang Junyang.
- (3) Ms. Zhang Dandan is a member of the Wang Family and aunt-in-law of Mr. Wang Junyang.
- (4) Ms. Wang Aier is a member of the Wang Family and aunt of Mr. Wang Junyang.

附註：

- (1) 根據委託管理協議，康帝實業、張丹丹女士及王愛兒女士各自均不可撤回地將其於仁康醫院任何股東大會的全部投票權歸屬於本公司。
- (2) 王正仁先生及王可瑩女士各自於康帝實業持有50%股權，其全部為王氏家族的成員及王君揚先生的表親。
- (3) 張丹丹女士是王氏家族成員及王君揚先生的孀母。
- (4) 王愛兒女士是王氏家族成員及王君揚先生的姑母。

Save as disclosed above, as at 30 June 2019, to the knowledge of the Directors, no other person had, or were deemed or taken to have interest or short position in the Shares or underlying Shares which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the registry kept by the Company pursuant to Section 336 of the SFO.

除上文所披露者外，於二零一九年六月三十日，據董事所知，概無其他人士於或被視作或當作於股份或相關股份中擁有根據證券及期貨條例第XV部第2及3分部之條文須向本公司披露，或記錄在本公司根據證券及期貨條例第336條存置的登記冊內的權益或淡倉。

Report on Review of Condensed Consolidated Financial Statements

簡明綜合財務報表之審閱報告

Deloitte.

德勤

TO THE BOARD OF DIRECTORS OF
GUANGDONG KANGHUA HEALTHCARE CO., LTD.
(a joint stock company incorporated in the People's Republic of China with limited liability)

致廣東康華醫療股份有限公司董事會

(於中華人民共和國註冊成立的股份有限公司)

INTRODUCTION

We have reviewed the condensed consolidated financial statements of Guangdong Kanghua Healthcare Co., Ltd. (the "Company") and its subsidiaries (collectively referred to as the "Group") set out on pages 54 to 95, which comprise the condensed consolidated statement of financial position as of 30 June 2019 and the related condensed consolidated statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the six months period then ended, and certain explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 "Interim Financial Reporting" ("IAS 34") issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of these condensed consolidated financial statements in accordance with IAS 34. Our responsibility is to express a conclusion on these condensed consolidated financial statements based on our review, and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

引言

本行已審閱載於第54至95頁廣東康華醫療股份有限公司(「貴公司」)及其附屬公司(統稱「貴集團」)之簡明綜合財務報表，其中包括於二零一九年六月三十日的簡明綜合財務狀況表及截至該日止六個月期間的相關簡明綜合損益及其他全面收益表、權益變動表及現金流量表以及若干說明附註。香港聯合交易所有限公司證券上市規則規定，編製中期財務資料之報告必須符合以上規則之有關條文以及國際會計準則委員會頒佈的國際會計準則第34號「中期財務報告」(「國際會計準則第34號」)。貴公司董事須負責根據國際會計準則第34號編製該等簡明綜合財務報表。本行之責任是根據本行之審閱對該等簡明綜合財務報表作出結論，並按照雙方所協定之委聘條款，僅向全體董事報告本行之結論。除此以外，本行之報告不可用作其他用途。本行概不就本報告之內容對任何其他人士負責或承擔任何責任。

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants. A review of these condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

審閱範圍

本行已根據香港會計師公會頒佈之香港審閱工作準則第2410號「由實體的獨立核數師執行中期財務資料審閱」進行審閱。該等簡明綜合財務報表審閱工作包括主要向負責財務會計事項人員詢問，並實施分析和其他審閱程序。由於審閱之範圍遠較按照香港審計準則進行審核之範圍為小，故不能保證本行會注意到在審核中可能會被發現之所有重大事項。因此本行不會發表審核意見。

Report on Review of Condensed Consolidated Financial Statements

簡明綜合財務報表之審閱報告

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

Deloitte Touche Tohmatsu
Certified Public Accountants
Hong Kong
30 August 2019

結論

根據本行之審閱工作，本行並未注意到任何事項，令本行相信簡明綜合財務報表在所有重大方面並無按照國際會計準則第34號而編製。

德勤•關黃陳方會計師行
執業會計師
香港
二零一九年八月三十日

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

簡明綜合損益及其他全面收益表

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

		Six months ended 30 June 截至六月三十日止六個月	
		2019 二零一九年 RMB'000 人民幣千元 (unaudited) (未經審核)	2018 二零一八年 RMB'000 人民幣千元 (unaudited) (未經審核)
		NOTES 附註	
Revenue	收益	3	914,364
Cost of revenue	收益成本		(728,418)
Gross profit	毛利		185,946
Other income	其他收入	4	19,611
Other expenses, gains and losses	其他開支、收益及虧損	5	(960)
Administrative expenses	行政開支		(113,013)
Finance costs	融資成本		(6,895)
Profit before taxation	除稅前溢利	6	84,689
Income tax expenses	所得稅開支	7	(29,140)
Profit and total comprehensive income for the period	期內溢利及全面收入總額		55,549
Profit (loss) and total comprehensive income (expense) for the period attributable to:	下列各項應佔期內溢利(虧損)及全面收入(開支)總額:		
– owners of the Company	– 本公司擁有人		67,637
– non-controlling interests	– 非控股權益		(12,088)
			55,549
Earnings per share, basic (RMB cents)	每股基本盈利(人民幣分)	9	20.2
			25.6

Condensed Consolidated Statement of Financial Position

簡明綜合財務狀況表

At 30 June 2019
於二零一九年六月三十日

			At 30 June 2019 於二零一九年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2018 於二零一八年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
		NOTES 附註		
Non-current assets	非流動資產			
Property, plant and equipment	物業、廠房及設備	10	839,158	814,390
Right-of-use assets	使用權資產	10	331,511	–
Prepaid lease payment	預付租賃款項		–	150,398
Goodwill	商譽		182,013	182,013
Deposits paid for acquisition of property, plant and equipment	收購物業、廠房及設備已付 按金		101,555	81,133
Fixed bank deposit	定期銀行存款		33,000	16,000
			1,487,237	1,243,934
Current assets	流動資產			
Inventories	存貨		53,421	45,358
Accounts and other receivables	應收賬款及其他應收款項	11	259,732	207,016
Amount due from a non-controlling shareholder of a subsidiary	應收一間附屬公司的一名 非控股股東款項		4,300	–
Prepaid lease payment	預付租賃款項		–	3,248
Financial assets at fair value through profit or loss	按公平值計入損益的金融 資產	12	496,313	479,142
Restricted bank balances	受限制銀行結餘		4,567	21,098
Bank balances and cash	銀行結餘及現金		208,474	203,256
			1,026,807	959,118
Current liabilities	流動負債			
Accounts and other payables	應付賬款及其他應付款項	13	496,951	481,839
Amount due to a shareholder	應付一名股東款項		682	682
Amounts due to non-controlling shareholders of subsidiaries	應付附屬公司的非控股股東 款項		213,004	152,204
Dividend payable	應付股息		53,363	–
Tax payables	應付稅項		34,908	38,368
Lease liabilities	租賃負債		23,716	–
			822,624	673,093
Net current assets	流動資產淨值		204,183	286,025
Total assets less current liabilities	總資產減流動負債		1,691,420	1,529,959
Non-current liabilities	非流動負債			
Deferred tax liabilities	遞延稅項負債	14	20,753	20,485
Lease liabilities	租賃負債		206,298	–
			227,051	20,485
Net assets	資產淨值		1,464,369	1,509,474

Condensed Consolidated Statement of Financial Position

簡明綜合財務狀況表

At 30 June 2019

於二零一九年六月三十日

			At 30 June 2019 於二零一九年 六月三十日	At 31 December 2018 於二零一八年 十二月三十一日
		NOTE 附註	RMB'000 人民幣千元 (unaudited) (未經審核)	RMB'000 人民幣千元 (audited) (經審核)
Capital and reserves	資本及儲備			
Share capital	股本	15	334,394	334,394
Reserves	儲備		1,015,404	1,044,543
Equity attributable to owners of the Company	本公司擁有人應佔權益		1,349,798	1,378,937
Non-controlling interests	非控股權益		114,571	130,537
Total equity	權益總額		1,464,369	1,509,474

Condensed Consolidated Statement of Changes in Equity

簡明綜合權益變動表

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

		Attributable to owners of the Company 本公司擁有人應佔					Non-controlling interests 非控股權益		Total 總計
		Share capital 股本	Share premium 股份溢價	Capital reserve 資本儲備	Statutory reserve 法定儲備	Retained earnings 保留盈利	Sub-total 小計	RMB'000 人民幣千元	RMB'000 人民幣千元
		RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元
		(note) (附註)							
At 31 December 2018 (audited)	於二零一八年十二月三十一日 (經審核)	334,394	698,214	53,394	62,584	230,351	1,378,937	130,537	1,509,474
Adjustment (Note 2)	調整 (附註 2)	-	-	-	-	(43,413)	(43,413)	(3,878)	(47,291)
At 1 January 2019 (restated)	於二零一九年一月一日 (經重列)	334,394	698,214	53,394	62,584	186,938	1,335,524	126,659	1,462,183
Profit (loss) and total comprehensive income (expense) for the period	期內溢利 (虧損) 及全面收入 (開支) 總額	-	-	-	-	67,637	67,637	(12,088)	55,549
Dividend (Note 8)	股息 (附註 8)	-	-	-	-	(53,363)	(53,363)	-	(53,363)
At 30 June 2019 (unaudited)	於二零一九年六月三十日 (未經審核)	334,394	698,214	53,394	62,584	201,212	1,349,798	114,571	1,464,369
At 1 January 2018 (audited)	於二零一八年一月一日 (經審核)	334,394	698,214	53,394	28,464	150,758	1,265,224	24,175	1,289,399
Profit and total comprehensive income for the period	期內溢利及全面收入總額	-	-	-	-	85,632	85,632	3,801	89,433
Dividend (Note 8)	股息 (附註 8)	-	-	-	-	(54,230)	(54,230)	-	(54,230)
Acquisition of a non-wholly owned subsidiary	收購一間非全資的附屬公司	-	-	-	-	-	-	16,641	16,641
Transfer	轉讓	-	-	-	9,528	(9,528)	-	-	-
At 30 June 2018 (unaudited)	於二零一八年六月三十日 (未經審核)	334,394	698,214	53,394	37,992	172,632	1,296,626	44,617	1,341,243

Note: Amount of RMB7,557,000 (31 December 2018: RMB3,713,000) included in the Group's retained earnings as at 30 June 2019 represents the profit generated from the private non-enterprise entities directly or indirectly held under Anhui Hualin Medical Investment Co., Ltd., a company acquired by the Group during the year ended 31 December 2018. Under the PRC laws and regulations, the retained earnings of the private non-enterprise entity is not distributable.

附註：本集團於二零一九年六月三十日的保留盈利包含的人民幣7,557,000元(二零一八年十二月三十一日：人民幣3,713,000元)，是指本集團截至二零一八年十二月三十一日止年度收購的安徽樺霖醫療投資有限公司直接或間接持有的私營非企業實體所產生的利潤。根據中國法律及法規，私營非企業實體的保留盈利是不可作分配的。

Condensed Consolidated Statement of Cash Flows

簡明綜合現金流量表

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

		Six months ended 30 June 截至六月三十日止六個月	
		2019 二零一九年 RMB'000 人民幣千元 (unaudited) (未經審核)	2018 二零一八年 RMB'000 人民幣千元 (unaudited) (未經審核)
Net cash generated from operating activities	經營活動所得現金淨額	65,696	35,341
Investing activities	投資活動		
Placement of restricted bank balances	存放受限制銀行結餘	(847,885)	(1,009,970)
Purchase of financial assets at fair value through profit or loss	購買按公平值計入損益的金融資產	(839,855)	(957,070)
Placement of fixed bank deposit	存放定期銀行存款	(33,000)	-
Purchase of property, plant and equipment	購買物業、廠房及設備	(57,247)	(34,752)
Deposits paid for acquisition of property, plant and equipment	收購物業、廠房及設備已付按金	(39,962)	(7,493)
Advance to a non-controlling shareholder of a subsidiary	向一間附屬公司的一名非控股股東提供的墊款	(4,300)	-
Proceeds from disposal of financial assets at fair value through profit or loss	出售按公平值計入損益的金融資產所得款項	829,162	988,230
Withdrawal of restricted bank balances	提取受限制銀行結餘	864,416	1,013,491
Withdrawal of fixed bank deposit	提取定期銀行存款	16,000	-
Investment income received from financial assets at fair value through profit or loss	按公平值計入損益的金融資產收取的投資收入	7,245	9,881
Interest received	已收利息	1,536	4,931
Proceeds from disposals of property, plant and equipment	出售物業、廠房及設備所得款項	128	128
Deposit paid for acquisition of a subsidiary	收購一間附屬公司已付按金	-	(81,000)
Net cash outflow on acquisition of a subsidiary	收購一間附屬公司的現金流出淨額	-	(51,092)
Net cash used in investing activities	投資活動所用現金淨額	(103,762)	(124,716)
Financing activities	融資活動		
Advances from non-controlling shareholders of subsidiaries	來自附屬公司的非控股股東的墊款	106,800	-
Repayments to non-controlling shareholders of subsidiaries	還款予附屬公司的非控股股東	(46,000)	-
Repayments of lease liabilities	償還租賃負債	(10,714)	-
Interest paid	已付利息	(6,805)	-
Repayments to a shareholder	還款予一名股東	-	(243)
Net cash generated from (used in) financing activities	融資活動所得(所用)現金淨額	43,281	(243)
Net increase (decrease) in cash and cash equivalents	現金及現金等價物增加(減少)淨額	5,215	(89,618)
Cash and cash equivalents at beginning of the period	期初現金及現金等價物	203,256	383,796
Effect of foreign exchange rate changes	匯率變動影響	3	530
Cash and cash equivalents at end of the period, represented by bank balances and cash	期末現金及現金等價物，即銀行結餘及現金	208,474	294,708

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

1. GENERAL INFORMATION AND BASIS OF PREPARATION

廣東康華醫療股份有限公司 (Guangdong Kanghua Healthcare Co., Ltd.) (the "Company") was established as a limited liability company in the People's Republic of China (the "PRC") and its overseas listed foreign invested ordinary shares ("H Shares") are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). The Company's immediate and ultimate holding company is 東莞市康華投資集團有限公司 (Dongguan Kanghua Group Co., Ltd.) ("Kanghua Group"), a limited liability company established in the PRC. The addresses of the registered office and principal place of business in Hong Kong of the Company are disclosed in the "Corporate Information" section to the interim report.

The Company and its subsidiaries (collectively referred as the "Group") are principally engaged in provision of hospital services, provision of rehabilitation and other healthcare services, provision of hospital management services, sale of pharmaceutical products and provision of other services (represents elderly care services) in the PRC.

The condensed consolidated financial statements are presented in Renminbi ("RMB"), which is also the functional currency of the Company. This condensed consolidated interim financial statements have been approved by the Board of Directors on 30 August 2019 but have not been audited.

The condensed consolidated financial statements have been prepared in accordance with International Accounting Standard ("IAS") 34 "Interim Financial Reporting" issued by the International Accounting Standards Board ("IASB") as well as with the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on the Stock Exchange (the "Hong Kong Listing Rules").

1. 一般資料及編製基準

廣東康華醫療股份有限公司(「本公司」)在中華人民共和國(「中國」)成立為一間有限責任公司及其境外上市外資普通股(「H股」)，在香港聯合交易所有限公司(「聯交所」)主板上市。本公司的直接及最終控股公司為東莞市康華投資集團有限公司(「康華集團」)，一間於中國成立的有限責任公司。本公司註冊辦事處及香港主要營業地點地址披露於中期報告「公司資料」一節。

本公司及其附屬公司(統稱「本集團」)主要在中國從事提供醫院服務，提供康復及其他醫療服務、提供醫院管理服務、銷售藥品及提供其他服務(指老年護理服務)。

簡明綜合財務報表以人民幣(「人民幣」)呈列，人民幣亦為本公司的功能貨幣。本簡明綜合中期財務報表已於二零一九年八月三十日獲董事會批准，但尚未經審核。

簡明綜合財務報表乃根據國際會計準則委員會(「國際會計準則委員會」)頒佈的國際會計準則(「國際會計準則」)第34號「中期財務報告」以及聯交所證券上市規則(「香港上市規則」)附錄十六的適用披露規定編製。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for financial assets at fair value through profit or loss ("FVTPL") which are measured at fair values at the end of each reporting period.

Other than changes in accounting policies resulting from application of new and amendments to International Financial Reporting Standards ("IFRSs"), the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2019 are the same as those presented in the Group's annual financial statements for the year ended 31 December 2018.

Application of new and amendments to IFRSs

In the current interim period, the Group has applied, for the first time, the following new and amendments to IFRSs issued by the IASB which are mandatory effective for the annual period beginning on or after 1 January 2019 for the preparation of the Group's condensed consolidated financial statements:

IFRS 16
國際財務報告準則第16號
IFRIC 23
國際財務報告詮釋委員會詮釋第23號
Amendments to IAS 19
國際會計準則第19號(修訂本)
Amendments to IAS 28
國際會計準則第28號(修訂本)
Amendments to IFRSs
國際財務報告準則(修訂本)

Except as described below, the application of the amendments to IFRSs in the current period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in the condensed consolidated financial statements.

2. 主要會計政策

簡明綜合財務報表按歷史成本基準編製，惟按公平值計入損益(「按公平值計入損益」)的金融資產乃按各報告期末的公平值計量除外。

除因應用新訂國際財務報告準則(「國際財務報告準則」)及其修訂本而導致的會計政策變更外，截至二零一九年六月三十日止六個月的簡明綜合財務報表採用的會計政策及計算方法與本集團截至二零一八年十二月三十一日止年度的年度財務報表所呈列者一致。

應用新訂國際財務報告準則及其修訂本

於本中期期間，本集團已首次應用以下於二零一九年一月一日當日或之後的年度期間強制生效的國際會計準則委員會頒佈的新訂國際財務報告準則及其修訂本，以編製本集團簡明綜合財務報表：

Leases
租賃
Uncertainty over Income Tax Treatments
所得稅處理的不確定性
Plan Amendment, Curtailment or Settlement
計劃修訂、削減或結算
Long-term Interests in Associates and Joint Ventures
聯營公司和合資企業的長期權益
Annual Improvements to IFRSs 2015–2017 Cycle
國際財務報告準則二零一五年至二零一七年週期的年度改進

除下文所述者外，於本期間應用國際財務報告準則的修訂本，對本集團本期間及過往期間的財務狀況及表現及／或簡明綜合財務報表所載披露事項並無重大影響。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases"

The Group has applied IFRS 16 for the first time in the current interim period. IFRS 16 superseded IAS 17 "Leases" and the related interpretations.

2.1.1 Key changes in accounting policies resulting from application of IFRS 16

The Group applied the following accounting policies in accordance with the transition provisions of IFRS 16.

Definition of a lease

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

For contracts entered into or modified on or after the date of initial application, the Group assesses whether a contract is or contains a lease based on the definition under IFRS 16 at inception or modification date. Such contract will not be reassessed unless the terms and conditions of the contract are subsequently changed.

2. 主要會計政策(續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動

本集團已於本中期間首次採納國際財務報告準則第16號。國際財務報告準則第16號取代國際會計準則第17號「租賃」及相關詮釋。

2.1.1 應用國際財務報告準則第16號導致會計政策的主要變動

本集團根據國際財務報告準則第16號的過渡條文應用下列會計政策。

租賃的定義

倘合約賦予以代價換取於一段時間內控制可識別資產的使用權利，則該合約為租賃或包含租賃。

就首次應用當日或之後訂立或修訂的合約而言，本集團會於開始或修訂日期根據國際財務報告準則第16號項下的定義評估合約是否為租賃或包含租賃。有關合約將不會被重新評估，除非合約中的條款與條件隨後被改動。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.1 Key changes in accounting policies resulting from application of IFRS 16 (Cont'd)

As a lessee

Allocation of consideration to components of a contract

For a contract that contains a lease component and one or more additional lease or non-lease components, the Group allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

Short-term leases

The Group applies the short-term lease recognition exemption to leases of leasehold land and buildings that have a lease term of 12 months or less from the commencement date and do not contain a purchase option. Lease payments on short-term leases are recognised as expense on a straight line basis over the lease term.

Right-of-use assets

Except for short-term leases, the Group recognises right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities.

2. 主要會計政策 (續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動 (續)

2.1.1 應用國際財務報告準則第16號導致會計政策的主要變動 (續)

作為承租人

將代價分配至合約組成部分

就包含租賃組成部分以及一項或多項額外租賃或非租賃組成部分的合約而言，本集團根據租賃組成部分的相對獨立價格及非租賃組成部分的合計獨立價格基準將合約代價分配至各項租賃組成部分。

短期租賃

本集團對於租期自開始日期起計為12個月或以內且並無包含購買選擇權的租賃土地及樓宇的租賃應用短期租賃確認豁免。短期租賃的租賃付款按直線基準於租期內確認為開支。

使用權資產

除短期租賃外，本集團於租賃開始日期(即相關資產可供使用的日期)確認使用權資產。使用權資產按成本計量，減去任何累計折舊及減值虧損，並就租賃負債的任何重新計量作出調整。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.1 Key changes in accounting policies resulting from application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

Right-of-use assets (Cont'd)

The cost of right-of-use asset includes:

- the amount of the initial measurement of the lease liability;
- any lease payments made at or before the commencement date, less any lease incentives received;
- any initial direct costs incurred by the Group; and
- an estimate of costs to be incurred by the Group in dismantling and removing the underlying assets, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease.

Right-of-use assets in which the Group is reasonably certain to obtain ownership of the underlying leased assets at the end of the lease term is depreciated from commencement date to the end of the useful life. Otherwise, right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term.

The Group presents right-of-use assets as a separate line item on the condensed consolidated statement of financial position.

2. 主要會計政策(續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動(續)

2.1.1 應用國際財務報告準則第16號導致會計政策的主要變動(續)

作為承租人(續)

使用權資產(續)

使用權資產的成本包括：

- 租賃負債的初步計量金額；
- 於開始日期或之前作出的任何租賃付款，減任何已收租賃獎勵；
- 本集團產生的任何初始直接成本；及
- 本集團於拆除及拆遷相關資產、復原相關資產所在場地或復原相關資產至租賃的條款及條件所規定的狀況而產生的成本估計。

本集團於租期結束時合理確定獲取相關租賃資產所有權的使用權資產而言，有關使用權資產自開始日期起至使用年期結束期間計提折舊。在其他情況下，使用權資產於其估計使用年期及租期內(以較短者為準)按直線基準計提折舊。

本集團於簡明綜合財務狀況表內將使用權資產呈列為單獨項目。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.1 Key changes in accounting policies resulting from application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

Leasehold land and building

For payments of a property interest which includes both leasehold land and building elements, the entire property is presented as property, plant and equipment of the Group when the payments cannot be allocated reliably between the leasehold land and building elements.

Refundable rental deposits

Refundable rental deposits paid are accounted under IFRS 9 "Financial Instruments" and initially measured at fair value. Adjustments to fair value at initial recognition are considered as additional lease payments and included in the cost of right-of-use assets.

2. 主要會計政策 (續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動 (續)

2.1.1 應用國際財務報告準則第16號導致會計政策的主要變動 (續)

作為承租人 (續)

租賃土地及樓宇

就包括租賃土地及樓宇部分的物業權益付款而言，當付款無法於租賃土地與樓宇部分之間可靠地進行分配時，整項物業獲呈列為本集團的物業、廠房及設備。

可退回租賃按金

已付可退回租賃按金乃根據國際財務報告準則第9號「金融工具」入賬，初步按公平值計量。首次確認時對公平值作出的調整被視為額外租賃付款且計入使用權資產成本。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.1 Key changes in accounting policies resulting from application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

Lease liabilities

At the commencement date of a lease, the Group recognises and measures the lease liability at the present value of lease payments that are unpaid at that date. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable.

The lease payments include:

- fixed payments (including in-substance fixed payments) less any lease incentives receivable;
- variable lease payments that depend on an index or a rate;
- amounts expected to be paid under residual value guarantees;
- the exercise price of a purchase option reasonably certain to be exercised by the Group; and
- payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate.

2. 主要會計政策(續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動(續)

2.1.1 應用國際財務報告準則第16號導致會計政策的主要變動(續)

作為承租人(續)

租賃負債

於租賃開始日期，本集團按該日未付的租賃付款的現值確認及計量租賃負債。於計算租賃付款現值時，倘租賃隱含的利率難以釐定，則本集團使用租賃開始日期的增量借款利率計算。

租賃付款包括：

- 固定付款(包括實質性的固定付款)減任何應收租賃獎勵；
- 視乎指數或比率而定的可變租賃付款；
- 根據剩餘價值擔保預期將支付的金額；
- 本集團合理確定將予行使購買選擇權的行使價；及
- 倘租期反映本集團會行使選擇權終止租賃，則計入終止租賃的罰款。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.1 Key changes in accounting policies resulting from application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

Lease liabilities (Cont'd)

Variable lease payments that do not depend on an index or a rate are not included in the measurement of lease liabilities and right-of-use assets, and are recognised as expense in the period on which the event or condition that triggers the payment occurs.

After the commencement date, lease liabilities are adjusted by interest accretion and lease payments.

The Group remeasures lease liabilities (and makes a corresponding adjustment to the related right-of-use assets) whenever:

- the lease term has changed or there is a change in the assessment of exercise of a purchase option, in which case the related lease liability is remeasured by discounting the revised lease payments using a revised discount rate at the date of reassessment.
- the lease payments change due to changes in market rental rates following a market rent review, in which cases the related lease liability is remeasured by discounting the revised lease payments using the initial discount rate.

2. 主要會計政策 (續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動 (續)

2.1.1 應用國際財務報告準則第16號導致會計政策的主要變動 (續)

作為承租人 (續)

租賃負債 (續)

並不視乎指數或比率而定的可變租賃付款不計入租賃負債及使用權資產計量，而於觸發付款的事件或條件發生期間確認為開支。

於開始日期後，租賃負債就應計利息及租賃付款作出調整。

倘出現以下情況，本集團重新計量租賃負債（並就相關使用權資產作出相應調整）：

- 租賃期有所變動或行使購買選擇權的評估發生變動，在該情況下，相關租賃負債於重新評估日期透過使用經修訂貼現率貼現經修訂租賃付款而重新計量。
- 租賃付款因市場租金率於市場租金審核後有所變動而發生變化，在此情況下，相關租賃負債使用初始貼現率貼現經修訂租賃付款而重新計量。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.1 Key changes in accounting policies resulting from application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

Lease modifications

The Group accounts for a lease modification as a separate lease if:

- the modification increases the scope of the lease by adding the right to use one or more underlying assets; and
- the consideration for the leases increases by an amount commensurate with the stand-alone price for the increase in scope and any appropriate adjustments to that stand-alone price to reflect the circumstances of the particular contract.

For a lease modification that is not accounted for as a separate lease, the Group remeasures the lease liability based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification.

2. 主要會計政策(續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動(續)

2.1.1 應用國際財務報告準則第16號導致會計政策的主要變動(續)

作為承租人(續)

租賃修訂

倘出現以下情況，本集團將租賃修訂作為一項單獨的租賃入賬：

- 該項修訂通過增加使用一項或多項相關資產的權利擴大租賃範圍；及
- 租賃代價的增加金額相當於範圍擴大對應的單獨價格及為反映特定合約情況而對單獨價格進行的任何適當調整。

就未作為一項單獨租賃入賬的租賃修訂而言，本集團透過使用修訂生效日期的經修訂貼現率貼現經修訂租賃付款，按經修訂租賃的租賃期重新計量租賃負債。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.1 Key changes in accounting policies resulting from application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

Taxation

For the purposes of measuring deferred tax for leasing transactions in which the Group recognises the right-of-use assets and the related lease liabilities, the Group first determines whether the tax deductions are attributable to the right-of-use assets or the lease liabilities.

For leasing transactions in which the tax deductions are attributable to the lease liabilities, the Group applies IAS 12 "Income Taxes" requirements to right-of-use assets and lease liabilities separately. Temporary differences relating to right-of-use assets and lease liabilities are not recognised at initial recognition and over the lease terms due to application of the initial recognition exemption.

2. 主要會計政策 (續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動 (續)

2.1.1 應用國際財務報告準則第16號導致會計政策的主要變動 (續)

作為承租人 (續)

稅項

就本集團對租賃交易確認使用權資產及相關租賃負債的遞延稅項計量而言，本集團首先釐定減稅是否歸屬於使用權資產或租賃負債。

就租賃交易中租賃負債應佔的減稅而言，本集團將國際會計準則第12號「所得稅」的規定獨立應用於使用權資產及租賃負債。由於應用首次確認豁免，與使用權資產及租賃負債相關的暫時性差異於租賃期首次確認時不予確認。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.1 Key changes in accounting policies resulting from application of IFRS 16 (Cont'd)

As a lessor

Refundable rental deposits

Refundable rental deposits received are accounted under IFRS 9 and initially measured at fair value. Adjustments to fair value at initial recognition are considered as additional lease payments from lessees.

Sublease

When the Group is an intermediate lessor, it accounts for the head lease and the sublease as two separate contracts. The sublease is classified as a finance or operating lease by reference to the right-of-use asset arising from the head lease, not with reference to the underlying asset.

Lease modification

The Group accounts for a modification to an operating lease as a new lease from the effective date of the modification, considering any prepaid or accrued lease payments relating to the original lease as part of the lease payments for the new lease.

2. 主要會計政策(續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動(續)

2.1.1 應用國際財務報告準則第16號導致會計政策的主要變動(續)

作為出租人

可退回租賃按金

已收可退回租賃按金乃根據國際財務報告準則第9號入賬，初步按公平值計量。對首次確認時的公平值作出的調整被視為自承租人的額外租賃付款。

分租

當本集團為中介出租人，本集團會將主租約及分租約入賬為兩項獨立合約。分租約乃參照主租約所產生的使用權資產分類為融資或經營租賃，而非參照相關資產分類。

租賃修訂

本集團將修訂經營租賃視為自修訂生效日期起計的新租賃，並考慮與原租賃相關的任何預付或應計租賃付款，作為新租賃的部分租賃付款。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.2 Transition and summary of effects arising from initial application of IFRS 16

Definition of a lease

The Group has elected the practical expedient to apply IFRS 16 to contracts that were previously identified as leases applying IAS 17 and IFRIC 4 "Determining whether an Arrangement contains a Lease" and not apply this standard to contracts that were not previously identified as containing a lease. Therefore, the Group has not reassessed contracts which already existed prior to the date of initial application.

For contracts entered into or modified on or after 1 January 2019, the Group applies the definition of a lease in accordance with the requirements set out in IFRS 16 in assessing whether a contract contains a lease.

As a lessee

The Group has applied IFRS 16 retrospectively with the cumulative effect recognised at the date of initial application, 1 January 2019. Any difference at the date of initial application is recognised in the opening retained profits and comparative information has not been restated.

2. 主要會計政策 (續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動 (續)

2.1.2 因首次應用國際財務報告準則第16號而進行的過渡及產生的影響概要

租賃的定義

本集團已選擇可行權宜方法，對先前應用國際會計準則第17號及國際財務報告詮釋委員會—詮釋第4號「釐定安排是否包含租賃」識別為租賃的合約應用國際財務報告準則第16號，而並無對先前並未識別為包含租賃的合約應用該準則。因此，本集團並無重新評估於初始應用日期前已存在的合約。

就於二零一九年一月一日或之後訂立或修訂的合約而言，本集團於評估合約是否包含租賃時根據國際財務報告準則第16號所載的規定應用租賃的定義。

作為承租人

本集團已追溯應用國際財務報告準則第16號，而累計影響於首次應用日期二零一九年一月一日確認。於首次應用日期的任何差額於期初保留溢利確認，及並無重列比較資料。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.2 Transition and summary of effects arising from initial application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

When applying the modified retrospective approach under IFRS 16 at transition, the Group applied the following practical expedients to leases previously classified as operating leases under IAS 17, on lease-by-lease basis, to the extent relevant to the respective lease contracts:

- i. elected not to recognise right-of-use assets and lease liabilities for leases with lease term ends within 12 months of the date of initial application;
- ii. excluded initial direct costs from measuring the right-of-use assets at the date of initial application;
- iii. applied a single discount rate to a portfolio of leases with a similar remaining terms for similar class of underlying assets in similar economic environment. Specifically, discount rate for certain leases of properties and land leases in the PRC was determined on a portfolio basis; and
- iv. used hindsight based on facts and circumstances as at date of initial application in determining the lease terms for the Group's leases with extension and termination options.

2. 主要會計政策(續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動(續)

2.1.2 因首次應用國際財務報告準則第16號而進行的過渡及產生的影響概要(續)

作為承租人(續)

於過渡期間根據國際財務報告準則第16號應用經修定追溯法時，本集團對先前根據國際會計準則第17號分類為經營租賃的租賃按租賃基準對分別相關的租賃合約應用以下可行權宜方法：

- i. 就租期為自首次應用之日期起12個月內結束的租賃，選擇不確認使用權資產及租賃負債；
- ii. 於首次應用日期計量使用權資產時排除初始直接成本；
- iii. 對於相若經濟環境中相若類別相關資產的相若剩餘條款的租賃組合應用單一貼現率。尤其是，於中國的若干物業租賃及土地租賃的貼現率乃以組合基準釐定；及
- iv. 根據於首次應用日期的事實及情況使用事後分析，為本集團具有延期及終止選擇權的租賃釐定租期。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.2 Transition and summary of effects arising from initial application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

On transition, the Group has made the following adjustments upon application of IFRS 16:

As at 1 January 2019, the Group recognised additional lease liabilities and measured right-of-use assets at the carrying amount as if IFRS 16 had been applied since commencement dates, but discounted using incremental borrowing rates of the relevant group entities at the date of initial application by applying IFRS 16.C8(b)(i) transition. Amounts of RMB43,413,000 and RMB3,878,000 of transition upon adoption of IFRS 16 is recognised as decrease to retained earnings and non-controlling interests on 1 January 2019 respectively.

When recognising the lease liabilities for leases previously classified as operating leases, the Group has applied incremental borrowing rates of the relevant group entities at the date of initial application. The incremental borrowing rates applied by the relevant group entities range from 5.1% to 5.9%.

2. 主要會計政策 (續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動 (續)

2.1.2 因首次應用國際財務報告準則第16號而進行的過渡及產生的影響概要 (續)

作為承租人 (續)

於過渡期間，本集團於應用香港財務報告準則第16號後作出下列調整：

於二零一九年一月一日，本集團確認額外租賃負債並以賬面金額計量使用權資產，猶如國際財務報告準則第16號自生效日期起已應用，惟應用國際財務報告準則第16.C8(b)(i)號過渡，於首次應用日期使用相關集團實體的增量借款利率貼現。採納國際財務報告準則第16號時的過渡金額為人民幣43,413,000元及人民幣3,878,000元於二零一九年一月一日分別確認為保留盈利及非控股權益的減少。

於確認過往分類為經營租賃的租賃負債時，本集團於首次應用日期已應用有關集團實體的增量借款利率。相關集團實體應用的增量借款利率介乎5.1%至5.9%。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.2 Transition and summary of effects arising from initial application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

2. 主要會計政策(續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動(續)

2.1.2 因首次應用國際財務報告準則第16號而進行的過渡及產生的影響概要(續)

作為承租人(續)

		At 1 January 2019 於二零一九年 一月一日 RMB'000 人民幣千元
Operating lease commitments disclosed as at 31 December 2018	於二零一八年十二月三十一日所披露之經營租賃承擔	259,570
Add: Lease liabilities resulting from lease modifications of existing leases (note)	加：現有租賃的租賃修訂產生的租賃負債(附註)	39,686
Less: Recognition exemption – short-term leases	減：確認豁免－短期租賃	(103)
		299,153
Lease liabilities discounted at relevant incremental borrowing rates	按相關增量借款利率貼現的租賃負債	(59,429)
Lease liabilities relating to operating leases recognised upon application of IFRS 16 and as at 1 January 2019	於二零一九年一月一日應用國際財務報告準則第16號後確認與經營租賃有關之租賃負債	239,724
Analysed as:	分析為：	
Current	流動	21,512
Non-current	非流動	218,212
		239,724

Note: The Group renewed the leases of certain leasehold land and buildings by entering into new lease contracts which commence after date of initial application, these new contracts are accounted as lease modifications of the existing contracts upon application of IFRS 16.

附註：本集團通過訂立新租賃合約續租若干租賃土地及樓宇，該等新合約於首次應用日期後開始，並於應用國際財務報告準則第16號後入賬列為現有合約的租賃修訂。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.2 Transition and summary of effects arising from initial application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

The carrying amount of right-of-use assets as at 1 January 2019 comprises the following:

		Right-of-use assets 使用權資產 RMB'000 人民幣千元
Right-of-use assets relating to operating leases recognised upon application of IFRS 16	應用國際財務報告準則第16號後確認與經營租賃有關的使用權資產	192,433
Reclassified from prepaid lease payment (note)	自預付租賃款項重新分類(附註)	153,646
		346,079
By class:	按類別劃分:	
Leasehold lands	租賃土地	153,646
Leasehold land and buildings	租賃土地及樓宇	192,433
		346,079

Note: Upfront payments for leasehold lands in the PRC were classified as prepaid lease payment as at 31 December 2018. Upon application of IFRS 16, prepaid lease payment amounting to RMB153,646,000 were reclassified to right-of-use assets.

附註：中國租賃土地的預付款項於二零一八年十二月三十一日分類為預付租賃款項。應用國際財務報告準則第16號後，預付租賃款項人民幣153,646,000元已重新分類至使用權資產。

2. 主要會計政策(續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動(續)

2.1.2 因首次應用國際財務報告準則第16號而進行的過渡及產生的影響概要(續)

作為承租人(續)

於二零一九年一月一日的
使用權資產賬面值包括以下各項：

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.1 Impacts and changes in accounting policies of application on IFRS 16 "Leases" (Cont'd)

2.1.2 Transition and summary of effects arising from initial application of IFRS 16 (Cont'd)

As a lessee (Cont'd)

The following adjustments were made to the amounts recognised in the condensed consolidated statement of financial position at 1 January 2019. Line items that were not affected by the changes have not been included.

2. 主要會計政策(續)

2.1 應用國際財務報告準則第16號「租賃」的會計政策影響及變動(續)

2.1.2 因首次應用國際財務報告準則第16號而進行的過渡及產生的影響概要(續)

作為承租人(續)

對於二零一九年一月一日的簡明綜合財務狀況表內確認的金額作出下列調整。未受變動影響的項目不包括在內。

		Carrying amounts previously reported at 31 December 2018	Adjustments	Carrying amounts under IFRS 16 at 1 January 2019
		於二零一八年十二月三十一日過往呈報的賬面值 RMB'000 人民幣千元	調整 RMB'000 人民幣千元	於二零一九年一月一日根據國際財務報告準則第16號的賬面值 RMB'000 人民幣千元
Non-current assets	非流動資產			
Prepaid lease payment	預付租賃款項	150,398	(150,398)	-
Right-of-use assets	使用權資產	-	346,079	346,079
Current asset	流動資產			
Prepaid lease payment	預付租賃款項	3,248	(3,248)	-
Current liability	流動負債			
Lease liabilities	租賃負債	-	(21,512)	(21,512)
Non-current liability	非流動負債			
Lease liabilities	租賃負債	-	(218,212)	(218,212)
Capital and reserves	資本及儲備			
Reserves	儲備	(1,044,543)	43,413	(1,001,130)
Non-controlling interests	非控股權益	(130,537)	3,878	(126,659)

Note: For the purpose of reporting cash flows for the six months ended 30 June 2019, movements have been computed based on opening statement of financial position as at 1 January 2019 as disclosed above.

附註：就呈報截至二零一九年六月三十日止六個月現金流量而言，變動根據上文所披露於二零一九年一月一日的期初財務狀況表計算。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

2. PRINCIPAL ACCOUNTING POLICIES (Cont'd)

2.2 Impacts and changes in accounting policies of application of other new and amendments to IFRSs

2.2.1 Significant changes in significant judgements and key sources of estimation uncertainty

The following are significant judgements relating to application of IFRS 16 for consideration, the list is not exhaustive:

Lease term

In determination on lease term of contracts with renewal options, the Group applies judgement to determine the lease term for lease contracts in which it is a lessee that include renewal option. The assessment of whether the Group is reasonably certain to exercise such options impacts the lease term, which significantly affects the amount of lease liabilities and right-of-use assets recognised.

Incremental borrowing rate

In determination on incremental borrowing rate, the Group applies judgement to determine the applicable rate to calculate the present value of lease payments. The incremental borrowing rate of the Group applies, which significantly affects the amount of lease liabilities and right-of-use assets recognised.

The directors of the Company do not anticipate that the application of the other new and amendments to IFRSs will have a material effect on the condensed consolidated financial statements in the foreseeable future.

2. 主要會計政策 (續)

2.2 應用其他新訂國際財務報告準則及其修訂本的會計政策影響及變動

2.2.1 重大判斷的重大變動及估計不確定性的主要來源

以下為有關應用國際財務報告準則第16號的重大判斷(作考慮用途)，未詳盡列出：

租賃期

於釐定附帶續約選擇權合約的租賃期時，本集團應用判斷釐定其為承租人且包括續約選擇權的租賃合約租賃期。評估本集團是否合理確定行使該等選擇權影響該租賃期，並對已確認的租賃負債及使用權資產金額有重大影響。

增量借款利率

於釐定增量借款利率時，本集團應用判斷以釐定計算租賃款項之現值的適用利率。本集團應用的增量借款利率對所確認的租賃負債及使用權資產金額有重大影響。

本公司董事預計，於可預見未來應用其他新訂國際財務報告準則及其修訂本將不會對簡明綜合財務狀況表產生重大影響。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

3. REVENUE AND SEGMENT INFORMATION

The Group is principally engaged in (i) provision of hospital services; (ii) provision of rehabilitation and other healthcare services; (iii) provision of hospital management services; (iv) sale of pharmaceutical products; and (v) provision of other services.

Revenue

An analysis of the Group's revenue for the period is as follows:

3. 收益及分部資料

本集團主要從事(i)提供醫院服務；(ii)提供康復及其他醫療服務；(iii)提供醫院管理服務；(iv)藥品銷售；及(v)提供其他服務。

收益

本集團期內收益分析如下：

		Six months ended 30 June 截至六月三十日止六個月	
		2019 二零一九年 RMB'000 人民幣千元 (unaudited) (未經審核)	2018 二零一八年 RMB'000 人民幣千元 (unaudited) (未經審核)
Recognised over time:	隨時間確認：		
Hospital services:	醫院服務：		
– Inpatient healthcare services	– 住院醫療服務	536,185	426,169
– Outpatient healthcare services	– 門診醫療服務	299,581	258,761
– Physical examination services	– 體檢服務	33,668	30,163
Rehabilitation and other healthcare services:	康復及其他醫療服務：		
– Rehabilitation hospital services	– 康復醫院服務	22,662	10,436
– Rehabilitation centre services and other healthcare services	– 康復中心服務及其他醫療服務	12,907	4,215
Hospital management services	醫院管理服務	–	1,922
Others	其他	522	–
		905,525	731,666
Recognised at a point in time:	於某一時間點確認：		
Sale of pharmaceutical products	藥品銷售	8,839	6,923
		914,364	738,589

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

3. REVENUE AND SEGMENT INFORMATION (Cont'd)

Segment information

Information reported to the executive directors of the Company, being the chief operating decision maker (the "CODM"), for the purposes of resource allocation and assessment of segment performance focuses on types of service provided.

The Group's operating segments are classified as (i) hospital services; (ii) rehabilitation and other healthcare services; (iii) hospital management services; (iv) sale of pharmaceutical products; and (v) others. The details of the Group's operating segments are as follows:

- | | |
|--|---|
| (i) Hospital services: | Provision of hospital services includes (i) inpatient healthcare services generally refer to the treatment of patients who are hospitalised overnight or for an indeterminate period of time; (ii) outpatient healthcare services generally refer to the treatment of patients who are hospitalised for less than 24 hours; (iii) physical examinations services generally refer to the clinical examination of individuals for signs of diseases and health advisory services. |
| (ii) Rehabilitation and other healthcare services: | Provision of rehabilitation services generally refer to the provision of special care services to patients with permanent or long-term physical or mental disabilities. Other healthcare services include elderly care and training services for the disabled. |
| (iii) Hospital management services: | Provision of management services to a hospital owned by an independent third party. |
| (iv) Sale of pharmaceutical products: | Sale of pharmaceutical products to patients of the Group's hospitals and outside customers. |
| (v) Others: | Provision of elderly care services to patients. |

These operating segments also represent the Group's reportable segments. No operating segments identified by the CODM have been aggregated in arriving at the reportable segments of the Group.

3. 收益及分部資料(續)

分部資料

為進行資源分配及評估分部表現而向本公司執行董事(即主要經營決策者(「主要經營決策者」))呈報的資料側重於所提供服務的類型。

本集團的經營分部分為(i)醫院服務；(ii)康復及其他醫療服務；(iii)醫院管理服務；(iv)藥品銷售；及(v)其他。本集團經營分部的詳情如下：

- | | |
|-----------------|--|
| (i) 醫院服務： | 提供的醫療服務包括(i)住院醫療服務一般指為過夜或不定時入院的病人提供治療；(ii)門診醫療服務一般指為入院少於24小時的病人提供治療；(iii)體檢服務一般指為個人提供有關疾病徵兆的臨床檢驗及保健諮詢服務。 |
| (ii) 康復及其他醫療服務： | 提供康復服務一般指向永久或長期身體或精神殘疾的患者提供特殊護理服務。其他醫療服務包括老年護理及殘疾人士訓練服務。 |
| (iii) 醫院管理服務： | 向獨立第三方擁有的醫院提供管理服務。 |
| (iv) 藥品銷售： | 向本集團醫院的患者及外部客戶銷售藥品。 |
| (v) 其他： | 向患者提供老年護理服務。 |

該等經營分部亦代表本集團的可呈報分部。於釐定本集團的可呈報分部時，概無合併主要經營決策者確定的經營分部。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

3. REVENUE AND SEGMENT INFORMATION (Cont'd)

Segment revenues and results

The following is an analysis of the Group's revenue and results by operating segments:

For the six months ended 30 June 2019 (unaudited)

3. 收益及分部資料(續)

分部收益及業績

以下為按經營分部劃分的本集團收益及業績分析：

截至二零一九年六月三十日止六個月
(未經審核)

		Hospital services 醫院服務 RMB'000 人民幣千元	Rehabilitation and other healthcare services 康復及其他 醫療服務 RMB'000 人民幣千元 note (i) 附註 (i)	Sale of pharmaceutical products 藥品銷售 RMB'000 人民幣千元	Others 其他 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
SEGMENT REVENUE	分部收益					
External revenue	外部收益	869,434	35,569	8,839	522	914,364
Segment profit	分部溢利	175,281	8,184	2,053	428	185,946
Other income	其他收入					19,611
Other expenses, gains and losses	其他開支、 收益及虧損					(960)
Administrative expenses	行政開支					(113,013)
Finance costs	融資成本					(6,895)
Profit before taxation	除稅前溢利					84,689

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

3. REVENUE AND SEGMENT INFORMATION (Cont'd)

Segment revenues and results (Cont'd)

For the six months ended 30 June 2018 (unaudited)

		Hospital services 醫院服務 RMB'000 人民幣千元	Rehabilitation and other healthcare services 康復及 其他醫療服務 RMB'000 人民幣千元 note (i) 附註(i)	Hospital management services 醫院 管理服務 RMB'000 人民幣千元 note (ii) 附註(ii)	Sale of pharmaceutical products 藥品銷售 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
SEGMENT REVENUE	分部收益					
External revenue	外部收益	715,093	14,651	1,922	6,923	738,589
Segment profit	分部溢利	157,804	7,819	981	1,444	168,048
Other income	其他收入					28,513
Other expenses, gains and losses	其他開支、 收益及虧損					248
Administrative expenses	行政開支					(80,580)
Profit before taxation	除稅前溢利					116,229

Notes:

- (i) Operation in rehabilitation and other healthcare services was acquired since April 2018.
- (ii) Operation of hospital management services represents provision of hospital management services to 重慶康華眾聯心血管病醫院有限公司 (Chongqing Kanghua Zhonglian Cardiovascular Hospital Co., Ltd.) ("Zhonglian Cardiovascular Hospital"). The Group acquired 60% equity interest in Zhonglian Cardiovascular Hospital in August 2018. Segment revenue and profit for the six months ended 30 June 2018 represented segment results prior to acquisition.

3. 收益及分部資料(續)

分部收益及業績(續)

截至二零一八年六月三十日止六個月
(未經審核)

附註：

- (i) 康復及其他醫療服務營運自二零一八年四月收購。
- (ii) 醫院管理服務的運作指向重慶康華眾聯心血管病醫院有限公司(「眾聯心血管病醫院」)提供醫院管理服務。本集團於二零一八年八月收購眾聯心血管病醫院60%的股權。截至二零一八年六月三十日止六個月的分部收益及溢利指收購前的分部業績。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

3. REVENUE AND SEGMENT INFORMATION (Cont'd)

Segment revenues and results (Cont'd)

There were no inter-segment sales during both periods.

The accounting policies of the operating segments are the same as the Group's accounting policies. Segment profit represents the profit earned by each segment without allocation of other income, other expenses, gains and losses, administrative expenses and finance costs. This is the measure reported to the CODM for the purposes of resource allocation and performance assessment.

Except as disclosed above, no other amounts are regularly provided to the CODM and therefore, no further analysis is presented.

4. OTHER INCOME

3. 收益及分部資料(續)

分部收益及業績(續)

於兩個期間並無分部間銷售。

經營分部的會計政策與本集團會計政策相同。分部溢利指各分部賺取的溢利，而並無分配其他收入、其他開支、收益及虧損、行政開支及融資成本。此乃就資源分配及表現評估而呈報予主要經營決策者的計量方式。

除上文所披露者外，並無其他金額定期提供予主要經營決策者，故並無呈列進一步分析。

4. 其他收入

		Six months ended 30 June 截至六月三十日止六個月	
		2019 二零一九年 RMB'000 人民幣千元 (unaudited) (未經審核)	2018 二零一八年 RMB'000 人民幣千元 (unaudited) (未經審核)
Bank and other interest income	銀行及其他利息收入	579	5,566
Fair value gain on financial assets at FVTPL	按公平值計入損益的金融資產的公平值收益	5,824	6,283
Investment income from financial assets at FVTPL	按公平值計入損益的金融資產的投資收入	7,245	9,881
Rental income	租金收入	3,400	2,206
Government subsidies (note)	政府補貼(附註)	112	138
Others	其他	2,451	4,439
		19,611	28,513

Note: The government subsidies mainly represent the subsidies on costs incurred for operation of rehabilitation centres and hospitals, research and development projects, medical related seminars and forums with no special and unfulfilled conditions attached.

附註：政府補貼主要指無附帶特殊及未履行條件的康復中心及醫院的營運、研發項目、醫療相關講座及座談會產生的成本的補貼。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

5. OTHER EXPENSES, GAINS AND LOSSES

5. 其他開支、收益及虧損

		Six months ended 30 June 截至六月三十日止六個月	
		2019	2018
		二零一九年	二零一八年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Net exchange gain	匯兌收益淨額	1,011	1,096
Loss on disposals of property, plant and equipment	出售物業、廠房及設備的虧損	(38)	(72)
Allowance for credit loss	信貸虧損撥備	(223)	(776)
Donations	捐款	(1,710)	-
		(960)	248

6. PROFIT BEFORE TAXATION

6. 除稅前溢利

		Six months ended 30 June 截至六月三十日止六個月	
		2019	2018
		二零一九年	二零一八年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Profit before taxation has been arrived at after charging:	除稅前溢利經扣除下列項目後達致：		
Depreciation of property, plant and equipment	物業、廠房及設備折舊	44,118	30,339
Depreciation of right-of-use assets	使用權資產折舊	15,572	-
Research and development expenditure	研發開支	606	389
Short-term lease rentals in respect of rehabilitation centres and staff quarters	與康復中心及員工宿舍有關的短期租賃租金	1,012	-
Variable lease rentals in respect of hospitals	與醫院有關的可變租賃租金	3,024	-
Operating lease rentals in respect of hospitals and rehabilitation centres	與醫院及康復中心有關的經營租賃租金	-	14,794
Cost of inventories recognised as expenses (representing pharmaceutical products, consumables and others used, included in cost of revenue)	確認為開支的存貨成本（指所用藥品、耗材及其他，計入收益成本內）	432,208	346,815

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

7. INCOME TAX EXPENSES

7. 所得稅開支

		Six months ended 30 June	
		截至六月三十日止六個月	
		2019	2018
		二零一九年	二零一八年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Current tax:	即期稅項：		
PRC Enterprise Income Tax ("EIT")	中國企業所得稅(「企業所得稅」)	28,840	26,131
Underprovision of PRC EIT in prior years	過往年度中國企業所得稅撥備不足	32	665
		28,872	26,796
Deferred tax (Note 14)	遞延稅項(附註14)	268	-
		29,140	26,796

Under the Law of the PRC on EIT (the "EIT Law") and Implementation Regulation of the EIT Law, the statutory income tax rate of the Company and its PRC subsidiaries is 25% for both periods.

根據中國企業所得稅法(「企業所得稅法」)及企業所得稅法實施條例，本公司及其中國附屬公司於兩個期間內的法定所得稅稅率為25%。

8. DIVIDENDS

During the current interim period, a final dividend of RMB16 cents per share in respect of the year ended 31 December 2018 (six months ended 30 June 2018: RMB16 cents per share in respect of the year ended 31 December 2017) was declared to the owners of the Company. The directors of the Company have determined that no dividend will be paid in respect of the current interim period (six months ended 30 June 2018: nil).

8. 股息

於本中期期間，本公司就截至二零一八年十二月三十一日止年度向本公司擁有人宣派末期股息每股人民幣16分(截至二零一八年六月三十日止六個月：就截至二零一七年十二月三十一日止年度宣派每股人民幣16分)。本公司董事已釐定概不會就本中期期間派付股息(截至二零一八年六月三十日止六個月：無)。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

9. EARNINGS PER SHARE

The calculation of basic earnings per share attributable to the owners of the Company is based on the following data:

		Six months ended 30 June 截至六月三十日止六個月	
		2019 二零一九年 RMB'000 人民幣千元 (unaudited) (未經審核)	2018 二零一八年 RMB'000 人民幣千元 (unaudited) (未經審核)
Earnings:	盈利：		
Profit for the period attributable to the owners of the Company for the purpose of calculating earnings per share	用於計算每股盈利的本公司擁有人應佔期內溢利	67,637	85,632

9. 每股盈利

本公司擁有人應佔每股基本盈利基於以下數據計算：

		Six months ended 30 June 截至六月三十日止六個月	
		2019 二零一九年 (unaudited) (未經審核)	2018 二零一八年 (unaudited) (未經審核)
Number of shares:	股份數目：		
Weighted average number of ordinary shares for the purpose of calculating basic earnings per share	用於計算每股基本盈利的普通股加權平均數	334,394,000	334,394,000

No diluted earnings per share has been presented since there were no potential ordinary shares in issue for both periods.

由於在兩個期間內沒有發行潛在普通股，故並無呈列每股攤薄盈利。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

10. MOVEMENTS IN PROPERTY, PLANT AND EQUIPMENT/RIGHT-OF-USE ASSETS

During the current interim period, the Group disposed of certain property, plant and equipment with an aggregate carrying amount of RMB166,000 (six months ended 30 June 2018: RMB200,000) for cash proceeds of RMB128,000 (six months ended 30 June 2018: RMB128,000), resulting in a loss on disposals of RMB38,000 (six months ended 30 June 2018: RMB72,000).

In addition, during the current interim period, the Group acquired property, plant and equipment and incurred expenditure on construction in progress of RMB36,654,000 and RMB32,398,000 (six months ended 30 June 2018: RMB34,076,000 and RMB10,211,000), respectively, for the purpose of upgrading and expanding the service capacity of the Group's hospital operations.

During the current interim period, the Group entered into new lease agreements for the use of properties in the PRC for 2 to 3 years. The Group is required to make fixed monthly payments. On lease commencement, the Group recognised right-of-use assets and lease liabilities of RMB1,004,000 each relating to those new leases.

10. 物業、廠房及設備／使用權資產的變動

於本中期期間，本集團出售總賬面值為人民幣166,000元之物業、廠房及設備（截至二零一八年六月三十日止六個月：人民幣200,000元），所得現金為人民幣128,000元（截至二零一八年六月三十日止六個月：人民幣128,000元），產生出售虧損為人民幣38,000元（截至二零一八年六月三十日止六個月：人民幣72,000元）。

此外，於本中期期間，本集團分別收購物業、廠房及設備及在建工程所產生的支出分別為人民幣36,654,000元及人民幣32,398,000元（截至二零一八年六月三十日止六個月：人民幣34,076,000元及人民幣10,211,000元），以升級及擴大其醫院營運的服務能力。

於本中期期間，本集團訂立新租賃協議，以在中國使用物業2至3年。本集團須按月支付固定費用。於租賃開始時，本集團就該等租賃確認各自使用權資產及租賃負債為人民幣1,004,000元。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

11. ACCOUNTS AND OTHER RECEIVABLES

11. 應收賬款及其他應收款項

		At 30 June 2019 於二零一九年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2018 於二零一八年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Accounts receivables	應收賬款	236,558	186,063
Less: Allowance for credit loss	減：信貸虧損撥備	(9,573)	(9,573)
		226,985	176,490
Prepayments to suppliers	預付供應商款項	9,090	11,715
Interest receivables	應收利息	91	1,048
Others	其他	23,566	17,763
		259,732	207,016

The individual patients of the Group would usually settle payments by cash, credit cards or governments' social insurance schemes. For credit card payments, the banks will normally settle the amounts approximately 30 days after the transaction date. Payments by governments' social insurance schemes will normally be settled by the local social insurance bureau or similar government departments which are responsible for the reimbursement of medical expenses for patients who are covered by the government medical insurance schemes ranged from 30 to 180 days (31 December 2018: 30 to 90 days) from the transaction date. Corporate customers will normally settle the amounts within 90 days after the transaction date by bank transfers.

本集團的個人病人一般以現金、信用卡或政府社保計劃繳費，對於信用卡支付，銀行通常會在交易日期後約30天結算賬款。透過政府的社保計劃繳費，則通常須由當地社保局或負責向辦理政府醫療保險計劃的病人報銷醫療開支的類似政府部門，自交易日期起介乎30至180天(二零一八年十二月三十一日：30天至90天)內結清。公司客戶將一般於交易日期後90天內以銀行轉賬方式結算款項。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

11. ACCOUNTS AND OTHER RECEIVABLES (Cont'd)

The following is an aged analysis of accounts receivables, net of allowance for credit loss, presented based on the revenue recognition date at the end of the reporting period:

11. 應收賬款及其他應收款項(續)

基於報告期末收益確認日期呈列的應收賬款(扣除信貸虧損撥備)的賬齡分析如下:

		At 30 June 2019 於二零一九年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2018 於二零一八年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Within 30 days	30天以內	113,760	115,761
31 to 90 days	31至90天	59,299	21,351
91 to 180 days	91至180天	13,253	25,954
181 to 365 days	181至365天	38,209	12,847
Over 365 days	超過365天	2,464	577
		226,985	176,490

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

12. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS 12. 按公平值計入損益的金融資產

		At 30 June 2019 於二零一九年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2018 於二零一八年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Unlisted fund (note (i))	非上市基金(附註(i))	-	23,162
Portfolio investment fund (note (ii))	投資組合基金(附註(ii))	73,843	53,980
Structured bank deposits (note (iii))	結構性銀行存款(附註(iii))	422,470	402,000
		496,313	479,142

Notes:

- (i) The unlisted fund represents an investment in equity securities of an unlisted company in the PRC and is measured at fair value. In January 2019, all of the unlisted fund was disposed at a consideration of RMB23,162,000.
- (ii) The Group invested into a portfolio investment fund with a fund manager in Hong Kong for investment returns. The portfolio includes a mixture of cash and shares which are primarily listed in Hong Kong and is measured at fair value.
- (iii) The Group invested into structured deposits with a bank in the PRC for investment returns. Majority of these structured deposits are with maturities of less than six months and the principal is generally renewed when matured.

附註：

- (i) 非上市基金指於中國一家私人公司的權益證券投資，乃按公平值計量。於二零一九年一月，所有非上市基金以代價為人民幣23,162,000元出售。
- (ii) 本集團通過投資於由香港一名基金經理管理的投資組合基金賺取投資回報。該投資組合包括現金與主要在香港上市的股份的組合，並按公平值計量。
- (iii) 本集團投資於一家中國銀行的結構性存款以賺取投資回報。大部份結構性存款的到期日少於六個月，本金一般於到期時重續。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

13. ACCOUNTS AND OTHER PAYABLES

13. 應付賬款及其他應付款項

		At 30 June 2019 於二零一九年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2018 於二零一八年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Accounts payables	應付賬款	312,279	263,927
Accrued expenses	應計開支	53,507	77,541
Receipts in advance (note)	預收款項(附註)	69,364	73,182
Payables for acquisition of property, plant and equipment	收購物業、廠房及 設備應付款項	46,725	54,460
Other tax payables	其他應付稅項	3,514	3,129
Provision for medical dispute claims	醫療糾紛索償撥備	1,032	1,280
Others	其他	10,530	8,320
Other payables	其他應付款項	184,672	217,912
		496,951	481,839

Note: Included in the balance are advances from social insurance which represent operating cash of RMB41,481,000 (31 December 2018: RMB42,831,000) advanced from the PRC government for the daily operations of the hospitals operated by the Group.

附註：結餘包括社會保險墊款，相當於中國政府為本集團營運醫院的日常營運提供經營現金為人民幣41,481,000元（二零一八年十二月三十一日：人民幣42,831,000元）。

The credit period of accounts payables is from 30 to 90 days from the invoice date.

應付賬款的信用期自發票日期起計介乎30至90天。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

13. ACCOUNTS AND OTHER PAYABLES (Cont'd)

The following is an aged analysis of accounts payables based on the date of receipt of goods:

Within 30 days	30天以內
31 to 90 days	31至90天
91 to 180 days	91至180天
181 to 365 days	181至365天
Over 365 days	超過365天

13. 應付賬款及其他應付款項(續)

基於收貨日期的應付賬款的賬齡分析如下：

		At 30 June 2019 於二零一九年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2018 於二零一八年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
		80,699	66,394
		128,763	94,213
		64,702	64,499
		18,863	20,769
		19,252	18,052
		312,279	263,927

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

14. DEFERRED TAX LIABILITIES

The following are the major deferred tax liabilities (assets) recognised and movements thereon during the current interim and preceding interim periods:

14. 遞延稅項負債

以下是於本中期及過往中期期間確認的主要遞延稅項負債(資產)及其變動:

		Accelerated tax depreciation 加速稅項 折舊 RMB'000 人民幣千元	Pre-operating expenses written off 撇銷營業 前開支 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
At 1 January 2018 (audited) and 30 June 2018 (unaudited)	於二零一八年一月一日 (經審核)及二零一八年 六月三十日(未經審核)	-	-	-
Acquisitions of subsidiaries	收購附屬公司	26,456	(4,262)	22,194
Credit to profit or loss	計入損益	(231)	(1,478)	(1,709)
At 31 December 2018 (audited)	於二零一八年十二月 三十一日(經審核)	26,225	(5,740)	20,485
(Credit) charge to profit or loss (Note 7)	(計入)扣除損益(附註7)	(277)	545	268
At 30 June 2019 (unaudited)	於二零一九年六月三十日 (未經審核)	25,948	(5,195)	20,753

At 30 June 2019, the Group had unused tax losses of approximately RMB125,163,000 (31 December 2018: RMB84,665,000) available for offset against future profits. No deferred tax asset was recognised in respect of such tax losses due to unpredictable profit stream. The unused tax losses can be carried forward up to five years from the year in which the loss was originated, to offset future taxable profits.

於二零一九年六月三十日，本集團有未使用稅項虧損約為人民幣125,163,000元(二零一八年十二月三十一日：人民幣84,665,000元)可抵銷未來溢利。由於溢利流難以預測，因此並無就該等稅項虧損確認遞延稅項資產。未使用的稅項虧損可以自發生虧損之年度起最多五年結轉，以抵銷未來的應納稅所得額。

At 30 June 2019, the Group has deductible temporary difference amounted to approximately RMB20,778,000 (31 December 2018: RMB22,962,000). A deferred tax asset has been recognised in respect of the deductible temporary difference of RMB20,778,000 (31 December 2018: RMB22,962,000) at the end of the reporting period.

於二零一九年六月三十日，本集團的可抵扣暫時性差額約為人民幣20,778,000元(二零一八年十二月三十一日：人民幣22,962,000元)。於報告期末，已就可抵扣暫時性差額為人民幣20,778,000元(二零一八年十二月三十一日：人民幣22,962,000元)確認遞延稅項資產。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

15. SHARE CAPITAL

		Number of domestic shares 內資股數目 '000 千股	Number of H shares H股數目 '000 千股	Share capital 股本 RMB'000 人民幣千元
At 1 January 2018 (audited), 31 December 2018 (audited) and 30 June 2019 (unaudited)	於二零一八年一月一日(經 審核)、二零一八年十二 月三十一日(經審核)及二 零一九年六月三十日(未 經審核)	250,000	84,394	334,394

15. 股本

16. CAPITAL COMMITMENTS

		At 30 June 2019 於二零一九年 六月三十日 RMB'000 人民幣千元 (unaudited) (未經審核)	At 31 December 2018 於二零一八年 十二月三十一日 RMB'000 人民幣千元 (audited) (經審核)
Capital expenditure in respect of property, plant and equipment contracted for but not provided in the condensed consolidated financial statements	於簡明綜合財務報表中已訂約但未 撥備的物業、廠房及設備的資本 開支	112,864	115,950

16. 資本承擔

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

17. RELATED PARTY DISCLOSURES

In addition to the transactions, balances and commitments disclosed elsewhere in the condensed consolidated financial statements, the Group had entered into the following significant related party transactions:

17. 關聯方披露

除簡明綜合財務報表其他章節所披露的交易、結餘及承擔外，本集團已訂立以下重大關聯方交易：

Name of related companies 關聯公司名稱	Relationship 關係	Nature of transactions 交易性質	Six months ended 30 June 截至六月三十日止六個月	
			2019 二零一九年 RMB'000 人民幣千元 (unaudited) (未經審核)	2018 二零一八年 RMB'000 人民幣千元 (unaudited) (未經審核)
Kanghua Group 康華集團	Shareholder 股東	Right-of-use assets recognised 已確認之使用權資產	154,323	–
		Rental expense 租金開支	–	12,525
Dongguan Tongli Enterprise Co., Ltd. 東莞市同力實業有限公司	Non-controlling shareholder of Dongguan Renkang Hospital Co., Ltd. 東莞仁康醫院有限公司的非控股股東	Right-of-use assets recognised 已確認之使用權資產	28,246	–
		Rental expense 租金開支	–	1,812

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

17. RELATED PARTY DISCLOSURES (Cont'd)

Compensation of key management personnel

Key management personnel includes directors and supervisors. The remuneration of the key management personnel during the current interim period is as follows:

		Six months ended 30 June	
		截至六月三十日止六個月	
		2019	2018
		二零一九年	二零一八年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Fees	袍金	1,080	1,080
Salaries and allowances	薪金及津貼	781	879
Retirement benefit schemes contributions	退休福利計劃供款	39	28
		1,900	1,987

18. CONTINGENT LIABILITIES

The Group is involved as defendants in certain medical disputes arising from its normal business operations. Except for those disputes with provision made as disclosed in Note 13, the management of the Group believes that the final result of other medical disputes with total claims of RMB6,773,000 (31 December 2018: RMB9,807,000) as at 30 June 2019 will not have a material impact on the financial position or operations of the Group and the amount of outflow, if any, cannot be determined with sufficient reliability prior to judicial appraisals. Accordingly, no provision is made in this regard.

17. 關聯方披露 (續)

主要管理人員薪酬

主要管理人員包括董事及監事。於本中期期間，主要管理人員的薪酬如下：

18. 或然負債

本集團作為被告牽涉於其一般業務營運中產生的若干醫療糾紛。除附註13所披露就此等糾紛作出的撥備外，本集團管理層相信於二零一九年六月三十日，涉及索償總額為人民幣6,773,000元(二零一八年十二月三十一日：人民幣9,807,000元)的其他醫療糾紛的最終結果將不會對本集團的財務狀況或營運造成重大影響，而流出金額(如有)無法於司法鑒定前充分可靠地釐定。因此，本集團並無就此作出撥備。

Notes to the Condensed Consolidated Financial Statements

簡明綜合財務報表附註

For the six months ended 30 June 2019
截至二零一九年六月三十日止六個月

19. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS

Other than the financial assets carried at fair value as detailed in the following table, the directors of the Company consider that the carrying amounts of other financial instruments that are recorded at amortised cost in the condensed consolidated financial statements approximate their fair values.

	Fair value as at 30 June 2019 於二零一九年 六月三十日的 公平值 RMB'000 人民幣千元	Fair value as at 31 December 2018 於二零一八年 十二月三十一日 的公平值 RMB'000 人民幣千元	Fair value hierarchy	Valuation techniques and key inputs 估值技巧及 主要輸入數據
Financial assets 金融資產				
Unlisted fund 非上市基金	–	23,162	Level 2 第二級	Quoted price from a financial institution 報價來自 金融機構
Portfolio investment fund 投資組合基金	73,843	53,980	Level 2 第二級	Quoted price from a financial institution 報價來自 金融機構
Structured bank deposits 結構性銀行存款	422,470	402,000	Level 2 第二級	Quoted price from a financial institution 報價來自 金融機構

There was no transfer amongst Level 2 and other Levels in both periods.

19. 金融工具的公平值計量

除下表所詳述按公平值列賬的金融資產外，本公司董事認為，按攤銷成本於本簡明綜合財務報表中入賬的其他金融工具的賬面金額與其公平值相若。

於兩個期間內，第二級及其他級別之間並無轉撥。

Definitions

釋義

Adjusted EBITDA 「經調整EBITDA」	the earnings before accounting for bank and other interest income, interest expenses, taxes, depreciation and amortisation, fair value gain and investment income from financial assets at FVTPL and exchange gain/loss 除銀行及其他利息收入、利息開支、稅項、折舊及攤銷、按公平值計入損益的金融資產投資收入及公平值收益及匯兌收益／虧損前的盈利
Anhui Hualin 「安徽樺霖」	Anhui Hualin Medical Investment Co., Ltd. (安徽樺霖醫療投資有限公司), a limited liability company established in the PRC on 19 December 2016 with 57% of its equity interest being held by Dongguan Kanghua Medical Rehabilitation Investment Company Limited (東莞康華康復醫療投資有限公司), our wholly-owned subsidiary and 43% held by Hefei Haihua Enterprises Management Consulting Partnership (Limited Partnership) (合肥海樺企業管理諮詢合夥企業(有限合夥)), an Independent Third Party 安徽樺霖醫療投資有限公司，於二零一六年十二月十九日在中國成立的有限公司，其57%的股權由我們的全資附屬公司東莞康華康復醫療投資有限公司持有，及43%由獨立第三方合肥海樺企業管理諮詢合夥企業(有限合夥)持有
Audit Committee 「審核委員會」	the audit committee of the Board 董事會審核委員會
Board of Directors or Board 「董事會」	the board of Directors of the Company 本公司董事會
CG Code 「企業管治守則」	the Corporate Governance Code contained in Appendix 14 to the Hong Kong Listing Rules 香港上市規則附錄十四所載的《企業管治守則》
Company 「本公司」	Guangdong Kanghua Healthcare Co., Ltd. (廣東康華醫療股份有限公司), a joint stock limited liability company established under the laws of the PRC, the H Shares of which are listed on the Main Board of the Hong Kong Stock Exchange (Stock code: 3689) 廣東康華醫療股份有限公司，一家根據中國法律成立的股份有限公司，其H股於香港聯交所主板上市(股份代號：3689)
Controlling Shareholders 「控股股東」	has the meaning ascribed under the Hong Kong Listing Rules and unless the context otherwise requires, refers to Mr. Wang Junyang, Ms. Wang Aici, Kanghua Group, Xingye Group, Mr. Chen Wangzhi, Ms. Wang Aiqin and Xingda Property as a group of Controlling Shareholders of the Company, and each of them, a “Controlling Shareholder” 具有香港上市規則所賦予的涵義，除非文義另有所指，指王君揚先生、王愛慈女士、康華集團、興業集團、陳旺枝先生、王愛勤女士及興達物業作為一組本公司控股股東，而彼等各自為一名「控股股東」
Director(s) 「董事」	the director(s) of the Company 本公司董事
Domestic Share(s) 「內資股」	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in RMB and are unlisted Shares which are currently not listed or traded on any stock exchange 本公司股本中每股面值為人民幣1.00元並以人民幣認購或入賬列為繳足股本的普通股，並且是目前未在任何證券交易所上市或交易的非上市股份

Group or we or our 「本集團」或「我們」	the Company and its subsidiaries 本公司及其附屬公司
H Share(s) 「H股」	overseas listed foreign invested ordinary share(s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, listed on the Main Board of the Hong Kong Stock Exchange 本公司普通股股本中每股面值人民幣1.00元的境外上市外資普通股，於香港聯交所主板上市
HK\$ or Hong Kong dollars 「港元」	Hong Kong dollars, the lawful currency of Hong Kong 港元，香港法定貨幣
Hong Kong 「香港」	the Hong Kong Special Administrative Region of the PRC 中國香港特別行政區
Hong Kong Listing Rules 「香港上市規則」	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time 《香港聯合交易所有限公司證券上市規則》，經不時修訂、補充或以其他方式修改
Hong Kong Stock Exchange 「香港聯交所」	The Stock Exchange of Hong Kong Limited 香港聯合交易所有限公司
Huaxin Building 「華心樓」	refers to the complex (華心樓) at Kanghua Hospital which was commissioned to provide VIP healthcare services 康華醫院華心樓，獲分派提供貴賓醫療服務
Independent Third Party(ies) 「獨立第三方」	Any entity or person who is not a connected person of our Company within the meaning ascribed thereto under the Hong Kong Listing Rules 根據香港上市規則，歸因於香港上市規則賦予的涵義，並非本公司關連人士的任何實體或人士
Kangdi Enterprise 「康帝實業」	Dongguan Kangdi Enterprise Co., Ltd. (東莞市康帝實業有限公司), a limited liability company established in the PRC on 25 July 2014 with 50% of its equity interest held by Mr. Wang Zhengren (王政仁) and 50% by Ms. Wang Keying (王可瑩), all of whom are members of the Wang Family, being cousins of Mr. Wang Junyang. Kangdi Enterprise holds a 15% equity interest in Renkang Hospital 東莞市康帝實業有限公司，一家於二零一四年七月二十五日在中國成立的有限公司，其股權由王政仁先生及王可瑩女士各持有50%，彼等均為王氏家族的成員及王君揚先生的堂兄弟姐妹。康帝實業於仁康醫院持有15%的股權
Kanghua Group 「康華集團」	Dongguan Kanghua Investment Group Co., Ltd. (東莞市康華投資集團有限公司), a limited liability company established in the PRC on 29 March 2002 and one of the Controlling Shareholders holding approximately 59.06% interest in the Company. It is owned as to 97.46% by Mr. Wang Junyang and as to 2.54% by Ms. Wang Aici. Kanghua Group, Mr. Wang Junyang, Ms. Wang Aici, Xingye Group, Mr. Chen Wangzhi, Ms. Wang Aiqin and Xingda Property are acting together as a group of Controlling Shareholders 東莞市康華投資集團有限公司，一家於二零零二年三月二十九日在中國成立的有限公司及我們其中一名控股股東，持有本公司約59.06%權益，其分別由王君揚先生及王愛慈女士擁有97.46%及2.54%。康華集團、王君揚先生、王愛慈女士、興業集團、陳旺枝先生、王愛勤女士及興達物業作為一組控股股東一致行動

Definitions

釋義

Kanghua Hospital 「康華醫院」	Dongguan Kanghua Hospital Co., Ltd. (東莞康華醫院有限公司), a limited liability company established in the PRC on 15 September 2005 and a wholly-owned subsidiary of the Company 東莞康華醫院有限公司，一家於二零零五年九月十五日在中國成立的有限公司，且為本公司的全資附屬公司
Model Code 「標準守則」	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix 10 to the Hong Kong Listing Rules 香港上市規則附錄十所載《上市發行人董事進行證券交易標準守則》
Nomination Committee 「提名委員會」	the nomination committee of the Board 董事會提名委員會
O&G 「婦產科」	obstetrics and gynaecology 婦產科
PRC or China 「中國」	the People's Republic of China 中華人民共和國
PRC Company Law 「中國公司法」	the Company Law of the People's Republic of China (中華人民共和國公司法), as amended and adopted by the Standing Committee of the Twelfth National People's Congress on 28 December 2013 and effective on 1 March 2014, as amended, supplemented and otherwise modified from time to time 《中華人民共和國公司法》，由第十二屆全國人民代表大會常務委員會於二零一三年十二月二十八日修訂並通過，自二零一四年三月一日起生效，經不時修訂、補充及以其他方式修改
Prospectus 「招股章程」	the prospectus of the Company dated 27 October 2016 本公司日期為二零一六年十月二十七日的招股章程
Reporting Period 「報告期」或「報告期間」	the six months ended 30 June 2019 截至二零一九年六月三十日止六個月
Remuneration Committee 「薪酬委員會」	the remuneration committee of the Board 董事會薪酬委員會
Renkang Hospital 「仁康醫院」	Dongguan Renkang Hospital Co., Ltd. (東莞仁康醫院有限公司), a limited liability company established in the PRC on 23 August 2005 with 57% of its equity interest being held by the Company, 15% by Kangdi Enterprise, 15% by Ms. Zhang Dandan and 13% by Ms. Wang Aier, respectively 東莞仁康醫院有限公司，一家於二零零五年八月二十三日在中國成立的有限公司，其股權分別由本公司、康帝實業、張丹丹女士及王愛兒女士持有57%、15%、15%及13%
RMB 「人民幣」	the lawful currency of the PRC 中國法定貨幣

SFO 「證券及期貨條例」	the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong), as amended, supplemented or otherwise modified from time to time 香港法例第 571 章《證券及期貨條例》(經不時修訂、補充或以其他方式修改)
Share(s) 「股份」	share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, including the Domestic Share(s) and the H Share(s) 本公司股本中每股面值人民幣 1.00 元的股份，包括內資股及 H 股
Shareholder(s) 「股東」	holder(s) of the Share(s) 股份持有人
subsidiary or subsidiaries 「附屬公司」	has the meaning ascribed thereto in the Companies Ordinance (Chapter 622 of the laws of Hong Kong) 具有香港法例第 622 章《公司條例》賦予該詞的含義
substantial shareholder(s) 「主要股東」	has the meaning ascribed thereto in the Hong Kong Listing Rules 具有香港上市規則賦予該詞的含義
Supervisor(s) 「監事」	the members of the Supervisory Committee 監事會成員
Supervisory Committee 「監事會」	the Company's supervisory committee established pursuant to the PRC Company Law 本公司根據中國公司法設立的監事會
Tongli Enterprise 「同力實業」	Dongguan Tongli Enterprise Co., Ltd. (東莞市同力實業有限公司), a limited liability company established in the PRC on 23 June 2003 with 43% of its equity interest being held by Ms. Wang Aiqin, 29% by Ms. Wang Aici, 15% by Ms. Zhang Dandan (張丹丹) and 13% by Ms. Wang Aier (王愛兒), respectively, all of whom are members of the Wang Family, being aunts of Mr. Wang Junyang. Pursuant to a nominee arrangement among the Wang Family, (i) Ms. Wang Aici (an aunt of Mr. Wang Junyang) agreed to hold 16% of her equity interest in Tongli Enterprise on behalf of Mr. Wang Junyang; (ii) Ms. Wang Aiqin (an aunt of Mr. Wang Junyang and the spouse of Mr. Chen Wangzhi) agreed to hold 15% and 6.5% of her equity interest in Tongli Enterprise on behalf of Mr. Wang Junyang and Mr. Chen Wangzhi, respectively; and (iii) Ms. Wang Aiqin agreed to hold 15% of her equity interest in Tongli Enterprise on behalf of Mr. Wang Wencheng (王文成) 東莞市同力實業有限公司，一家於二零零三年六月二十三日在中國成立的有限公司，其股權分別由王愛勤女士、王愛慈女士、張丹丹女士及王愛兒女士持有 43%、29%、15% 及 13%，彼等均為王氏家族的成員及王君揚先生的姑母或姨母。根據王氏家族中的代名人安排，(i) 王愛慈女士(王君揚先生的姑母)同意代表王君揚先生持有其於同力實業 16% 權益；(ii) 王愛勤女士(王君揚先生的姑母及陳旺枝先生的配偶)同意代表王君揚先生及陳旺枝先生分別持有其於同力實業 15% 權益及 6.5% 權益；及 (iii) 王愛勤女士同意代表王文成先生持有其於同力實業 15% 權益

Definitions

釋義

Wang Family	The family members of the founder of the Group, the late Mr. Wang Jincheng (王金城), including (i) his children; (ii) his siblings; (iii) the spouses of his siblings; and (iv) the children of his siblings
「王氏家族」	本集團創辦人已故王金城先生的家庭成員，包括(i) 其子女；(ii) 其兄弟姊妹；(iii) 其兄弟姊妹的配偶；及(iv) 其兄弟姊妹的子女
Xingda Property	Dongguan Xingda Property Investment Co., Ltd. (東莞市興達物業投資有限公司), a limited liability company established in the PRC on 14 December 2001 and one of the Controlling Shareholders holding approximately 8.22% interest in the Company. It is owned as to 50% each by Mr. Chen Wangzhi and Ms. Wang Aiqin. Xingda Property, Mr. Chen Wangzhi, Ms. Wang Aiqin, Mr. Wang Junyang, Ms. Wang Aici, Kanghua Group and Xingye Group are acting together as a group of Controlling Shareholders
「興達物業」	東莞市興達物業投資有限公司，一家於二零零一年十二月十四日在中國成立的有限公司及我們其中一名控股股東，持有本公司約8.22%權益，其由陳旺枝先生及王愛勤女士各擁有50%。興達物業、陳旺枝先生、王愛勤女士、王君揚先生、王愛慈女士、康華集團及興業集團作為一組控股股東一致行動
Xingye Group	Dongguan Xingye Group Co., Ltd. (東莞市興業集團有限公司), a limited liability company established in the PRC on 15 April 1997 and one of the Controlling Shareholders holding approximately 7.48% interest in the Company. It is owned as to 80% by Mr. Wang Junyang and as to 20% by Ms. Wang Aici, respectively. Xingye Group, Mr. Wang Junyang, Ms. Wang Aici, Kanghua Group, Mr. Chen Wangzhi, Ms. Wang Aiqin and Xingda Property are acting together as a group of Controlling Shareholders
「興業集團」	東莞市興業集團有限公司，一家於一九九七年四月十五日在中國成立的有限公司及我們其中一名控股股東，持有本公司約7.48%權益，其由王君揚先生及王愛慈女士分別擁有80%及20%。興業集團、王君揚先生、王愛慈女士、康華集團、陳旺枝先生、王愛勤女士及興達物業作為一組控股股東一致行動
Zhonglian Cardiovascular Hospital	Chongqing Kanghua Zhonglian Cardiovascular Hospital Co., Ltd. (重慶康華眾聯心血管病醫院有限公司), a limited liability company established in the PRC on 10 June 2014 and a non-whollyowned subsidiary of the company
「眾聯心血管病醫院」	重慶康華眾聯心血管病醫院有限公司，一家於二零一四年六月十日在中國成立的有限責任公司及非全資子公司
%	percentage ratio
%	百分比比率



廣東康華醫療股份有限公司*

Guangdong Kanghua Healthcare Co., Ltd.